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The ATP-sensitive potassium (KATP) channel is a vital link between cellular 
metabolism and electrical excitability in a variety of cell types, including 
pancreatic beta cells and hypothalamic neurons where they are involved in the 
response to changing plasma glucose levels. Blockade of KATP channels using 
sulfonylureas is a common therapeutic target for Type 2 diabetes (T2D) 
treatment. However, long-term sulfonylurea therapy is associated with a 33% 
chance of failure, reducing overall drug efficacy and pancreatic beta cell function, 
reducing their lasting effectiveness. Furthermore, gain-of-function mutations in 
KATP channels, leading to NDM and DEND syndrome, can drastically alter basal 
cellular metabolism and mitochondrial function, indicating a potential role of KATP 
channel activity in the regulation of glucose metabolism. In addition, DEND 
mutations have been shown to cause a wide array of neurological conditions, 
currently untreatable with sulfonylurea therapy.  
The aim of these studies was to answer three main questions; what is the impact 
of chronic blockade on membrane conductance and KATP channel activity after 
removal of the drug? does the alteration of KATP channel activity to regulate 
cellular glucose metabolism? And lastly, what concentration does memantine 
block native KATP channels at? Chapter 3 presents evidence that both gliclazide 
(5 μM) and tolbutamide (50 μM) caused a significant augmentation of KATP-
mediated membrane conductance in GT1-7 cells after 48 hours of treatment of 
~2x and 1.5x, respectively. Overall, these data provide an alternative explanation 
to the increased rate of drug failure after long term therapy with sulfonylureas. 
Chapter 4 shows that the acute modulation of KATP channel activity caused little 





been previously described. However, chronic KATP channel blockade with 
glibenclamide increased mitochondrial ATP production and decreased basal 
glycolysis, potentially as a response to increased cellular excitability. Chapter 5 
shows that external exposure of GT1-7 cells to memantine (100 μM) caused 
significant reduction in KATP-dependent whole-cell membrane conductance 
(~80% maximal). However, no significant effect was observed at either 10 μM or 
1 μM memantine. Overall, these data suggest that memantine does block KATP 
channels, but at a much higher concentration than is therapeutically relevant. 
Overall, this work provides new evidence that supplements our understanding of 
both the impacts of pharmacological treatment on KATP channel activity, as well 
as the role of KATP channel activity on cellular glucose metabolism. Furthermore, 
and most importantly, this work furthers our understanding of the effects of 
memantine on KATP mediated membrane conductance and its effectiveness, or 
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1.1 Diabetes and Neonatal Diabetes 
1.1.1 Diabetes 
As of 2017, it was approximated that 9% of the global adult population was living 
with diabetes, with half of these remaining undiagnosed (Cho et al., 2018). A 
combination of relatively recent changes in lifestyle, such as increased sugar 
intake and sedentary behaviour (Grøntved & Hu, 2011; Kolb & Martin, 2017), and 
genetic factors that can predispose individuals to diabetes (e.g. KATP E23K 
polymorphism (McTaggart et al., 2010), can be used to explain this rise in 
diabetes prevalence. In the United Kingdom the prevalence of diabetes is 6.6%, 
with this figure expected to rise to 7.4% over the next 20 years, putting an ever 
increasing strain on health providers. (Guariguata et al., 2014; Cho et al., 2018). 
Type 2 diabetes (T2D), the most common form of diabetes, is characterised by 
high blood sugar, insulin resistance, and an eventual lack of insulin. Metformin 
and sulfonylureas are the most common therapeutics for T2D (Xu et al. 2018). 
Type 1 diabetes (T1D) results from the autoimmune destruction of insulin-
producing pancreatic beta (β)-cells, rendering patients insulin deficient. T1D, and 
to a lesser extent T2D, are both polygenic in origin and account for the majority 
of diagnosed diabetes. However, monogenic forms of diabetes such as Maturity 
onset diabetes of the young (MODY) or neonatal diabetes mellitus (NDM), whilst 
rare, offer a greater potential to improve care and treatment with targeted 
therapeutic intervention due to their monogenic nature.  
1.1.2 Neonatal Diabetes Mellitus 
NDM is defined as insulin-requiring persistent hyperglycaemia occurring in the 
first 6 months of life. It affects approximately one in 400,000 new-borns (Shield 




(TNDM), which resolves within 18 months, and permanent NDM (PNDM), 
requiring lifelong therapy.  
The majority of TNDM cases result from the overexpression of the chromosome 
region 6q24 (Cavé et al., 2000) due to errors in parental genetic imprinting 
(incomplete gene methylation, duplication of paternal/maternal genes at 6q site 
or uniparental disomy), all resulting in gene overexpression.  However, mutations 
in the Adenosine-5’-triphosphate (ATP) sensitive potassium (KATP) channel genes 
(KCNJ11 and ABCC8) account for a small number of cases (Temple et al., 1996; 
Flanagan et al., 2007).   
PNDM is caused by a large array of genes involved in pancreatic development 
and β-cell apoptosis (Wen & Yang, 2017; Balboa et al., 2018), however, around 
33 to 50% of cases are due to gain-of-function activating mutations in the gene 
(KCNJ11) encoding the pancreatic KATP channel pore forming subunit, Kir6.2 
(Gloyn et al., 2004, 2006), reducing the ability to link alterations in cellular 
metabolism to changes in membrane excitability (as will be discussed further on). 
The overexpression of mutant KATP channels with reduced ATP sensitivity in β-
cells caused mice to develop severe neonatal diabetes (Koster et al., 2000). The 
majority of mutations that lead to PNDM have been shown to arise from de novo 
mutation, however, common mutation sites at amino acids 201 and 59 have been 
identified (Sagen et al., 2004). KCNJ11 gain-of-function mutations can increase 
the current magnitude of KATP channels in two ways, by facilitating Mg-ATP 
dependent channel activation through SUR1 or decreasing ATP-dependent 
channel inhibition on Kir6.2 (Proks, Girard, & Ashcroft, 2005). In addition, 
mutations in KCNJ11 that lead to neonatal diabetes are most commonly split into 





The first and most aggressive type of channel mutation is the channel gating 
mutations in Kir6.2 (i.e. V59M). These mutations indirectly reduce ATP sensitivity 
by stabilising the channel open-state and affecting the ability of the binding of 
ATP to the channel to cause changes to its conformation (Joseph C. Koster et 
al., 2005). The other is an ATP-binding mutation in Kir6.2 (i.e. R201H), affecting 
the ability for ATP to bind to and close the pore-forming subunit, leading to 
increased channel activity at basal levels and reduced sensitivity to changing ATP 
levels (Joseph C. Koster et al., 2005)(detailed description of this follows below). 
The I296L mutation impairs ATP sensitivity directly, stabilising the channel open 
state and causing a marked increase in resting whole-cell KATP currents (Proks, 
Girard, Haider, et al., 2005).  
 Kir6.2/SUR1 KATP channels are expressed in pancreatic β-cells and hypothalamic 
neurons, significantly contributing to glucose sensing (as will be discussed later). 
However, they are also expressed in a variety of other neuronal populations, 
playing important roles in seizure propagation and the regulation of neuronal 
firing, as is discussed in detail below. As a result, in addition to diabetes, severe 
mutations are associated with a neurological phenotype. It has been proposed 
that these neurological features present in NDM patients are part of a discrete 
neurological condition termed developmental delay, epilepsy and neonatal 
diabetes (DEND), with severity of symptoms being closely associated with the 
extent of Kir6.2 ATP-insensitivity (Hattersley & Ashcroft, 2005b). In general, the 
severity of the observed CNS features are associated with the impact of the 
mutation on channel open probability (Proks et al., 2004; Ashcroft et al., 2017), 
therefore those that affect channel gating generate more severe neurological 




common KCNJ11 mutations can be found here (Proks, Girard, & Ashcroft, 2005; 
Lang & Light, 2010). A selection of key mutations are detailed in Table 1.1.  
Genotype 
(KCNJ11) 
Position in Kir6.2 Mechanism Phenotype 
E23K N-terminus - T2D 
V59G Side Helix Increased Po DEND 
V59M Side Helix Increased Po iDEND 








C166F Gating - DEND 
I167L Pore Increased Po DEND 
 
Table 1.1: Mutations in KATP channel KCNJ11 genes causing diabetes in 
terms of T2D, PNDM and DEND. 
T2D, Type-2 diabetes; PNDM, permanent neonatal diabetes mellitus; DEND, 
developmental delay, epilepsy, and neonatal diabetes; iDEND; intermediate 
developmental delay, epilepsy, and neonatal diabetes; Po, channel open 
probability (adapted from (Lang & Light, 2010)) 
 
KCNJ11 gain-of-function mutations are associated with impaired attention, 
working memory and a reduced intelligence quotient in adults (Bowman et al., 
2019), as well as an increased risk for delays in learning and behavioural 
development, as well as increased susceptibility to sleep difficulties (Landmeier 
et al., 2017). Furthermore, children with the heterozygous V59M mutation, 




diabetes-matched controls (Shah et al., 2012). This impact on hand-eye 
coordination is also observed in adults with iDEND (McTaggart et al., 2013).  
Whilst these gain-of-function mutations cause defects in neurological function, no 
structural abnormalities in the brain are observed with magnetic resonance 
imaging (Bowman et al., 2019), however, it has been assumed based on literature 
searching that an in depth analysis of the impact of activating mutations on 
neurological morphology has not been performed. Furthermore, whilst  Kir6.2 is 
also expressed in cardiac tissue, no neonatal diabetes mutations are linked to 
cardiac dysfunction (Clark et al., 2012).   
Whilst there are neurological consequences of chronic or acute hyperglycaemic, 
present in NDM and DEND sufferers, restoring glycaemic control does not 
alleviate or improve DEND symptoms (Bowman et al., 2018), indicating that 
neurological symptoms are as a direct consequence of Kir6.2 mutations in the 
brain.  However, whilst sulfonylurea (KATP channel antagonist) treatment is  
ineffective in adults, improved restoration of neurological function and restriction 
of mutation induced behavioural problems are observed if treatment initiated 
during childhood (Shah et al., 2012). 
Taken together, these data indicate the important role for the KATP channel in 
normal neuronal function, as well as its role in glucose sensing, as will be 
discussed further.  
1.2 The KATP channel: Structure, localisation, and regulation. 
1.2.1 The KATP Channel 
Organisms have developed various ways in which to monitor energy status to 




potassium ion permeability upon increases in intracellular ATP concentration to 
enhance membrane excitability, and visa versa. Therefore, physiologically, the 
KATP channel acts as a metabolic sensor, coupling the output of cellular 
metabolism to the electrical excitability of the cell, in a wide range of tissues, 
including pancreatic β-cells, cardiacardiomyocytes, skeletal muscle, smooth 
muscle, neurons and glia (Noma, 1983; D. L. Cook & Hales, 1984; Spruce et al., 
1985; M. L. J. Ashford et al., 1988; Thomzig et al., 2005). Due to this expression 
profile, the KATP channel is involved in numerous essential biological processes 
from insulin secretion (Markworth et al., 2000), ischemic pre-conditioning (Jain et 
al., 2003; Broadhead et al., 2004; Wojtovich et al., 2013), regulation of neuronal 
function (T Miki et al., 2001; T. G. J. Allen & Brown, 2004; Tanner et al., 2011; 
Lutas et al., 2014), microglial activation (Du et al., 2018) and seizure prevention 
(Giménez-Cassina et al., 2012; H. Yang et al., 2013; MartÍnez-François et al., 
2018), which will be discussed later. 
Under conditions of low fuel metabolism and ATP generation, KATP channels open 
and the membrane hyperpolarises, reducing cellular excitability. However, during 
periods of heightened fuel availability and glucose oxidation, KATP channels close 
producing membrane depolarisation permitting greater action potential firing  that 
leads to the initiation of cellular responses, such as hormone and incretin 
secretion (Miki et al., 1998; Zhang et al., 2013; Han et al., 2018) and 
neurotransmitter release (During et al., 1995; Kawano et al., 2009). The 
mechanisms behind this effect will be discussed in detail below.  
1.2.2 Structure and localisation 
KATP channels are large macromolecular complexes comprised of four inwardly 




receptor (SUR) subunits, as illustrated in Fig 1.1 (Mikhailov et al., 2005; N. Li et 
al., 2017).  Kir6.x subunits form the central ATP-sensitive K+-selective pore, whilst 
the SUR subunits modulate channel gating properties and confer sensitivity to 
Mg-nucleotides and pharmacological agents.  Both Kir6.x and SUR subunits 
contain well-conserved endoplasmic reticulum retention signals (-LKRK-), 
requiring co-expression to mask, or deletion, to enable trafficking of the KATP 
channel complex to the membrane (Clement et al., 1997; Zerangue et al., 1999; 
Hough et al., 2000).  
1.2.2.1 Inwardly rectifying potassium (Kir6.x) channel subunits 
The inward rectifying, pore forming Kir6.x subunits are expressed as two isoforms,  
Kir6.1 and Kir6.2.  
Kir6.1 is predominately expressed in vascular smooth muscle (Cui et al., 2002), 
astrocytes (Thomzig et al., 2001), microglia (Du et al., 2018) and mitochondria of 
skeletal muscle (Suzuki et al., 1997) where it plays important roles in  regulation 
of vascular tone , microglial activation state (Du et al., 2018), regulation of 
mitophagy in astrocytes (Hu et al., 2019) and the regulation of mitochondrial 
membrane potential (Suzuki et al., 1997).  
Kir6.2 on the other hand is expressed predominantly in pancreatic β-cells, 
cardiomyocytes, glucose excited (GE) neurons of the hypothalamus (Gribble et 
al., 1998; Thomzig et al., 2005) where it plays important roles in nutrient sensing 
(F M Gribble et al., 1998; T Miki et al., 2001; Parton et al., 2007; Han et al., 2018), 
ischemic preconditioning (Tanaka et al., 2005). Kir6.2 is also expressed in a 
variety of other neuronal populations where it is involved in the prevention of 
seizure propagation (MartÍnez-François et al., 2018) and the regulation of 




Functional cell-type KATP (Kir6.2) expression in hippocampus shows predominant 
expression in interneurons (89%) and granule cells (89%), but only limited 
expression in excitatory pyramidal neurons (17%) (Zawar et al., 1999), potentially 
explaining the development of epileptiform activity in DEND due to reduced 
interneuron excitability. In addition, Kir6.2 expression is particularly high at post 
synaptic densities in CA1, potentially involved in long-term potentiation induction 
and hippocampus-dependent memory (S. Moriguchi et al., 2016). Whilst 
prevalent in the hippocampus,  Kir6.2 containing KATP channel expression has 
also been described in the dentate gyrus (Pelletier et al., 2000; Tanner et al., 
2011), substantia nigra (Schmid-Antomarchi et al., 1990; Lutas et al., 2014), 
cerebellar purkinje cells (Zhou et al., 2002) and the striatum (Avshalumov & Rice, 
2003). This expression profile goes someway to explaining the detrimental effects 
of Kir6.2 mutations on brain function.  
Kir6.1 and Kir6.2 are both regulated by alterations in ATP/ADP ratio , amongst a 
range of other factors (see 1.3 for further detail), however Kir6.1 has been shown 
to have a smaller single unitary conductance than Kir6.2 (Beech et al., 1993). 
Additionally, they have the ability to form a heteromeric KATP channel with lower 
sensitivity to Mg-ATP than Kir6.2 alone (Kono et al., 2000), however evidence for 
this in a physiological setting is limited (Seharaseyon et al., 2000). Furthermore, 
overall sensitivity to ATP and other secondary messengers can be significantly 
altered by the SUR isoform associated with Kir6.x. 
1.2.2.2 Sulfonylurea Receptor (SUR) subunits 
SUR subunits are members of the ATP-binding cassette (ABC) membrane 
protein family and contain an NH2-terminal transmembrane domain (TMD0) and 
cytoplasmic linker (L0) that interacts with  Kir6 and two additional transmembrane 




(NBD), as shown in Fig 1.1. These NBDs interact to form two nucleotide binding 
sites (NBS), a degenerate site (NBS1) wherein nucleotides bind tightly causing 
structural rearrangements and consensus (NBS2) site in which ATP is hydrolysed 
(Michinori Matsuo et al., 1999).  
SUR subunits are expressed as three isoforms, expressed in different tissue 
types around the body: The product of the ABCC8 gene, SUR1, is predominantly 
expressed in β-cells and neurons (Aguilar-Bryan et al., 1995; Donley et al., 2005; 
K. Zhao et al., 2013), whereas the splice variants of the ABCC9 gene, SUR2A 
and SUR2B, are expressed in cardiac muscle and vascular smooth muscle, 
respectively (Inagaki et al., 1996; Isomoto et al., 1996). All three of the SUR 
isoforms have been found to display divergent pharmacological properties and 
ATP inhibition relationships (M. Matsuo et al., 2000; Shi et al., 2005), impacting 
their physiological functions. Furthermore, in pancreatic β-cells Kir6.2/SUR1 
channels are partial active at rest, whilst in cardiomyocytes Kir6.2/SUR2A are 
mostly closed.  potentially due to the higher sensitivity to stimulation by Mg-ADP 
of SUR1 compared to SUR2A therefore endowing a higher sensitivity to 
metabolic stress (Masia et al., 2005). This divergence in activation state is 
therefore partially due to differences in the functional association of SUR with 
Kir6.2 (Principalli et al., 2015), altering their intrinsic properties. 
For the purposes of this introduction further discussion will focus on the regulation 





Figure 1.1:  A cartoon topology of Kir6.2 and SUR1 subunits, as well as the 
sites of interaction of various regulators.  
 (A) Representative image indicating the structure of a single Kir6.2 (blue) and 
SUR1 (red) pair, as well as the effects of various regulators of channel activity. 
Kir6.2, Inwardly rectifying potassium channel; SUR, Sulfonylurea receptor; mKATP, 
Mitochondrial KATP channel; ATP, Adenosine triphosphate; Mg2+ADP, 
Magnesium-Adenosine diphosphate; GK, Glucokinase; PT, Pyruvate 
translocase; UCP2, mitochondrial uncoupling protein 2; ROS, reactive oxygen 
species; NBD, nucleotide binding domain; EPAC2, cAMP-regulated guanine 
nucleotide exchange factors;  cAMP, Cyclic Adenosine Mono-phosphate. KATP 
channel antagonist (red text), KATP channel agonist (green text). Direct 
stimulatory modification (  ), Direct Inhibitory Modification ( ). Agonistic effect 
on channel activity (green, —), antagonistic effect on channel activity (red, —), 
partial antagonist effect on channel activity (grey, —). (B) Top down cartoon 





1.2.3 Regulation of KATP channel activity 
The open probability of KATP channels is predominantly modulated through 
interactions with intracellular nucleotides. However, this interaction can be 
modulated by a variety of signalling molecules and membrane proteins. As will 
be discussed below. 
1.2.3.1 Intracellular Nucleotides (ATP/ADP) 
The hallmark property of these channels is their high sensitivity to inhibition by 
intracellular ATP. This sensitivity, and the converse activating potency of Mg-ADP 
make the KATP channel a metabolic sensor, linking metabolic state to electrical 
excitability. 
In the absence of intracellular nucleotides, KATP channels are spontaneously 
active (Craig et al., 2008b). With gating of these channels characterised by short 
openings and closings, termed bursts, interspersed with long inter-burst closures. 
KATP channel ATP sensitivity is a dynamic parameter dictated by the interactions 
between SUR1 and Kir6.2 (Babenko & Bryan, 2002). 
Several reports have concluded that channel inhibition is produced by the binding 
of ATP to  Kir6.2 in a Mg-independent manner (Tucker et al., 1997; F M Gribble 
et al., 1998). ATP binds to both open and closed states of the channel, producing 
a decrease in the mean open time, a reduction in burst duration and an increase 
in both the frequency and duration of the inter burst closed states (Gribble et al., 
1998; Trapp et al., 1998; Li et al., 2002; Tarasov et al., 2006; Craig et al., 2008b). 
Furthermore, analysis of single–channel kinetics has shown that ATP  binds to a 
single ATP-binding site with a dissociation constant of ~ 300 μM when the 
channel is open (Craig et al., 2008b), therefore as the channel has four binding 




that at physiological intracellular ATP levels, an open KATP channel will more than 
often have ATP bound to Kir6.2.  
Conversely, occupancy of the nucleotide-binding domains of SUR1 by Mg-ADP 
with a dissociation constant of 8 µM stimulates channel activity (Proks, de Wet, 
et al., 2010). Furthermore, Mg-ATP is also able to stimulate channel activity 
through SUR1, albeit a much higher concentration (dissociation constant of ~ 112 
µM) than Mg-ADP. The consensus view is that Mg-ATP has to be hydrolysed to 
Mg-ADP at the NBS to stimulate channel activity, However, more recent reports 
show that the application of a non-hydrolysable ATP analogue Mg-ATPγS is as 
effective as Mg-ATP in stimulating KATP channel activity (Proks, de Wet, et al., 
2010). KATP channel activity inside intact pancreatic β-cells is quite low due to the 
dominant inhibitory effect of large intracellular ATP concentrations, thus, the 
principal regulators of activity are hypothesised to be Mg-ATP and Mg-ADP (A. I. 
Tarasov et al., 2006).  
Due to the interactions outlined above, the activity of the KATP channel and 
therefore the excitability of the cell is modulated through alterations in cellular 
metabolism. This provides the basis for glucose-sensing in a wide variety of 
tissues. Interestingly, affinity of ATP for the KATP channel is increased with high 
concentrations of Ca2+ in rat beta cells (Nakano et al., 2002), indicating that ATP 
affinity may reduce as membrane excitability increases. Potentially acting as a 
check of hyperexcitability.  
The Kir6.2ΔC36 channel is commonly used to assess the impacts of 
pharmacological agents or endogenous compounds on Kir6.2 alone. Kir6.2ΔC36 
involves the deletion of the last 26-36 amino acids of Kir6.2, removing the ER 




al., 1997). Interestingly Kir6.2/SUR1 and Kir6.2ΔC36 expressed alone, have 
similar rundown properties in the absence of nucleotides (Tucker et al., 1997), 
indicating that channel rundown is due to Kir6.2 inactivation. Rundown has been 
shown to be due to reductions in mean open time and burst duration (Proks, De 
Wet, et al., 2010), potentially as a result of PIP2 loss (Okamura et al., 2001) or 
Ca2+ -dependent inactivation (M. Hussain & Wareham, 1994), or a combination 
of the two (Furukawa et al., 1996). 
1.2.3.2 Membrane Phospholipids 
Phosphatidylinositol 4,5-biphosphate (PIP2) has been previously shown to 
simulate the activity of KATP channels by increasing channel open probability 
(Rohács et al., 2003), as well as shifting ATP sensitivity by several orders of 
magnitude (Baukrowitz et al., 1998). Primarily acting through interactions with 
Kir6.2 (Haider et al., 2007), further work has concluded that PIP2 also decreases 
syntaxin-1A/SUR1 interactions that cause reductions in channel activity (T. Liang 
et al., 2014) and neurotransmitter release from the presynapse. PIP2 also acts to 
uncouple Kir6.2 from SUR1, rendering it insensitive to glibenclamide inhibition (N. 
Li et al., 2017). Overall, PIP2 modulates the open probability and ATP sensitivity 
of KATP channels, potentially playing a role in the differing sensitivities and basal 
activity of Kir6.2/SUR1 channels between pancreatic β-cells and hypothalamic 
neurons. 
1.2.3.3 Cyclic adenosine mono phosphate (cAMP) 
The EPAC family of cAMP-regulated guanine nucleotide exchange factors 
(Epac1 and Epac2) mediate stimulatory actions of the second messenger cAMP 
in a PKA-independent manner. Epac2 has been previously demonstrated in vitro 
to interact with isolated nucleotide-binding fold-1 (NBF-1) of the SUR1 receptor, 




ADP-dependent stimulation of KATP channel activity in both pancreatic β-cells 
(Gribble et al., 1997; Kang et al., 2008) and neurons ( Zhao et al., 2013). As such, 
sulfonylurea efficacy is reduced in Epac2 -/- mouse pancreatic islets, indicating 
that sulfonylurea sensitivity is linked to Epac2 activity (Leech et al., 2010). 
Furthermore, the sulfonylureas glibenclamide and tolbutamide (but interestingly 
not gliclazide) have also been shown to act cooperatively with cAMP to activate 
Epac2A (C. L. Zhang et al., 2009; T. Takahashi et al., 2013; H. Takahashi et al., 
2015), stabilising its open activated state and increasing insulin secretion through 
a Rap1-dependent mechanism in β-cells. 
1.2.3.4 Glycolytic enzymatic activity 
In cardiomyocytes KATP channels (Kir6.2/SUR2A) have been found to physically 
associate with various glycolytic enzymes, wherein enzymatic activity and 
substrates of adolase, GAPDH and pyruvate kinase functionally modulate KATP 
channels (Dhar-Chowdhury et al., 2005; Hong et al., 2011b), reducing current 
flow by ~ 30%.  In addition, in SH-SY5Y cells inhibition of pyruvate kinase activity 
directly reduces KATP channel conductance (Mele et al., 2012). However, whether 
this inhibition is due to a direct interaction or reduced ATP generation in the KATP 
channel micro domain is not yet known. 
1.2.3.5 Cytoplasmic pH 
Cloned KATP channels are strongly stimulated by intracellular acidosis. The 
observed pH-sensitivity is independent of SUR1 and other cytosolic factors, 
indicating that the sensing mechanism is located on the Kir6.x subunit (H. Xu et 
al., 2001). Further study has identified that the proton-dependent gating requires 
at least three protein domains (N-terminus, C terminus and the M2 region) (Piao 




1.2.3.6 Mitochondrial uncoupling protein (UCP2) 
UCP2 is a mitochondrial protein that reduces ATP production through an increase 
in proton leak across the inner mitochondrial membrane, thus uncoupling 
oxidative phosphorylation from ATP synthesis. As such, increased expression of 
UCP2, potentially through increased glutamine exposure (Hurtaud et al., 2007), 
can perturb glucose-stimulated closure of KATP channels through a reduction in 
ATP generation. UCP2 deletion or inhibition augments KATP channel closure and 
therefore the sensitivity of glucose sensing in both pancreatic β-cells (C. Y. Zhang 
et al., 2001) and POMC and MCH glucose-excited neurons (Parton et al., 2007; 
Kong et al., 2010), potentially through the regulation of intracellular ROS levels 
that contribute to glucose stimulated insulin secretion in β-cells (Pi et al., 2007; 
Affourtit et al., 2011; Robson-Doucette et al., 2011). 
1.2.3.7 Reactive oxygen species (ROS) 
ROS are chemically reactive chemical species containing oxygen that are formed 
as a natural by-product of metabolism (e.g. superoxide (O2-) or hydrogen 
peroxide (H2O2)) (Krenz et al., 2002). Evidence in the literature suggests that KATP 
channels (specifically SUR1- based channels) are activated by both exogenous 
and endogenous H2O2, leading to reductions in GSIS from β-cells (Krippeit-Drews 
et al., 1999), and reduced neuronal excitability and transmitter release from both 
glutamatergic CA1 pyramidal neurons and dopaminergic striatal neurons (Seutin 
et al., 1995; Avshalumov & Rice, 2003; Patel et al., 2011).   
1.3 Glucose Sensing 
The brain relies on circulating blood glucose as its primary source of energy, 
therefore maintaining plasma glucose concentrations high enough to support 




hyperglycaemia, requires tight regulation of plasma glucose levels. Whilst 
transient elevations in plasma glucose are usually well tolerated, acute deficits in 
blood glucose < 3 mM, termed hypoglycaemia, are not well tolerated and can 
have profound effects on brain function (Rosenthal et al., 2001), such as irritability 
(Wredling et al., 1992), anxiety (Khan et al., 2011) and impaired cognitive function 
(McAulay et al., 2001; Warren et al., 2004). Therefore, In order to monitor and 
respond appropriately to fluctuations in circulating glucose levels, peripheral and 
central glucose sensors have evolved in order to maintain glucose levels within 
a healthy euglycaemic range (3.9 – 5.5 mM).   
1.3.1 Hallmarks of a glucose-sensing cell 
1.3.1.1 Glucose transporters (GLUTs) 
Glucose is the primary energy source for the majority of cells and is an important 
substrate for a large quantity of biochemical reactions. Therefore, as glucose is 
a need of each cell of the body, so are GLUTs which allow the transport of glucose 
across the cell membrane. GLUTs are proteins comprising 12 membrane-
spanning regions with intracellularly located amino and carboxyl terminals. Class 
I facilitative glucose transporters are represented by GLUT1 to GLUT4, among 
which GLUT2 is expressed mainly in pancreatic β-cells, liver and kidney. GLUT3 
is mainly present in the brain. It has high affinity for glucose, a property which is 
consistent with its function to transfer glucose into cells having a higher 
requirement of glucose. GLUT4 is an insulin-responsive glucose transporter that 
is found in the heart, skeletal muscle, adipose tissue, and brain.  
GLUT2 acts as a glucose sensor in β-cells of rodents, but human beta cells 
express mainly GLUT1 (De Vos et al., 1995) showing ~10 fold lower glucose 




animal and clinical studies have shown that the primary β-cell sensor is 
glucokinase and not GLUT1 or GLUT2 (Efrat et al., 1994).  
1.3.1.2 Glucokinase 
Glucokinase (GK), also known as hexokinase IV, catalyses the conversion of 
glucose to glucose-6-phosphate, which constitutes the first step of glycolysis. In 
most cells, it is catalyzed by hexokinase, however, GK has certain biochemical 
properties that allow it to function as a glucose-sensing enzyme (Matschinsky & 
Wilson, 2019), namely;. it has a lower affinity for glucose than other hexokinases 
(Km ∼10 mmol/l), it is not saturated at physiological glucose concentrations and 
is not inhibited by the product of the reaction it catalyses. These properties allow 
the rate of glucose phosphorylation to be dependent on and proportional to 
intracellular glucose levels (Matschinsky et al., 2006). GK is expressed in 
numerous hypothalamic nuclei, including the arcuate nucleus (ARC), 
ventromedial nucleus (VMN), and lateral hypothalamic area (LHA) (Lynch et al., 
2000; Li et al., 2003; Hussain et al., 2015), as well as in the nucleus of the solitary 
tract (NTS) (Boychuk et al., 2015a) and pancreatic beta-cells (Efrat et al., 1994; 
Liang et al., 1994; Dunn-Meynell et al., 2002) 
1.3.1.3 AMP activated protein kinase (AMPK) 
Loss of AMPK has been reported to alter the sensitivity of glucose sensing cells, 
through poorly defined mechanisms. Loss of the AMPKα2 subunit in pancreatic 
beta cells and hypothalamic neurons decreases the sensitivity of these cells to 
changes in extracellular glucose concentration ( Beall et al., 2010; Beall et al., 
2012). Moreover, exposure of rats to recurrent and acute hypoglycaemia reduces 
hypothalamic AMPK activation, whilst also inhibited the counterregulatory 
response to hypoglycaemia (McCrimmon et al., 2008). Furthermore, 




the counterregulatory response to hypoglycaemia (McCrimmon et al., 2006; Fan 
et al., 2009). AMPK has been shown to increase KATP channel expression on the 
cell surface (P.-C. Chen et al., 2013; S.-H. Park et al., 2013), as well as increasing 
activation of KATP channels in the pancreas and hypothalamus (Yoshida et al., 
2012; Beall, et al., 2013).  
1.3.1.4 Voltage gated ion-channels (VGICs) 
VGICs play a fundamental role in GSIS in β-cells and glucose sensing ability of 
neuronal populations in the hypothalamus. In addition, Ca2+ influx through 
voltage-gated Ca2+ (Cav) channels (L-, P/Q- and T-type (Braun et al., 2008)) 
triggers exocytosis of insulin-containing secretory granules and potassium efflux 
through voltage-gated K+ (Kv) channels mediates membrane repolarisation (P. 
Rorsman, 1997). Voltage gated Na+ (Nav1.6/1.7) channel activation plays an 
important contributary role in the upstroke of action potentials, with inhibition 
reducing GSIS by 55-70% (Braun et al., 2008). Human β-cells also express 
large-conductance Ca2+-activated (BK) channels, in which inhibition leads to an 
increased action potential amplitude and enhanced insulin secretion by ~70% 
(Braun et al., 2008), similar to the effect observed in Kv2.1 KO studies in mice (X. 
N. Li et al., 2013). Furthermore, dynamic modulation of Kv2.1, via leptin 
signalling, in NPY neurons of the ARC modulated spontaneous activity and the 
integration of synaptic inputs (Baver et al., 2014), indicating that modulation of 
delayed rectifier currents can impact excitability of both β-cells and neuronal 
populations.  
1.3.2 Pancreatic β-cells 
Pancreatic β-cells detect increases in plasma glucose concentrations and under 




Glucose can equilibrate across the β-cell membrane rapidly due to the extensive 
expression of the low affinity glucose transporter 2 (GLUT2), allowing fast glucose 
uptake. Whilst GLUT2 is the predominant glucose transporter in rodent β-cells, 
this is not the case in human islets and β-cells where the predominant isoforms 
are GLUT1 and GLUT3  (McCulloch et al., 2011). Glucose is then phosphorylated 
to glucose-6-phosphate by glucokinase, constituting the flux determining step for 
glycolysis. Further glycolytic metabolism produces pyruvate, as well as a small 
amount of ATP. Pyruvate is then shuttled into the mitochondria where it is further 
metabolised via the citric acid cycle, reducing NAD+ to NADH. This is then 
oxidised via the electron transport chain using oxygen as the final electron 
acceptor, generating a proton gradient across the mitochondrial membrane. This 
is then utilised to produce a large amount of ATP through ATP synthase. 
Subsequent binding of produced ATP to KATP channels induces channel closure 
(Tucker et al., 1997), leading to a depolarisation of the resting membrane 
potential and the activation of L-type voltage-dependant Ca2+ channels, allowing 
the influx of extracellular Ca2+ (F M Ashcroft et al., 1994). This increase in 
intracellular Ca2+ induces exocytosis of insulin containing vesicles (as seen in Fig 
1.2). Insulin then circulates in the blood stream instigating increases in glucose 
uptake into tissue (for example, adipose tissue and skeletal muscle) and glycogen 
synthesis in the liver, leading to the subsequent reduction of glucose levels.  
Therefore, the conductance of KATP channels and the membrane potential are 
key determinants of the level of insulin secretion in β-cells and the initial response 
to rising plasma glucose concentrations. A very similar mechanism is also utilised 






1.3.3 Brain Glucose Sensing 
1.3.3.1 Glucose-sensing cell types in the CNS 
Glucose-sensing neurons are mainly located in the hypothalamic nuclei, playing 
important role in the regulation of feeding, energy homeostasis (regulating 
glucose concentrations between 3.9 – 5.5 mM) and whole-body nutrient 
metabolism, in addition to the regulation of the counter regulatory response 
(CRR) to hypoglycaemia (Evans et al., 2004; McCrimmon et al., 2005) and the 
regulation of behavioural patterns (T Miki et al., 2001; King, 2006).  Hypothalamic 
glucose-sensing neurons also respond to a variety of metabolites such as 
ketones, fatty acids and lactate. In addition, they express a multitude of receptors 
Figure 1.2: Glucose sensing in Pancreatic Beta cells  
When metabolism is low, KATP channels are open, keeping the membrane 
hyperpolarized (membrane voltage = Vm) and voltage-gated Ca2+ channels 
(VGCCs) closed, so that [Ca2+]i remains low and insulin secretion is prevented. 
However, when metabolism increases (due to increases in glucose availability), 
[ATP]i increases and [Mg-ADP]i falls, closing KATP channels and preventing K+ 
movement. This triggers depolarization of the β-cell membrane potential, opening 
of voltage-gated Ca2+ channels, Ca2+ influx, and exocytosis of insulin (green 




for hormones (such as insulin, leptin, ghrelin and GLP), which correlates with 
nutritional status and fat stores.  
The presence of glucose-sensitive neurons in the CNS was first described in the 
1960’s. The glucostatic hypothesis, first proposed by Jean Mayer, postulated that 
glucose receptors exist within the hypothalamus and that glucose concentrations 
are sensed by these receptors to regulate food intake (Mayer, 1955). This 
hypothesis was confirmed when glucose-sensing neurons were discovered in 
1964. Using dogs and cats, changes in single unit activity were measured in the 
Ventromedial hypothalamus (VMH) and Lateral Hypothalamus (LH) during 
intravenous glucose injections, increasing neuronal activity in the VMH whilst 
decreasing it in the LH (Anand et al., 1964). Later work then demonstrated that 
hypothalamic neuronal firing rate was directly regulated by glucose concentration 
in vivo (Oomura et al., 1964). Insulin exposure significantly decreases the activity 
of the mediobasal hypothalamus decreasing hepatic glucose production. 
However, infusion of the high-affinity KATP channel blocker glibenclamide negates 
the effect of central insulin on hepatic gluconeogenesis (Pocal et al., 2005). 
Furthermore, Intracerebroventricular perfusion of sulfonylureas, closing KATP 
channels, suppressed the CRR to systemic hypoglycaemia (Evans et al., 2004), 
whilst activation of KATP channels can amplify the CRR hormone responses to 
hypoglycaemia (McCrimmon et al., 2005). These studies act to differentiate two 
key populations of neurons: “glucose-excited” (GE) neurons and “glucose-
inhibited” (GI) neurons, found mainly within the hypothalamus and the brainstem. 
These neurons play an essential role in the onset of the CRR to hypoglycaemia. 
The involvement of different brain regions in glycaemic control and energy 
homeostasis will be discussed further on. However, it is prudent to first define the 




impacts on neuronal activity, as well as the role of astrocytes in hypothalamic 
glucose sensing. 
GE neurons are primarily activated by elevated glucose concentrations, 
producing a inhibitory effect on the response systems to hypoglycemia (Borg et 
al., 1997) and activating the response to hyperglycemia through stimulation of γ-
aminobutyric acid (GABA) neurotransmitter release in the VMH (L. Kang et al., 
2004; Zhu et al., 2010) and nucleus of the solitary tract (NTS) (Boychuk et al., 
2015a), as well as neuropeptides in the arcuate nucleus (ARC) of the 
hypothalamus (Parton et al., 2007). 
The main GE mechanism in the brain in analogous to that employed by 
pancreatic β-cells in response to hyperglycaemia, replying primarily on three 
main components: GLUT2/3, GK and Kir6.2/SUR1 KATP channels. GLUT2 has 
been identified in several nuclei of the hypothalamus  and the brainstem (Y. Liang 
et al., 1994; Mounien et al., 2010; Lamy et al., 2014). However, GLUT3 is 
assumed to play a more important role in glucose-sensing of VMH neurons (L. 
Kang et al., 2004), especially in humans (McCulloch et al., 2011). However, the 
reduction in GLUT2 expression in the ARC of adult rats abolished insulin 
response to rising glucose levels (Leloup et al., 1998). 
GK expression is also distributed widely in hypothalamic glucose-sensing 
neurons (L. Kang et al., 2006; Levin et al., 2008; S. Hussain et al., 2015), with 
the inhibition of GK via alloxan exposure decreasing ARC GE neuronal sensitivity 
to hyperglycemia (R. Wang et al., 2004). Lastly, Kir6.2/SUR1 KATP channels have 
been detected in a variety of glucose-sensing neurons in the medio basal 
hypothalamus (C. Zhang et al., 2007), VMH (Evans et al., 2004; L. Kang et al., 
2004), NTS (Dallaporta et al., 2000; Boychuk et al., 2015b) and ARC (van den 




counterregulatory response to hypoglycemia through reductions in glucagon and 
adrenaline secretion (Evans et al., 2004). Furthermore, a reduction in AMPK 
activity has also been shown to decrease glucose-sensing behaviour of GE 
neurons in vitro (C. Beall et al., 2012), demonstrating the importance of AMPK 
activity in glucose sensing of GE neurons, especially to hypoglycemia. 
The canonical mechanism by which GE neurons sense glucose involves the entry 
of glucose the GLUT2/3, its rapid phosphorylation by GK and oxidisation through 
glycolysis, the TCA cycle and oxidative phosphorylation, resulting in an increase 
in ATP production. This increase in the ATP:ADP ratio and the binding of ATP to 
the KATP channel promotes channel closure, membrane depolarisation and the 
activation of Cav channels. This increased neuronal activity leads to the 
stimulation of GABA secretion, decreasing the secretion of glucagon and 
adrenaline (Borg et al., 1995; Evans et al., 2004; Zhu et al., 2010), as well as the 
cessation of feeding behaviours. Furthermore, in vivo inhibition glucokinase and 
GLUT2/3 in the VMH decreased sensitivity of pancreatic β-cells to elevated 
glucose levels and reduced GSIS (Osundiji et al., 2012). These data indicate that 
hypothalamic glucose sensing and excitability can alter islet cell hormone 
secretion and systemic glucose homeostasis.  
Whilst important, GABA is not the only neuromodulator present in the 
hypothalamus (Kong et al., 2010). Under constant hyperglycaemia, such as is 
found in individuals suffering from T2D, there is a significant increase in UCP2 
protein in POMC-neurons of the ARC (Parton et al., 2007; Kong et al., 2010). 
Overexpression of UCP2 reduces mitochondrial ATP production, decreasing the 
sensitivity of neuronal membrane potential to increases in extracellular glucose 
concentration (Kong et al., 2010), leading to both directly and in-directly mediated 




reduce neuronal excitability through interactions with, and activation of,  KATP 
channels, as observed in dopaminergic neurons of the striatum (Avshalumov & 
Rice, 2003). However, Increased ROS generation in the hypothalamus produces 
effects similar to hyperglycaemia, closure of KATP channels and increases in 
insulin secretion (Leloup et al., 2006).  
Nevertheless, while KATP channels represent the canonical pathway by which GE 
neurons sense glucose, a variety of metabolism- and KATP-independent glucose 
sensing mechanisms have been described. For Example, those dependent on 
the sodium-dependent glucose transporters (SGLTs) (Gonzàlez et al., 2009) and 
sweet taste receptor binding (Ren et al., 2009).  However, as this introduction 
focuses on the role of KATP, these will not be discussed further.   
 
In contrast to GE neurons, the activation of GI neurons increases upon decrease 
in glucose concentration, associated with increased secretion of glutamate and 
nor-adrenaline, as well as orexigenic signals and glucagon secretion. Under 
hyperglycaemic and hyperinsulinemic conditions, GI neuronal activity is proposed 
to be minimal, regulating hormonal activity as a counterregulatory response to 
hyperglycaemia (Diggs-Andrews et al., 2010). The mechanism underpinning 
glucose-induced inhibition of neuronal activity is not as well understood as the 
GE glucose-sensing mechanism. However, a variety of potential pathways have 
been proposed; the Na+/K+ ATPase-, the cystic fibrosis transmembrane regulator 
Cl- channel (CFTR)- and the tandem two-pore potassium channel (K2P)- 
dependent mechanisms.  
GI neurons exhibiting the Na+/K+ ATPase-dependent mechanism are distributed 
throughout the LH where a decrease in glucose availability, oxidation and ATP 




causes an accumulation of intracellular Na+, and reduction of intracellular K+, and 
subsequent depolarisation of the membrane potential and stimulation of GI 
neuronal activity (Silver & Erecińska, 1998; Sohn, 2013). Inhibition of the Na+/K+ 
ATPase pump in ARC GI neurons increases Ca2+ influx due to increased 
membrane excitability, as well as initiating the onset of feeding behaviour (Kurita 
et al., 2015). This also indicates that a subpopulation of GI neurons also express 
GLUT2/3 and GK, similar to that observed with GE neurons (Dunn-Meynell et al., 
2002).  
The blockade of CFTR channels and subsequent intracellular accumulation of Cl-
, depolarisation of the membrane potential and increases in glutamate release is 
predominantly described in GI neurons of the VMH (Canabal et al., 2007; Murphy 
et al., 2009; Fioramonti et al., 2011). Decreased glucose availability and ATP 
production in VMH GI neurons leads to a reduction in the ATP:AMP ratio causing 
activation of AMPK (Sanders et al., 2007). The subsequent phosphorylation of 
neuronal nitric oxide (NO) synthase (nNOS) by AMPK leads to an increase in 
intracellular NO levels, increasing synthesis of cyclic GMP (cGMP) and a 
promotion of AMPK phosphorylation in a positive feedback loop (Almeida et al., 
2004; Murphy et al., 2009). Phosphorylation and resultant blockade of the CFTR 
channel by AMPK (King et al., 2009) results in Cl- accumulation and membrane 
depolarisation. Exposure of rat VMH GI neurons to an AMPK activator replicate 
the impacts of low glucose on neuronal activity and NO production (Canabal et 
al., 2007). Furthermore, due to the role of CFTR, the dysregulation of glucagon 
secretion is commonly observed in cystic fibrosis (CF) patients that develop CF 
related diabetes (Edlund et al., 2017). Similarly, in GI neurons of the NTS the 
resultant hypoglycaemia-induced increase in AMPK activation leads to the 




observed in the carotid body (Wyatt et al., 2007; Enyedi & Czirják, 2010), resulting 
in membrane depolarization and an increase in neuronal activity and glucagon 
secretion.   
Astrocytes are the most abundant of glial cells in the brain, and are deemed as 
metabolic and signalling supporters of neuronal activity (Bélanger et al., 2011). 
The knockdown of GLUT2 in the ARC of adult rats altered feeding behaviours 
and eliminated the insulin response to hyperglycaemic conditions (Leloup et al., 
1998), with GLUT2 expressing astrocytes being identified in the ARC (Fuente-
Martín et al., 2016), NTS (Leloup et al., 1994; Rogers et al., 2020) and VMH. This 
indicates that a proportion of GLUT2 expressing astrocytes may play a role in 
glucose sensing within the hypothalamus (Guillod-Maximin et al., 2004).  
Hypoglycaemia leads to an increase in astrocyte glycogenolysis and an increase 
in lactate production and release, essential in maintaining neuronal activity under 
hypoglycaemic conditions.  The astrocyte-neuron lactate shuttle premise 
suggests that under period of high neuronal activity, and thus energy demand, 
astrocytes release lactate that is consumed by neurons to meet the substrate 
requirements for glycolysis and ATP demand (Genc et al., 2011).  The 
monocarbohydrate transporter isoform 1 (MCT1), required for astrocytic lactate 
release, has also been detected in in vitro cultures of GE neurons, in which lactate 
induced the closure of KATP channels and membrane potential depolarisation 
(Ainscow et al., 2002). Furthermore, lactate release by astrocytes increases 
under hyperglycaemic conditions (Walz & Mukerji, 1988), inducing membrane 
depolarisation in GE but not non-GE VMH neurons, potentially due to the limited 
expression of KATP in non-GE neuronal subtypes (Song & Routh, 2005). Due to 
this effect of released lactate, the counterregulatory response to hypoglycaemia 




the reduction of VMH astrocytic metabolism, and thus lactate production and 
release, leads to a loss of hypothalamic GE excitability and a decrease in GSIS 
from pancreatic β-cells (Guillod-Maximin et al., 2004). These data therefore 
indicate that the contribution of the astrocyte-neuron lactate shuttle could act to 
maintain neuronal activity and increase glucose sensitivity of GE neurons of the 
hypothalamus. However, increased lactate uptake may act to impair the CRR 
during recurrent hypoglycaemia (Chan et al., 2008, 2013). 
Together, this clarifies the importance of the environment surrounding glucose-
sensitive neurons and the mechanisms of glucose sensing. However, it is 
necessary to describe which regions are involved in glucose-sensing and their 
role in the responses to glucose variations. 
 
1.3.3.2 The role of the hypothalamus in energy homeostasis 
The hypothalamus is an ensemble of interconnected heterogeneous nuclei that 
help to maintain energy homeostasis, including the ARC, LH, VMN, PVN, and the 
dorsal medial hypothalamus (DMH), regions demonstrated to contain populations 
of glucose-sensitive neurons (T. Moriguchi et al., 1999). The control of glucose 
homeostasis is established by a balance in the glucose-sensitive neuronal 
secretion of orexigenic peptides (stimulators of food intake and inhibitors of body 
energy expenditure) and anorexigenic peptides producing the converse effect. 
Furthermore, the hypothalamus is positioned adjacent to the third ventricle, 
allowing access to different peptides and hormones produced by adipose tissue 
(leptin), the stomach (ghrelin) and the pancreas (insulin, glucagon), all of which 
act to modulate the neuronal response according to nutritional status and body 





The ARC is respected as a centre of the integration of metabolic information and 
the control of whole-body energetic homeostasis, predominantly controlled by the 
activation of two distinct neuronal populations: NPY/AgRP GI neurons and 
POMC/CART GE neurons that generate orexigenic and anorexigenic signals, 
respectively (Schwartz et al., 2000). The balance in the secretion of these 
neuropeptides is therefore vital in the control of energy homeostasis and food 
intake, controlled by both glucose level (R. Wang et al., 2004; Parton et al., 2007) 
and the differing effects of circulating hormones (van den Top et al., 2007; 
Belgardt et al., 2009; Kurita et al., 2015). Leptin increases firing of POMC GE 
neurons, whilst reducing that of NPY GI neurons (Baver et al., 2014). Moreover, 
leptin has been shown to excite POMC neurons through the activation of a 
transient reception cation channel, resulting in membrane depolarisation (J. Qiu 
et al., 2010). Furthermore, electrophysiological studies show that leptin has no 
effect on the electrical activity of non-POMC expressing GE neurons in the ARC 
(Wang et al., 2004). In short, POMC/CART GE neurons are stimulated by insulin, 
leptin, and glucose, while NPY/AgRP GI neurons in the ARC are stimulated by 
ghrelin and inhibited by glucose, insulin and leptin, (Nogueiras et al., 2008). The 
LH is considered a hunger centre, containing two discrete neuronal populations: 
orexin A/B GI neurons, and MCH GE neurons.  Lesioning of the LH decreases 
food intake and increases energy expenditure (Lytle & Campbell, 1975; Briski & 
Sylvester, 2001). Similarly, stimulation of the LH has been shown to decrease 
glucose production through a reduction in hepatic gluconeogenesis (Shimazu & 
Ogasawara, 1975), due predominantly to the activation of MCH GE neurons 
through KATP channel inhibition (Kong et al., 2010).  
 
As opposed to the LH, the VMH considered a satiety centre, with VMH lesioning 




et al., 1991), in addition to disrupting glucagon, adrenaline and noradrenaline 
responses during hypoglycaemic conditions in rats (Borg et al., 1994, 1995). 
Furthermore, localised glucose infusion blocks central control of CRR in response 
to systemic hypoglycaemia (Borg et al., 1997), deemed to be through the 
promotion of KATP channel closure in GE neurons. However, electrical stimulation 
of the VMH results in rapid increases in plasma glucose concentration and a 
marked reduction of hepatic glycogen content due to increased glycogenolysis 
(Shimazu et al., 1966), potentially through activation of GI neuronal populations.  
Nevertheless, exposure of the VMH to diazoxide, a KATP channel agonist, also 
results in reduced hepatic glucose production. Furthermore, SUR1-/- mice 
display an impaired ability to reduce hepatic glucose production during insulin 
clamp studies (Pocai et al., 2005). These data indicating that activation of 
hypothalamic KATP channels in GE neurons, and resultant neuronal silencing, is 
also required to reduce hepatic glucose output and effective CRR to 
hypoglycemia (Evans et al., 2004). 
Whilst important in the regulation of hypothalamic GE neuronal activity and the 
regulation of whole-body energy state, KATP channels have been widely described 
in a variety of other brain regions and non-glucose-sensing neurons. Their 
proposed roles in these areas and cell types will now be discussed.  
1.4 The role of KATP in non-glucose sensing neuronal activity 
In addition to their role in regulating insulin secretion from pancreatic β-cells and 
the firing behaviours of glucose-sensing neurons in the hypothalamus. KATP 
channels have been proposed to be important in the regulation of the excitability 




1.4.1 Neuronal development 
Neuronal development and the complexity of the nervous system are dependent 
on a complex series of events involving numerous transcription factors and the 
coordinated activation/inactivation of various cell signalling pathways at different 
stages of development. Neuronal maturation and functional interaction of newly 
generated neurons in the hippocampus is regulated by activity-dependent 
plasticity (Piatti et al., 2011). Therefore, the maturation of neuronal networks, both 
in vivo and in vitro, require tight regulation of neuronal activity. For example, the 
generation of memory is thought to be due to the increase in long term 
potentiation, caused by increases in NMDA or AMPA receptor expression 
(Lüscher & Malenka, 2012). However, it can be proposed that effective activity-
dependent regulation of excitability is also important. KATP channels are 
expressed throughout the neonatal brain, with expression of KATP channels in rats 
increasing 5-6X from birth to adulthood, as has been shown in the hypoglossal 
nerve (Jiang et al., 1992). In the immature medial entorhinal cortex (mEC), KATP 
channels are expressed, controlling activity-dependent regulation of excitability 
(Lemak et al., 2014). In addition, activation of Kir6.1 KATP channels in neural stem 
cells enhances adult mouse hippocampal neurogenesis (J.-Z. Z. Yang et al., 
2012).  
A variety of behavioural studies confirm the role of KATP in the regulation of 
healthy neuronal function (Tanner et al., 2011). Kir6.2 KO animals show a number 
of behavioural deficits, including: reduced activity, impaired motor coordination 
and emotional reactivity, an effect augmented in novel environments (Deacon et 
al., 2006). However, it can be hypothesised that the lack of Kir6.2 and associated 
congenital hyperinsulinemia and hypoglycaemia is also involved in the observed 




mutations in the Kir6.2 subunit also lead to the generation of cognitive 
phenotypes, such as; developmental delay, irritability, memory impairment, 
epilepsy and cognitive impairment (Gloyn et al., 2004; Sagen et al., 2004; 
Hattersley & Ashcroft, 2005a; Beltrand et al., 2015; Bowman et al., 2019). High-
dose sulfonylurea therapy improved cognition in a patient with V59M KCNJ11 
mutation (Slingerland et al., 2008). However, these neurological phenotypes are 
not rescued by long-term glycaemic control with high doses of sulfonylureas 
(Sumnik et al., 2007; Bowman et al., 2018), showing that the phenotypes 
observed are not just due to chronic or continuous hyperglycaemia, however, it 
could also be due to the late stage in which treatment was initiated. This further 
indicates that KATP channels are important in the regulation of healthy neuronal 
development. 
As such any brain-permeable treatment that can specifically regulate KATP 
channel activity may aid in the treatment of people with severe neonatal diabetes 
mutations.   
1.4.2 Ischemia and seizure protection 
KATP channels have long been associated with ischemic preconditioning in heart 
tissue, in which acute ischemic events result in protection against tissue damage 
by subsequent and sustained ischemia through increased KATP expression. 
During a stroke or ischemic event, there is a shortage of oxygen and nutrient 
delivery, resulting in a reduction in cellular ATP generation and an increase in 
KATP activation through an alteration in cellular ATP/ADP ratio. This results in 
cellular hyperpolarisation and cessation of firing, thought to protect cells from 




In dentate granule cells of the hippocampus, activity-dependent opening of KATP 
channels act as a seizure gate (Tanner et al., 2011), thought to be due to sub 
membrane depletions of ATP. Furthermore, overexpression of SUR1 in mouse 
forebrain infers resistance to kainite-induced seizures and excitotoxicity-
mediated cell death without interfering with normal locomotor or cognitive function 
(Hernández-Sánchez et al., 2001). Pilocarpine induced status epilepticus has 
been shown to increase expression of both Kir6.1 and Kir6.2 in hippocampus of 
treated mice, an effect augmented with the additional exposure of the glycolytic 
inhibitor 2-DG (Yang et al., 2013). These data indicate that KATP surface 
expression can be regulated through alterations in cellular metabolic state, as 
well as overall cellular excitability and activity. Furthermore, glycolytic inhibition 
with 2-DG also suppresses spontaneous neuronal firing and epileptiform bursts 
in hippocampal slices (Shao & Stafstrom, 2017). Interestingly, knockout of Bcl-2 
associated  agonist of cell death (BAD), a protein involved in apoptosis and 
glucose metabolism, is associated with a protective effect against epileptiform 
activity (MartÍnez-François et al., 2018). However, this is abolished through 
genetic or pharmacological blockade of KATP channels, further indicating a role 
for KATP in protection against epileptic seizures. However, diazoxide pre-
treatment equally protected both SUR1 Knockout and wild-type animals from 
ischemic damage (Muñoz et al., 2003), indicating that β-cell/ neuronal KATP 
channels are not obligatory for ischemic preconditioning.  
Opioids, including morphine, induced post-conditioning protects against ischemic 
injury via the activation of the opioid receptor and KATP channel opening (Pateliya 
et al., 2008), hypothesised to be due to the activation of a mitochondrial KATP 
channel, increasing K+ flux across the mitochondrial membrane a decreasing 




suggest the presence of a neuronal mitoKATP channel (Nakagawa et al., 2005; 
Arabian et al., 2018), similar to that observed in heart tissue (Costa et al., 2006), 
reports are not conclusive due to their use of whole brain tissue. Furthermore, a 
study investigating the localisation of Kir6.2 in rat neurons and glia found no 
immunoreactivity in the mitochondria (Zhou et al., 2002) 
1.4.3 Neuronal function 
In addition to their well characterised role in insulin secretion and general glucose 
sensing, KATP channels have been shown to modulate the electrical excitability of 
a variety of non-glucose sensing neurons under physiological conditions.  
Single KATP channel opening has been observed in response to action potential 
firing in mouse dentate granule neurons, contributing to the slow after-
hyperpolarisation following an evoked burst of action potentials (Tanner et al., 
2011), potentially as a results of localised ATP depletion due to increased Na+/K+ 
ATPase activity and this removal of channel inhibition. Furthermore, diazoxide 
evoked KATP channel activation causes a reduction in the frequency and duration 
of field potential (fp) bursts recorded within layer III of the mEC (Lemak et al., 
2014). Conversely, glibenclamide-induced KATP channel antagonism causes an 
increase in field potential burst duration, however, has no impact on burst 
frequency (Lemak et al., 2014).  Taken together, these results suggest that the 
activity of endogenous KATP channels can modulate spontaneous bursting in the 
mEC. Exposure of the substantia nigra to KATP channel openers in vitro causes 
increases in K+ current and reductions in GABA release, an effect negated 
through administration of sulfonylureas (Schmid-Antomarchi et al., 1990). 
GABAergic nucleus tratus solitarii (NTS) neuronal membrane potential and/or 




glucokinase (GK)- KATP channel-dependent manner (Boychuk et al., 2015a). In 
addition, >95% cholinergic basal forebrain neurons express functional KATP 
channels, whose activation resulted in membrane hyperpolarisation and a fall in 
electrical excitability (T. G. J. Allen & Brown, 2004).  
These data show that activation of KATP channels in different neuronal 
populations can inhibit excitability and reduce firing rate. In keeping with the 
proposed effect of KATP on the regulation of neuronal excitability and function, 
Kir6.2 KO mice have been shown to display an increased anxiety phenotype 
(Deacon et al., 2006), as well as cognitive deficits and somewhat reduced 
hippocampal long term potentiation (S. Moriguchi et al., 2016), in addition to 
significant impairments of contextual and tone memories when compared to wild-
type controls (Betourne et al., 2009). Furthermore, mice lacking KATP channels in 
dopaminergic neurones of the substantia nigra exhibit impaired novelty-induced 
exploration (Schiemann et al., 2012). Taken together, these studies provide 
increasing evidence to support the role of neuronal KATP channels in normal 
neuronal function. 
1.5 KATP channels and cellular metabolism 
1.5.1 Roles of plasmalemmal KATP activity 
As has been previously discussed, alterations in cellular metabolism and ATP 
generation act to modulate the activity of KATP channels. However, the stimulation 
of neuronal activity increases glucose oxidation and neuronal glycolytic output, 
above that of oxidative phosphorylation (Díaz-García et al., 2017), indicating that 
increased neuronal activity and membrane depolarisation can transiently 
increase metabolic rate. This is potentially through increased ATP consumption 




been shown to increase KATP channel activity in several preparations (Kabakov, 
1998; Haller et al., 2001; Tanner et al., 2011). 
Studies of islets isolated from the pancreas of hyperinsulinemic individuals 
expressing loss-of-function KCNJ11 (Kir6.2) mutations show significant 
differences in β-cell gene expression and fuel metabolism, indicating that 
alterations in KATP channel activity may significantly impact cellular metabolism. 
In addition cells also displayed an increased mitochondrial mass, oxygen 
consumption and ATP synthase expression, increasing production of ATP (C. Li 
et al., 2017).  However, it has been suggested that these effects are not replicated 
in normal human islets after acute blockade of KATP channels (C. Li et al., 2017).  
Conversely, the gain-of-function V59M KCNJ11 mutation causes upregulation of  
genes involved in glycolysis, whilst downregulating genes involved in oxidative 
phosphorylation in mouse β-cells in vivo (Haythorne et al., 2019). However, β-
cells cultured chronically in hyperglycaemic conditions show similar alterations in 
gene expression, as well as impaired glucose stimulated oxygen consumption 
(Haythorne et al., 2019). Furthermore, comparisons between Type 1 diabetic 
patients experiencing recurrent hypoglycaemia and healthy controls, showed that 
that glucose metabolism through the citric acid cycle was 45% higher under 
hypoglycaemic conditions in hypoglycaemic patients (Van De Ven et al., 2013).  
Taken together, these data show that mutations in KATP channels may modulate 
cellular metabolism. However, it is possible that the observed effects are caused 
indirectly through whole-body alterations in plasma glucose concentrations. As 
such, the effects of altered KATP channel activity on metabolism, observed in vivo, 
may instead be due to pathologically high or low blood glucose, rather than due 




To assess the effects of mutant KATP channels on cellular excitability or cellular 
metabolism, a variety of pharmacological agents can be used as an alternative 
method to exogenously modulate KATP channel activity, irrespective of cellular 
metabolic state. 
1.5.2 Putative roles of MitoKATP 
MitoKATP channels have been proposed in both skeletal and cardiac tissue, aiding 
preconditioning to ischemia and hypoxia through modulation of the mitochondrial 
membrane potential (MMP)(Mironova et al., 2004). Glibenclamide exposure has 
been shown to cause mitochondrial swelling, decreased MMP and increased 
oxidative phosphorylation and ATP production in skeletal muscle. However, 
direct exposure of isolated myocardial mitochondria to KATP channel openers 
(such as diazoxide) causes MMP depolarisation (Holmuhamedov et al., 1999). 
Activation of mitoKATP and subsequent MMP depolarisation leads to an increase 
in reactive oxygen species (ROS) generation  (Krenz et al., 2002) in turn working 
through PKCε activation to stabilise the channel open state, depolarise MMP and 
confer mitochondrial resistance to future hypoxic events (Costa & Garlid, 2008). 
However, whilst diazoxide has purported to induce cardiac pre-conditioning 
through increased ROS generation and “mitoKATP” activation, evidence also 
suggests that diazoxide also inhibits succinate dehydrogenase (complex II) of the 
electron-transport chain in a mitoKATP independent manner (Anastacio, Kanter, 
Keith, et al., 2013; Anastacio, Kanter, Makepeace, et al., 2013), inducing 
cardioprotection.  
Further to its role in cardio myocytes, MitoKATP activation has been proposed to 
trigger the development of ischemic tolerance in the brain through a similar 




significantly reduces infarct volume and protects against neuronal death in rat 
venous ischemia (Nakagawa et al., 2005) and reduces neuronal damage after 
transient focal cerebral ischemia (Mayanagi et al., 2007). Whilst, in these same 
studies, inactivation of mitoKATP, using sulfonylureas, augment the effects of 
ischemia and increases neuronal damage, indicating the presence of a 
mitochondrial-expressed KATP channels important for neuronal protection under 
ischemic or hypoxic conditions. However, a study investigating the localisation of 
Kir6.2 in rat neurons and glia has shown no immunoreactivity in the mitochondria 
(Zhou et al., 2002), whilst more recently the presence of mitoKATP in astrocytes 
was detected (J. Wang et al., 2013).  Detection of the mitKATP usually employs 
the use of KATP channel antagonists (e.g. sulfonylureas) and agonists (e.g. 
diazoxide or pinacidil), both of which have shown to elicit pre-conditioning through 
direct inhibitory effects on elements of the ETC (Kis et al., 2003; Busija et al., 
2005; Salani et al., 2017). Therefore, It is important to note that whilst evidence 
for the existence of the mitoKATP exists, several laboratories have questioned its 
existence, a viewpoint summarized in (Garlid & Halestrap, 2012). 
1.5.3 Acute and long-term ATP regulation in neurons 
ATP is consumed as a biological energy source by many intracellular reactions. 
Thus, as the intracellular ATP supply is required to maintain cellular homeostasis 
the production of ATP is tightly regulated. The ATP:ADP ratio is also a critical 
parameter of cellular energy status that regulates many metabolic activities, 
including KATP channel activity (A. Tarasov et al., 2004).  
Brain ATP is almost entirely generated by the oxidation of glucose, with oxidative 
phosphorylation accounting for 87% of generated ATP (26 out of 30). In a model 
proposed by Magistretti and colleagues (Magistretti & Allaman, 2015), the 




which neurons generate ATP, indicating that lactate (released by astrocytes) and 
mitochondrial oxidative phosphorylation were the primary mechanisms behind 
neuronal ATP production (Hall et al., 2012). Furthermore, increased neuronal 
activity in hippocampal slices swiftly decreased the levels of extracellular O2 and 
intracellular NADH, even with lactate dehydrogenase blocked to prevent lactate 
generation (Hall et al., 2012). However, blockade of glycolysis in active 
hippocampal neurons leads to a significant drop in intracellular ATP 
concentrations and a rapid inhibition of presynaptic function (Rangaraju et al., 
2014). Therefore, this indicates, at least during active states, fast ATP production 
through glycolysis (Pfeiffer et al., 2001) is upregulated and inhibition of this 
upregulation is disastrous for synaptic transmission. In keeping with this, a variety 
of glycolytic enzymes have been demonstrated to be specifically enriched on 
synaptic vesicles (Ikemoto et al., 2003), as well as associated with the Na+/K+ 
pump in neurons (Lipton & Robacker, 1983) and KATP channels (Dhar-Chowdhury 
et al., 2005; Mele et al., 2012), allowing for the rapid and localised upregulation 
of ATP production and repolarisation of the membrane following depolarisation. 
Furthermore, modest increases cytosolic Ca2+, such as during periods of 
heightened electrical activity, can stimulate components of the malate–aspartate 
shuttle, upregulating respiration in cortical neurons by enhancing pyruvate supply 
into mitochondria. Therefore, Ca2+ signals may also play a key role in shaping 
mitochondrial bioenergetics and ATP production (Jouaville et al., 1999; Llorente-
Folch et al., 2015). 
Overall, this indicates that oxidative phosphorylation is the long-term regulator of 
ATP production in neurons, however, under periods of heightened energy 
demand glycolytic flux is acutely upregulated in order to meet ATP requirements 





1.6 Current therapeutics that target KATP channels 
A large number of anti-diabetic agents are available to treat T2D, including α-
glucosidase inhibitors (Derosa & Maffioli, 2012c), dipeptidyl peptidase-4 inhibitors 
(Derosa & Maffioli, 2012a) and glucagon-like peptide (GLP-1) receptor agonists 
(Derosa & Maffioli, 2012b). However, after treatment failure with the first-line 
therapy metformin, which is currently the fourth most prescribed drug in the USA,  
the most widely used drugs for treating patients with T2D remains sulfonylureas 
(Eldor & Raz, 2012; Christensen et al., 2016). 
Sulfonylureas primary mechanism of action is through the antagonism of KATP 
channels, inducing insulin secretion independently of cellular metabolic state. 
Sulfonylureas close KATP channels by binding with a high affinity to the nucleotide 
binding domains (NBDs) present on the SUR1 subunits of KATP channels (Proks 
et al., 2002), preventing activation of the channel through Mg bound nucleotides 
(Proks et al., 2014). In the absence of nucleotides, sulfonylureas only act as 
partial agonists, producing block of between 50-75% (F M Gribble et al., 1997). 
However, in the presence of intracellular nucleotides, the interaction of 
sulfonylureas with SUR1 abolishes the stimulatory effect of Mg-nucleotides, 
increasing ATP binding affinity to Kir6.2 (Proks, De Wet, et al., 2010) and the 
unmasking of the inhibitory effect of ATP on Kir6.2 (Tucker et al., 1997). 
Therefore, in the presence of intracellular nucleotides, sulfonylurea inhibitory 
effect is amplified. Tolbutamide and gliclazide specifically block Kir6.2/SUR1 
containing channels with high affinity (Fiona M. Gribble et al., 1998; F. M. Gribble 
& Ashcroft, 1999). Whilst glibenclamide blocks both SUR1 and SUR2A containing 




In addition to KATP channel antagonists, a variety of KATP channel agonists also 
exist, including diazoxide (D’Hahan et al., 1999) and the SUR1 selective, pre-
clinical agent, NN414 (Dabrowski et al., 2003). KATP channel activating drugs are 
commonly used to treat hypoglycaemia, reducing β-cell activation and insulin 
secretion (M. Ashcroft & M. Gribble, 2000), as well as correcting trafficking 
defects brought about by mutations (Partridge et al., 2001; Martin et al., 2016). In 
addition, diazoxide induced KATP channel activation has been shown to 
ameliorate Amyloid-β and tau pathologies and improve memory in a model of 
Alzheimer’s disease (Liu et al., 2010), potentially through reduced expression of 
the NR2B containing NMDA receptors (Zhu et al., 2015). Recent studies have 
shown however, that the chronic exposure of hypothalamic neurons to KATP 
channel agonist NN414 can attenuate KATP conductance and blunt 
hypoglycaemia detection (Craig Beall, Haythorne, et al., 2013; Haythorne et al., 
2016), most likely through confirmation changes to the channel.  
In summary, modulation of KATP channel activity can be beneficial for a variety of 
diseases, however the use of KATP selective pharmacological agents does come 
with certain drawbacks and limitations. 
1.6.1 Effectiveness and drawbacks of long-term sulfonylurea therapy 
Whilst sulfonylureas are effective at increasing insulin release and improving 
glucose homeostasis in T2D patients, a variety of studies have indicated that 
prolonged treatment can cause secondary treatment failure in ~33% of patients 
(H. Wang et al., 2017), characterised by failure of insulin secretion and the 
requirement of additionally therapeutics to provide adequate glycaemic control.  
Firstly, acute and chronic exposure of isolated human islets with glibenclamide 




with significantly lower concentrations (Maedler et al., 2005). However, in vivo 
studies on mice have concluded that 1 week of treatment with glibenclamide 
caused no significant alteration in islet size or any evidence of increased 
apoptosis (Remedi & Nichols, 2008), suggesting that chronic sulfonylurea failure 
is not due to increased β-cell apoptosis. Additionally, glibenclamide treatment 
reduced insulin secretion in response to glucose stimulation and produced a 
severely diabetic phenotype, hypothesised to be due to β-cell hyperexcitability 
caused by KATP channel inhibition. Chronic treatment of MIN6 pancreatic murine 
β-cells with either glibenclamide or tolbutamide also caused a significant 
reduction in insulin content and the number of functional KATP channels present 
on the membrane (Kawaki et al., 1999; A. Takahashi et al., 2007), further 
indicating that the chronic administration of sulfonylurea induced insulin secretory 
failure, potentially through a reduction in KATP channel expression. This is 
hypothesised to be due to endocytosis of KATP channels in response to stimulation 
and insulin release in β-cells (Han et al., 2018), rather than an effect of the drug 
itself on channel expression. In addition, insulin treatment preserved β-cell 
function more effectively than glibenclamide (Alvarsson et al., 2003).  
Interestingly, patients expressing the T2D associated gain-of-function 
E23K KATP channel mutation display a higher frequency of secondary treatment 
failure compared to patients with normal KATP channels (Sesti et al., 2006), 
however, this is not observed in patients with more severe Kir6.2 activating 
mutations (Bowman et al., 2018). These data indicate that mutations severely 
affecting ATP binding affinity or channel gating may protect against secondary 
treatment failure.  
Whilst gain-of-function KCNJ11 mutations were previously treated with insulin as 




based programme to improve glycaemic control (Klupa et al., 2005; Pearson et 
al., 2006). High dose sulfonylurea therapy has been shown to be safe and highly 
effective for the treatment of KCNJ11 mutations (Lawrence et al., 2001), 
maintaining excellent glycaemic control after 10 years of treatment (Bowman et 
al., 2018). However, even after long term therapy with sulfonylureas, CNS 
features are still observed in 64% of treated patients (Bowman et al., 2018). As 
previously described, this could be in part due to the age of treatment initiation 
(Shah et al., 2012), reducing effectiveness of treatment as age increases. 
In rats glibenclamide was not detectable in the CSF after implantation with 
subcutaneous glibenclamide pellets, despite high plasma concentrations. In 
addition, even after direct administration to the lateral ventricle, plasma 
concentration was twice that of the CSF, indicating that glibenclamide is actively 
exported from the CSF (Lahmann et al., 2015). A similar effect has also been 
observed with the sulfonylurea tolbutamide, in which, at therapeutic 
concentrations, the efflux rate from the CSF is faster than the influx rate 
(Takanaga et al., 1998). These data therefore suggest that the reduced effect of 
sulfonylureas on neurological phenotypes are potentially due to the sub-
therapeutic concentrations achieved through continuous therapy. However, 
sulfonylurea therapy has shown to improve central neuronal function in some 
case studies (Joseph C. Koster et al., 2008). Therefore, whether SU treatment is 
therapeutically useful for the treatment of neurological symptoms remains to be 
determined. This may be due to age of treatment, type of gain-of-function 




1.7 Potential for new KATP targeted therapeutics and current knowledge 
Due to the reduced effectiveness of current therapeutics for the treatment of 
neurological symptoms of gain-of-function KCNJ11 mutations, new therapeutics 
options are required to provide adequate therapy.  
Memantine was originally developed as an anti-diabetic agent by Elli Lilly in 1963, 
however it failed to show good glucose lowering effects. It was subsequently 
repurposed for treatment of dementia and later found to be a non-competitive 
antagonist of N-methyl-D-Aspartate (NMDA) receptors in the brain (Seeman et 
al., 2008). Various reports suggest an IC50 of ~5 µM, however, under more 
physiological conditions and in the presence of Mg2+ , the IC50 of memantine on 
NMDA increases at resting membrane potentials (~ 12 µM;(Kotermanski & 
Johnson, 2009)), potentially due to competition for binding at the deep site 
(Kotermanski & Johnson, 2009; Glasgow et al., 2018). In any case, various 
reports have shown that serum to CSF ratios obtained for memantine are 
observed to be around 0.5, indicating decent brain selectivity of the drug without 
accumulation (Kornhuber & Quack, 1995; Valis et al., 2019). Furthermore, with a 
‘normal’ dose of 20 mg/kg the projected brain/CSF free extracellular 
concentration has been proposed to be ~1 µM (Hesselink et al., 1999), much 
lower than the IC50 observed for NMDA.  
Interestingly, increasing evidence suggests that memantine has significant 
impacts on the activity of a variety of other membrane proteins, such as; 5-HT 
receptors (Reiser et al., 1988), acetylcholine receptors (Aracava et al., 2005) and 
voltage gated potassium (Kv) channels (Lowinus et al., 2016). However, most 
importantly for this study, evidence suggests that memantine may interact with 




Memantine (30-100 µM) increases the spontaneous firing rate of midbrain 
dopaminergic neurons in brain slices, an effect mediated by inhibition of KATP 
(Giustizieri et al., 2007). Additionally, more recent reports showed that 
memantine (10 nM) caused significant reductions in transfected Kir6.1/SUR1 and 
Kir6.2/SUR1 KATP channel conductance, as well as, initiated pinacidil (KATP 
channel agonist) sensitive enhancements of long-term potentiation in mouse 
hippocampus (S. Moriguchi et al., 2016). Further studies on pancreatic β-cells 
have shown that Memantine (1 µM) causes no alteration in KATP conductance, as 
well as causing no significant alteration in insulin secretion in response to 
increased extracellular glucose concentration (Imai et al., 2018). Taken together, 
these studies provide a variety of conflicting results concerning the impact of 
memantine on KATP channels.  
More importantly, memantine is safe and well tolerated by children (6-12 year 
olds; (Aman et al., 2017)) and can improve social responsiveness in children with 
Autism (Hardan et al., 2019). Therefore, memantine could be exploited for 
treatment of DEND syndrome. However, thorough investigation of the impact of 
memantine on KATP channel activity must first be conducted. To analyse these 
effects cell types expressing native- KATP channels are required.  
1.8 Cell models used 
1.8.1 Immortalised mature mouse hypothalamic GnRH neuronal cells 
Immortalised mature mouse hypothalamic GnRH neuronal (GT1-7) cell line first 
developed in the 1990’s (Mellon et al., 1990) displaying behaviour typical of GE 
neurons. This immortalised cell line has been demonstrated to be directly 
regulated by the modulation of glucose-sensing components, such as KATP 




GLUT4), glucokinase and AMPK (Mellon et al., 1990; C. Beall et al., 2012; Craig 
Beall, Haythorne, et al., 2013). GT1-7 cells also express gonadotrophin release 
hormone (GnRH) (Spergel et al., 1994; Kim et al., 2006), a hormone synthesised 
and released within the hypothalamus that has an important role in successful 
reproductive function. The release of this hormone as been shown to be tightly 
regulated by fluctuations in extracellular glucose concentration and KATP channel 
activation (C. Zhang et al., 2007). As such, due to its inherent KATP channel 
expression and glucose sensing ability, the GT1-7 model was deemed 
appropriate to investigate the impact of various targeted therapeutics on 
electrophysiological and metabolic properties.  
1.8.2 Rat insulinoma cell line   
The rat insulinoma cell line (INS-1) is a well-established model for studies of 
pancreatic islet beta-cell function (Rutter et al., 1992). The INS-1 832/13 line, 
used in the following work, is a subclone of INS-1 that was selected for robust 
glucose stimulated insulin secretion, producing and secreting both rat and human 
insulin. Furthermore, for the interests of these studies, INS-1 cells express 
functional KATP channel subunits (Kir6.2 and SUR1) (Crane & Aguilar-Bryan, 
2004; Han et al., 2018), wherein the overall activation state can determine cellular 
response to external stimuli i.e. increased extracellular glucose concentration. 
Therefore, due to these key parameters, the INS-1 832/13 cell line was deemed 
appropriate to investigate the impacts of acute and long-term KATP modulation on 






1.9 Aim of investigations 
1) Investigate the impact of chronic sulfonylurea application on membrane 
conductance.  
2) Investigate if acute or chronic KATP channel modulation alters cellular 
metabolism 
3) Investigate the antagonist effects of memantine on KATP channels and 





Chapter 2  































2.1 Cell Culture 
Cells were cultured under sterile and were maintained at a constant temperature 
of 37°C, with a humidified atmosphere consisting of 95% air and 5% CO2. Media 
components for the mouse gonadotrophin secreting neuronal cell line (GT1-7) 
and rat insulinoma cell line (INS-1 823/13) cell lines are listed as follows in Table 
2.1. INS-1 823/13 cells and respective growth medium was kindly provided by 
Prof Noel Morgan, University of Exeter.  
2.2 Cell Passaging 
Cell cultures were passaged every 3-5 days and kept between 60-80% 
confluency in T75 Starstedt vented cap flasks. As GT1-7 cells are non-adherent, 
plastic ware was coated with poly-L-lysine (PLL) to aid in cell attachment (used 
at 10 μg/ml for ≥ 30 minutes). Cultures were passaged by first removing media, 
washing cells gently with warmed PBS (1X) and then incubating with 2ml 0.05% 
Trypsin-EDTA (Gibco, #25-300-062) for 3-5 minutes at 37°C. After which time, 
trypsinisation was ceased by adding 8 ml of serum containing media to the flask 
and triturate the suspension. Cells were then centrifuged at 1000 rpm (~200 G) 
for 5 minutes. This process produced a cell pellet which was re-suspended in 5-
10ml of media. ~ 1 ml of cell suspension was then added to a fresh pre-coated 
T-75 flask (Starstedt), along with 10 ml of stock medium, to create a new stock 
flask. These stock flasks were given fresh medium every 48 hrs to replenish 
glucose and other nutrients, as well as to remove waste.  
2.3 Plating cells for experiments 
Prior to seeding for experiments, all plastic ware and coverslips were coated with 
PLL to aid cell attachment, Cells were plated in plating medium which contained 




respectively. Cells were maintained sub-confluent to ensure optimal response on 
experimental days: 
• 15mm coverslip (35mm dish) = 12,000 cells plus 3 ml plating media. 
• 60mm dish = 150,000 cells plus 5 ml plating media. 
• 96 well plate = 10’000/ 30,000 cells plus 200 μl plating media (24/ 72 hr 
incubation, respectively) 
For cells plated on coverslips, 100 μl of cell suspension was first added to 
coverslips and allowed to adhere for approximately 15 minutes before placing in 
the incubator. A respective quantity of plating medium was added (i.e. 3ml/ 35 
mm dish).  
2.4 Cell Treatments 
For all treatments, cells were first seeded into plating medium for 24 hrs. For 
some treatments, cells were then incubated in serum free (SF) medium (plating 
medium containing no serum) for 1 hr prior to the treatment.  In each case, cells 





















RPMI 1640 (ThermoFisher, # 
12633012) supplemented with: 
• 10% (v/v) Foetal Bovine Serum 
(SeraLabs (BioIVT), #EU-000-F) 
• 1% (v/v) Penicillin-streptomycin  
(Gibco, #15140122)  
• 2 mM L-Glutamine  
(Gibco, #25020081) 
• 10 mM HEPES  
(Gibco, #15630080) 
• 1 mM Sodium Pyruvate  
(Gibco, #11360070) 





DMEM (Sigma. #D5671) 
supplemented with: 
• 10% (v/v) Foetal Bovine Serum 
(SeraLabs (BioIVT), #EU-000-F) 
• 4% (v/v) L-Glutamine (Gibco, 
#25020081) 
• 2% (v/v) Penicillin-streptomycin  
(Gibco, #15140122)  
DMEM (Gibco, #11966) 
supplemented with: 
• 10% (v/v) Foetal 
Bovine Serum  
(SeraLabs (BioIVT) 
#EU-000-F) 
• 2% (v/v) penicillin-
streptomycin 
(Gibco, #15140122) 
• 0.1/ 2.5 mM Glucose 
(Sigma, #G8270-1KG) 
Table 2.1: A table illustrating components of medium used to culture GT1-





2.4.1 Chronic Cell Treatments, in vitro 
Cells were first seeded into the plating medium containing either 2.5 mM or 10 
mM Glucose for GT1-7 and INS-1 cells, respectively. Cells were incubated for 
18-24 hrs at 37°C in a humidified atmosphere consisting of 95% air and 5% CO2 
prior to initiation of cell treatment. Treatments were applied in respective plating 
medium and replenished every 24 hours for the duration of treatment.  
2.5 Electrophysiological recordings 
2.5.1 Preparation of solutions 
All internal solutions were prepared as 1X stocks in double distilled H20 (ddH20) 
and pH adjusted as denoted in Table 2.4; aliquoted into 1 ml Eppendorf tubes 
and stored at -20°C for a maximum of 3 months. Solutions containing ATP were 
stored for a maximum of 6 months. All external bath solutions were prepared as 
10X stock solution in ddH20 minus glucose and stored at 4°C for a maximum of 
Purpose Compounds used 
Pharmacological Agents Glibenclamide (Sigma-Aldrich, #PHR1287), 
Gliclazide (Sigma-Aldrich, #G2167), Tolbutamide 
(Fluka Analytical, #T0891), Diazoxide (Sigma-
Aldrich, #D9035), NN414 (Sigma-Aldrich, 
#SML0553), Memantine Hydrochloride (Tocris 
Biosciences, #0773), Oligomycin ( Agilent 
Technologies), 2-DG (Agilent Technologies), FCCP 
(Agilent Technologies ), Rotenone & Antimycin A 




Sodium Chloride (NaCl, Fisher Scientific, #7647-14-
5), Potassium Chloride (KCl, Fisher Scientific, 
#7447-40-7), D-Gluconic Acid (KGluc, Sigma-
Aldrich, #G-4500), Magnesium Chloride (MgCl2, 
AppliChem, #A3888), Calcium Chloride (CaCl2, 
VWR , #10043-52-4), EGTA (EGTA, Sigma-Aldrich, 
#E-4378), HEPES (Apollo Scientific Ltd, #BI8181), 
ATP-Magnesium salt (Mg-ATP, Sigma-Aldrich, 
#A9187) and Glucose (Fisher Scientific, #50-99-7) 




1 month. On the day of experiments, 100 ml of external stock solution was 
removed and placed into a 1 L volumetric flask. A respective volume of 1M 
glucose stock was then added to provide the required glucose concentration for 
experiments and cell type (e.g 2.5 ml of 1M glucose for 2.5 mM final 
concentration). The external solution was then topped up to 1L with ddH20 
providing a working solution for experiments. Concentrations of ionic 








Table 2.3: Composition of external solutions 
Solutions were all adjusted to pH 7.4 using 1M NaOH.  
 








KCl 20 140 20 
KGluc 135 - 135 
HEPES 10 10 10 
EGTA 0.2 10 10 
MgCl2 4 5 5 
CaCl2 - 3.8 3.8 
MgATP - - 1 
Table 2.4: Composition of Internal Solutions 
Solutions were all adjusted to pH 7.3 using 1M KOH.  
 Concentration (in mM) 
Compound External Solution A External Solution B 
NaCl 140 135 
KCl 3 5 
HEPES 10 10 
MgCl2 1 1 




2.5.2 Whole-cell Patch Clamp Configuration 
The recording chamber was continuously perfused with external solution (flow 
rate ~ 2ml/min) at room temperature (RT). All pharmacological agents mentioned 
in this work were introduced to the recording chamber via the perfusion system 
to naive cells, unless otherwise stated. Experiments were never performed on 
cells previously treated with pharmacological agents, unless this was required for 
the experiment in question. If performing on cells chronically treated with 
pharmacological agents, cells were placed under perfusion for ~30 minutes prior 
to experimentation to ensure adequate removal of pharmacological agent. 
Borosilicate glass capillaries with a filament with an outer diameter of 1.5 mm and 
an internal diameter of 0.86 mm were used to create patch pipettes and were 
pulled using the Flaming/Brown micropipette puller (Model P-97, Sutter 
Instrument Co). Pipettes were filled with required solution to a depth of 100-200 
mm from the tip of the pipette with one of the internal solutions detailed in Table 
2.4.  
Glass Borosilicate glass electrodes (2-4 MΩ) were filled with one of the internal 
solutions detailed in table 2.2 using a 1 ml syringe, 4 mm 0.2 μm syringe filter 
(Nalgene, #171-0020) and a Microfil needle (World Precision Instruments, 
#MF38G-5). The electrode was then lowered onto the cell membrane and, once 
touching the cell (observed by the presence of a “halo” around the end of the 
pipette using a Nikon Eclipse TE300 microscope with a 20X objective), positive 
pressure was released and gentle negative pressure was applied through mouth 
pipetting to form a GΩ seal. This is the cell-attached configuration. Holding 
voltage was reduced from 0 mV to -60 mV to stabilise the membrane; pipette 




membrane was zapped for 100 µs with a +1 mV pulse to facilitate membrane 
rupture and gain access to the whole-cell macroscopic currents. This creates the 
whole-cell configuration (As seen in Fig 2.1).  At which point the membrane 
capacitance (Cm) is compensated, providing a measurement of the cell size (pF) 
and the access resistance (MΩ). Following entry into whole-cell, a liquid junction 
potential arose as a result of the pairing of internal and external solutions. This 
was calculated using Clampex 10.4 and corrected for arithmetically during 
analysis. Details of the magnitude of liquid junction potential is presented in each 
section. 
Over time, dependent on cell size, access resistance and resistance of the 
electrode, the intracellular contents of the cell was dialysed with the contents of 
the glass pipette. The advantage of using this configuration is that the intracellular 
contents of the cells can be altered, whilst allowing whole-cell macroscopic 
currents to be visualised and manipulated using voltage-clamp protocols. 
All recordings were obtained using an Axopatch 700A amplifier, Axon™ 










Figure 2.1: Patch Clamp Illustration 
A cartoon representation of the steps involved in conducting whole cell patch 
clamp recordings. The microelectrode is represented here by the cylinder (grey) 
and the cell is represented by the sphere (blue). Direction of the arrows (black) 
indicated the direction of pressure. 1. Electrode is placed into solution and pipette 
capacitance is offset prior to continuation. 2. Electrode is slowly lowered onto the 
cell membrane and positive pressure is released until a GOhm seal is formed, 
termed the cell attached configuration. 3. Once a good seal is formed gentle 
negative pressure is applied until membrane is ruptured, termed the whole cell 
configuration.  
 
2.5.2.1 Voltage clamp recordings 
The voltage-clamp protocols used in the outlined experiments in the results 
section were performed by applying stepped (Protocol A and B, Table 2.5) or 
singular voltage steps (Protocol C, Table 2.5) across the membrane to evoke 
membrane currents and allow the measurement of leak current amplitude, whole-
cell leak conductance and voltage-activated outward currents.  A cell was 
considered suitable to record from if it had an access resistance of <20 MΩ. All 
data was low pass filtered at 6 kHz and digitised at 10 kHz.  
Current amplitude 
Current amplitude at each clamped voltage during protocol was determined as 




Whole-cell leak conductance 
To determine the conductance density of the cell, the amplitude of the current 
elicited by each voltage step (average of the last 10 ms) was plotted against the 
size of the test pulse (between -140 and -80 mV; junction potential corrected), 
generating a linear current-voltage (I-V) relationship (as shown in Fig 2.2D). 
Linear regression analysis of the best fit line of the I-V relationship allows the 
slope conductance (nS) to be determined from the gradient of this line. The 
reversal potential (mV) can also be determined from this relationship as the point 
where the line intercepts the x-axis. This was performed in experiments in which 
no current clamp recordings were performed. The slope conductance (nS) can 
then be normalised to the cell size (membrane capacitance; pF) to determine the 
conductance density of the cell (nS/pF). In terms of examining maximum KATP 
channel conductance, this was done in response to dialysing intracellular ATP 
from the cell (see Fig 2.2A) and then applying the voltage-clamp protocol (see 
Fig 2.2B, C), outlined above. In line with Ohm’s Law (voltage = current x 
resistance), as the KATP channels open in response to ATP dialysis the input 
resistance reduces, increasing the amplitude of the current achieved with each 
voltage step. Where the effects of pharmacological agents on membrane 
conductance were examined conductance after drug application (termed G) was 
presented as a ratio of the maximal conductance prior to pharmacological 
intervention (termed Gmax).  
Voltage-activated outward currents 
Membrane voltage (mV) was clamped at potentials from -80 to +60 mV utilising 




use of pre-pulses of opposing polarity (P/4) to estimate the size of the linear 
component using Ohm’s Law and isolate the voltage-activated currents.  
 
2.5.2.2 Current clamp recordings  
Measures of membrane potential (mV) alterations during ATP dialysis or during 
pharmacological agent exposure were made using the current clamp 
configuration where I=0, denoting zero current injection. These recordings were 
made without the injection of any direct current (Fig 2.2A). Where mean ± SEM 
mV values are presented, these denote an average of 5-10 seconds per 
recording for each time-point, as indicated. All data was low pass filtered at 6 kHz 

















A -70 -160 +40 +20 100 3 
B -70 -80 +60 + 10 150 3 
C -70 -120 N/A N/A 100 5 
Table 2.5: A table illustrating the different electrophysiological protocols 
used. 
Holding (the voltage (mV) at which the membrane was clamped in-between 
sweeps), Start (the voltage (mV) at which the membrane was clamped on the 
first sweep of the protocol), End (the voltage (mV) at which the membrane was 
clamped during the final sweep), Increment (the change in clamped voltage 
between sweeps (ΔmV)), Duration (the length of individual sweeps in the 








Figure 2.2: Example of ATP washout and analysis of whole-cell KATP 
conductance in GT1-7 cells. 
(A) Representative example of voltage trace in response to zero current injection 
and ATP dialysis, prior to tolbutamide (200 μM) exposure. (B) sample of voltage 
injection showing 4/11 steps in voltage-clamp protocol used to evoke linear 
currents (C) Linear currents observed using voltage clamp protocol (B) after 
rupture of the membrane (Break In; (1)) or after full ATP dialysis (Run Up; (2)). 
(D) Steady state current normalised to cell capacitance (last 10 ms of test pulse) 
plotted against respective voltage.  
 
2.5.3 The Nernst Equation 
All ions present within cells have an equilibrium potential, the potential at which 
there is no net flux of one particular ion across the membrane. This can be used 
to predict the membrane potential in response to the concentration of a particular 
ion on either side of a permeable membrane. In addition, for selective ion 
channels, where the selectivity filter strongly favours the permeation of ion over 













EX = Nernst potential for ion X (mV). 
[X]O = Concentration of X outside the cell. 
[X]i = Concentration of X inside the cell. 
R = Universal gas constant (8.314472 J/K/mol). 
T = Temperature (K). 
z = Valency of ion X. 
F = Faraday’s constant (C/mol). 
 
The Ex (equilibrium potential/reversal potential) at room temperature (22°C/ 
295.15 K) with an intracellular concentration of 140-150 mM and external 
concentration of 5 mM K+ is between -84.7 to -86.5 mV, respectively. This 
equation is based on the assumption that the membrane is only permeable to K+, 
whilst in reality other ion transport processes will be on going. As a result, the 
equilibrium potential will differ slightly from that calculated.  
2.6 Calcium Imaging 
2.6.1 Cell culture and Fura-2 AM Loading.  
GT1-7 cells were first plated 18-24 hours prior to experiments at a density of 
30’000 cells/ well in a clear bottomed 96 well culture plate in plating medium 
supplemented with 2.5 mM glucose.  
On the day of the assay, 50 μg aliquot Fura-2-acetoxymethyl ester (Fura-2 AM, 
ThermoFisher Scientific) was removed from the freezer (-20C) and allowed to 




had thawed, 12.5 µl of DMSO was added to the tube and vortexed for ~2 minutes 
to ensure it was well mixed. This mixture was then transferred to a 15 ml 
centrifuge tube. To this, 12.5 ml of External solution E supplemented with 0.1 mM 
Glucose (normal saline, see table 2.2) was quickly added and vigorously 
triturated, generating a Fura-2 AM solution (4 µM).   
Next, compounds were dissolved in normal saline ready for next steps. Always 
ensuring DMSO (used to dissolve compounds) concentration was 0.1% of final 
volume. Next, plating medium was aspirated from wells and cells were washed 
2-3X with warmed PBS (1X). Once washed, 100 μl of Fura-2 AM solution was 
added to each well and cells were incubated for ~60 minutes in a 37°C/ 5% CO2 
incubator. Fura-2 AM solution was then aspirated and cells were washed 1-2X 
with normal saline, before injecting 100 µl per well of normal saline + compounds. 
Cells were then incubated for ~30 minutes prior to recording to allow for 
desertification and cell treatment. 
2.6.2 Ratiometric calcium imaging 
Fluorescence excitation maximum of Fura2 shifts from 363 nm for Ca2+-free 
chelator to 335 nm for Ca2+-bound chelator. The largest dynamic range for Ca2+ 
dependent fluorescence signal is obtained by using excitation signals at 340 nm 
and 380 nm. Thus, the ratioing of the fluorescence intensities detected at ~ 510 
nm allows an estimate of the intracellular calcium concentration.   
After ~30 minutes, the culture plate was placed into the PHERAstar (BMG 
Labetch) and after adjusting the gain for each wavelength, measurements of 
emission at 510 nm was recorded after excitation with either 340 nm or 380 nm 
every 3 seconds for 27 seconds per well. Averages of emission values at 340 nm 




after excitation at 340 nm and 380 nm was then analysed post hoc to allow a 
quantification of respective intracellular calcium concentrations after cell 
treatment.  
2.7 Seahorse XF96 Extracellular flux Analyser 
The seahorse XF96 Extracellular Flux Bioanalyser (Agilent Technologies) allows 
the simultaneous measurement of oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) in real-time from live cells. Mitochondrial 
respiration is determined through measurements of OCR of the surrounding 
media over time (pmol/min), which is predominantly from the utilisation of O2 
during oxidative phosphorylation and the ETC.  Glycolysis is determined through 
measurements of the ECAR of the surrounding media over time (mpH/min), 
which is predominately from the excretion of lactic acid per unit time after its 
conversion from pyruvate (Wu et al., 2007) 
Both OCR and ECAR provide a systems-level view of cellular metabolic function 
in cultured cells.  produced from oxidative phosphorylation and proton extrusion 
from glycolysis, respectively. 10, 000 or 30, 000 cells/well were seeded into 96 
well Seahorse XF96 microculture plate, for chronic and acute treatments, 
respectively. Cells were seeded at least 18-24 hours before assay was 
performed. 30, 000 GT1-7 cells per well has been previously determined as an 
optimal cell number. On the day prior to the assay, the sensor cartridge was 
hydrated by submerging each sensor in 200 μl Seahorse XF Calibrant and 
incubating at 37°C in a non-CO2 incubator overnight.  
On the day of the assay, assay medium was prepared by supplementing 
Seahorse XF bicarbonate free base Medium (Agilent Technologies, #102353-




pharmacological agents. The pH of each assay medium was then adjusted to 7.4 
at 37°C using NaOH (1 N) or HCl (1 N), as required. This was done to limit effects 
of alterations in pH brought about through injections on assay measurements. 
Once prepared, all assay medium was sterile filtered using a 50 ml syringe and 
a 0.22 μm pore size syringe filter in a laminar flow hood.  
 
Table 2.6: Concentrations of media supplements used for different cell 
types and acute treatments prior to seahorse assay.  
KCO (Potassium channel opener) = Diazoxide or NN414. SU (Sulfonylurea) = 
Glibenclamide, Gliclazide or Tolbutamide. Glycolytic Stress Test (GST). 
Mitochondrial Stress Test (MST). Mouse hypothalamic neuronal cell line (GT1-
7). Rat insulinoma cell lines (INS-1). 
 
To begin the assay, growth/plating medium was aspirated and cells were washed 
2-3X in pre-warmed PBS (1X). Medium was then replaced with 200 μl of prepared 
XF base medium containing a respective quantity of glucose, L-glutamine and 
Sodium Pyruvate for the experiments in question (Table 2.6). The culture 
microplate was then placed in a non-CO2 incubator at 37°C for at least 1 hour 
prior to being placed in the Seahorse XF96 Bioanalyser. The purpose of this is to 









Assay Cell/Drug KCO SU KCO SU KCO SU 
GST 
GT1-7 0 0 2 2 2.5 2.5 
INS-1 N/A N/A N/A N/A N/A N/A 
MST 
GT1-7 2.5 0.1 2 2 2.5 2.5 




During this degassing session, any inhibitors/ compounds/ pharmacological 
agents (~10X in XF base medium) were loaded into the injector ports of the XF96 
sensor cartridge, allowing these compounds to be injected during the assay. If 
multiple injections were required, increasing volumes (20, 22, 25 μl etc) were 
loaded into the injector ports to ensure an accurate 1/10 dilution of compounds 
upon injection.  The sensor cartridge was then loaded into the XF96 Seahorse 
Bioanalyser to calibrate for pH and O2 saturation. After calibration and de-gassing 
of the culture plate, the culture plate was placed into the Seahorse XF96 and 
assay initiated. 
The respiration of cells determined that a 3 minute mix, 3 minute wait and 3 
minute measurement cycles were used during assays. 3-4 baseline 
measurements were obtained at the beginning of the experiment prior to 
compound injection to ensure basal respiration was stable. In most cases the first 
measurement was discarded. 3 to 4 mix, wait, measure cycles were then 
performed after the addition of each compound.  
After assay was completed, media was aspirated and 100 µl of NaOH (50 mM) 
was added to each well to lyse the cells. Culture plate was stored at 4°C overnight 
and analysis of protein concentration performed within 24 hours.  
 
2.7.1 Mitochondrial Stress Test 
The Agilent Seahorse XF Cell Mito Stress Test allows the assessment of key 
parameters of mitochondrial function by directly measuring the oxygen 
consumption rate (OCR) of cells. This assay uses the built-in injection ports on 
XF sensor cartridges to add modulators of respiration into the cell well during the 




Figure 2.3). Firstly, on the day of the assay cells are incubated for 1 hour in 200 
μl XF base medium, supplemented with a respective quantity of glucose, L-
glutamine and Sodium Pyruvate based on cell type and acute compound 
application (see Table 2.6), to maintain mitochondrial activity whilst modulating 
glycolytic activity based on pre-treatment required. Injector ports were loaded and 
the sensor cartridge calibrated prior to initiation of the assay (as detailed in 2.7). 
After baseline recording measurements are completed, Oligomycin is injected 
into the wells to inhibit ATP synthase (Complex V), decreasing electron flow 
through the electron transport chain and decreasing OCR linked to ATP 
production. After which, Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone 
(FCCP) is applied, which acts as an uncoupling agent that collapses the proton 
gradient and disrupts the mitochondrial membrane potential. Therefore, flow 
through the ETC is un-interrupted as oxygen consumption reaches in maximum, 
allowing calculation of the spare-respiratory capacity (maximum – basal). Finally, 
wells are injected with a cocktail of rotenone (Complex I inhibitor) and antimycin 
A (Complex III inhibitor). This combination of inhibitors shuts down mitochondrial 









Figure 2.3: Mitochondrial Stress Test Profile 
Mitochondrial stress test profile of the key parameters of mitochondrial function. 
Sequential injections allow measurement of Basal respiration and maximal 
respiration, as well as allowing the calculation of the Spare capacity, ATP-linked 
respiration, proton leak and Non-mitochondrial oxygen consumption. Adapted 
from (Agilent Technologies, 2019). 
 
2.7.2 Glycolytic Stress Test  
The Agilent Seahorse XF Glycolysis Stress Test allows the assessment of key 
parameters of glycolytic function in cells (as can be seen in Figure 2.4) by directly 
measuring the extracellular acidification rate, (ECAR), upon the administration of 
various compounds that alter glycolytic rate. When performing the glycolysis 
stress test, designed to examine glycolytic function the pre-incubation protocol 
was altered slightly than previously described. On the day of the assay, cells are 
incubated for 1-2 hours in unbuffered, serum free, phenol-red free DMEM with 
pyruvate and L-glutamine (concentrations shown in Table 2.6). This results in 
minimal glycolytic activity being observed at the start of the assay, as no glucose 
is present in this culture media but pyruvate and L-glutamine are still able to 




recording measurements were completed, glucose was injected into the wells to 
stimulate basal glycolysis, represented by a rise in ECAR. Oligomycin was then 
applied to inhibit mitochondrial ATP synthesis, making the cell reliant on glycolytic 
ATP production for maintaining bioenergetics. As such, this stimulates the 
maximal glycolytic rate, allowing calculation of the maximal glycolytic rate and the 
glycolytic reserve. 2-deoxyglucose (2DG) [10x the concentration of injected 
glucose] was then applied at the end of the assay to inhibit glucose uptake and 
glycolysis, allowing calculation of non-glycolytic acidification and showing 
observed changes in ECAR are due to glycolysis.  
 
Figure 2.4: Glycolytic Stress Test Profile  
Glycolytic stress test profile of the key parameters of glycolytic function. 
Sequential injections allow measurement of glycolysis, glycolytic capacity and 
allow the calculation of the glycolytic reserve and non-glycolytic acidification. 
Adapted from (Agilent Technologies, 2017).  
 
2.7.3 Bradford protein Assay 
Protein concentration of cell lysates was determined using the Bradford protein 




reagent (BioRad), in a 96-well micro culture plate well (reactions performed in 
triplicate for each sample). The reaction was left to incubate at room temperature 
(RT) for ~5 minutes, followed by analysis using a 96-well plate reader 
(PHERAStar FS, BMG LABTECH). Absorbance at OD595 nm was read, average 
values for triplicates were determined and values compared to a standard curve 
of known BSA protein concentrations.  
 
2.8 Data Analysis 
Electrophysiological data was analysed using custom written MATLAB scripts, 
unless otherwise stated. Seahorse metabolic data was analysing using Wave 
Desktop software (Agilent Technologies). All data was extracted and 
subsequently processed using Microsoft Excel and GraphPad Prism 8.1.1. 
Statistical analysis between 3 or more groups was ascertained using a One-way 
ANOVA, such as in the electrophysiological recordings. Two-way ANOVA 
repeated measures, with a post hoc multiple comparisons test was used to 
determine statistical significance between groups in which a dependent variable 
was measured between groups subject to two independent variables (e.g. drug 
treatment and voltage). All other data sets were analysed using an unpaired 
Student’s t-test. Bonferonni post hoc analysis was performed when comparing a 
set of means, Tukey methods used when comparing every mean with every other 
mean and Dunnett’s methods used when comparing every mean with a control 
mean. All statistical analysis was performed in the Graphpad, Prism 8.1.1 
software. All data are presented as mean ± SEM. Statistical significance was 
accepted at the 95% confidence value with a P value of less than 0.05. 





Chapter 3  
Effect of acute and chronic sulfonylurea 
exposure on KATP channel mediated 





















ATP sensitive potassium (KATP) channels play a pivotal role in coupling cellular 
metabolic activity to the electrical activity of the plasma membrane. As such, they 
are important in glucose sensing behaviour of a variety of cell types, namely 
pancreatic beta (β)-cells and glucose-excited hypothalamic neurons (T Miki et al., 
2001). In fasted animals, KATP channels provide the principal β-cell membrane 
conductance, maintaining cellular hyperpolarisation and cessation of insulin 
secretion (F. Ashcroft, 1988). However, in fed animals, increased glucose 
metabolism enhances cellular [ATP], closing KATP channels leading to membrane 
depolarisation and voltage-activated Ca2+ influx which stimulates the exocytosis 
of insulin-containing secretory granules (Patrik Rorsman et al., 2014). In the 
hypothalamus, particularly the ventral medial hypothalamus (VMH), glucose 
excited neurons increase their firing rate in response to increases in extracellular 
glucose levels, a mechanism dependent on KATP channel inhibition (T Miki et al., 
2001), important in maintenance of glucose homeostasis. KATP channels come in 
a variety of isoforms, however, as both β-cells and hypothalamic neurons (the 
focus of this chapter) express the Kir6.2/SUR1 subtype, this will be the only one 
discussed herein.  
Sulfonylureas are a class of drug commonly used to treat type-2 diabetes (Sola 
et al., 2015) as they stimulate the secretion of insulin from pancreatic β-cells . 
Their primary mechanism of action is by antagonism of KATP channels, inducing 
insulin secretion independently of cellular metabolic state. Sulfonylureas close 
KATP channels by binding with a high affinity to the nucleotide binding domains 
(NBDs) present on the SUR1 subunits of KATP channels (Proks et al., 2002), 
preventing activation of the channel by Mg2+ bound nucleotides (Proks et al., 




antagonists, producing block of between 50-75% (F M Gribble et al., 1997). 
However, in the presence of intracellular nucleotides, the interaction of 
sulfonylureas with SUR1 abolishes the stimulatory effect of Mg-nucleotides, 
increasing ATP binding affinity to Kir6.2 (Proks, De Wet, et al., 2010) and the 
unmasking of the inhibitory effect of ATP on Kir6.2 (Tucker et al., 1997). 
Therefore, in the presence of intracellular nucleotides, sulfonylurea inhibitory 
effect is amplified.  
Whilst sulfonylureas are effective at increasing insulin release and improving 
glucose homeostasis in T2D patients, a variety of studies have indicated that 
prolonged treatment can cause secondary treatment failure in ~33% of patients 
(H. Wang et al., 2017), characterised by insulin secretory failure and the 
requirement of adjunct therapeutics to provide adequate glycaemic control.  
Acute and chronic exposure of isolated human islets with glibenclamide (100 nM) 
has been shown to increase β-cell apoptosis, an effect not replicated with 
significantly lower concentrations (Maedler et al., 2005). However, in vivo studies 
on mice have concluded that 1 week of treatment with glibenclamide caused no 
significant alteration in islet size or any evidence of increased apoptosis (Remedi 
& Nichols, 2008), suggesting that chronic sulfonylurea failure is not due to 
increased β-cell apoptosis. Additionally, glibenclamide treatment reduced insulin 
secretion in response to glucose stimulation and produced a severely diabetic 
phenotype, hypothesised to be due to β-cell hyper excitability caused by KATP 
channel inhibition. Furthermore, chronic treatment with both glibenclamide and 
tolbutamide impairs sulfonylurea-induced insulin secretion but not the 
transcription of KATP channel components in BRIN-BD11 β-cells (Ball et al., 2004). 
Chronic treatment of MIN6 pancreatic β-cells with either glibenclamide or 




release, however this was associated with a reduction in the number of functional 
KATP channels present on the membrane (Kawaki et al., 1999; A. Takahashi et 
al., 2007). These data further indicate that the chronic administration of 
sulfonylureas induces insulin secretory failure, potentially through a reduction in 
KATP channel expression. This is hypothesised to be due to endocytosis of KATP 
channels in response to stimulation and insulin release in β-cells (Han et al., 
2018), rather than an effect of the drug itself on channel expression. In addition, 
insulin treatment preserved β-cell function more effectively than glibenclamide 
(Alvarsson et al., 2003).  
Interestingly, patients expressing the T2D associated gain-of-function 
E23K KATP channel mutation display a higher frequency of secondary treatment 
failure compared to patients with non-disease associated polymorphisms (Sesti 
et al., 2006). However, this effect is not observed in patients with more severe 
Kir6.2 gain-of-function mutations, due to long-term efficacy of sulfonylurea 
treatment (Bowman et al., 2018). These data indicate that mutations severely 
affecting ATP binding affinity, gating or expression may protect against 
secondary treatment failure. However, the reasons for this remain unclear. 
Potentially as a result of continuous hypothalamic GE neuron hyperpolarisation, 
amplifying the counter regulatory response and protecting against 
hypoglycaemia.  
Interestingly, for this chapter, previous work has shown that the chronic activation 
of KATP channels with the KATP channel opener NN414 causes a significant 
attenuation of KATP driven membrane conductance and glucose sensing 
behaviour in hypothalamic neurons in vitro (Haythorne et al., 2016). As such, it is 
hypothesised that the chronic blockade of channels with sulfonylureas may 




This chapter addresses the impacts of acute, short term and long term 
sulfonylurea treatment on KATP channel activity in an in vitro model of 
hypothalamic neurons. GT1-7 cells were chosen as a viable model of 
hypothalamic neurons due to their appropriate glucose sensing behaviour and 
significant KATP channel expression (Beall et al., 2012), similar to that observed 





















3.2.1 Acute sulfonylurea exposure significantly reduces KATP channel 
mediated membrane conductance in GT1-7 cells in absence of ATP 
Whilst the mouse hypothalamic neuronal cell line (GT1-7) have been previously 
used to examine the effects of drug exposure on KATP channel activity (Haythorne 
et al., 2016), it was important to confirm functional KATP channel expression prior 
to conducting additional experiments.  
To examine the effect of acute sulfonylurea application on KATP mediated 
membrane conductance in GT1-7 cells, whole-cell patch-clamp recordings were 
performed. The extracellular bath solution (External A, Table 2.3) contained 2.5 
mM glucose (termed Normal Saline (NS)) and the electrode solution contained 
140 mM KCl with 0 ATP (Internal solution B, Table 2.4), to measure the maximum 
KATP channel conductance through dialysation of intracellular ATP, alleviating 
nucleotide dependent channel inhibition. All recordings have been junction 
potential (JP) corrected, +2.6 mV. 
Currents were evoked by a voltage-clamp protocol holding potential of -70 (JP: -
67.4) and stepping to -120 (JP: -117.4) mV for 300 milliseconds. The voltage-
clamp protocol was initiated upon establishment of the whole cell configuration 
(termed Break In) and recordings were obtained every 5 seconds for the duration 
of the recording. This allowed the visualisation and quantification of conductance 
changes throughout treatment. Once conductance values (nS/pF) stabilised 
(termed Run Up), cells were treated with either 0.1 % DMSO (Veh; Fig 3.2A), 
glibenclamide (100 nM; Fig 3.2B), gliclazide (5 µM; Fig 3.2C) or tolbutamide (50 
µM; Fig 3.2D). Once no further change in conductance were observed (termed 




groups were obtained for the three sweeps prior to drug administration (Run Up) 
and three sweeps once drug effect had stabilised (Drug) (Fig 3.1Ai-Di). 
Compared to vehicle controls (n=6; Fig 3.1Aii), glibenclamide (n=5; Fig 3.1Bii), 
gliclazide (n=3; Fig 3.1Cii) and tolbutamide (n=3; Fig 3.1Dii) caused significant 
reductions in current evoked by a hyperpolarising voltage step compared to that 
observed at Run Up. No significant in cell capacitance was observed between 
the four treatment groups, indicating no significant impact of cell size on the 
normalised results (n=3-6; Veh 15.2 ± 1.1 vs Glib 13.6 ± 1.7 vs Glic 13.9 ± 1.2 vs 
Tol 17.9 ± 0.3 pF, P > 0.05, Fig 3.3A). In addition, compared to tolbutamide (50 
µM) treatment time, both vehicle (n=3-6; Veh 3.22 ± 0.45 vs Tol 1.99 ± 0.05 min, 
P = 0.004, Fig 3.3B) and glibenclamide (n=3-5; Veh 3.22 ± 0.45 vs Glib 2.15 ± 
0.14 min, P = 0.015, Fig 3.3B) were observed to be significantly lower. This 
indicated that even with shorter exposure time sulfonylureas significantly reduce 
KATP channel mediated membrane conductance compared to vehicle treatment. 
To analyse the effect of sulfonylurea treatment on KATP channel mediated 
membrane conductance, linear fitting of both Run Up and drug I-V curves (Fig 
3.1A-Dii) were performed providing normalised conductance values for each 
treatment group (Fig 3.3C). Membrane conductance after drug administration 
(Drug) was then reported as a fraction of maximal conductance (Run Up). 
Compared to vehicle controls, all three sulfonylurea treatments significantly 
attenuated membrane conductance in the absence of intracellular ATP (n=3-6; 
Veh, 0.99 ± 0.02 vs Glib, 0.32 ± 0.02 vs Glic, 0.29 ± 0.02 vs Tol, 0.48 ± 0.02 
G/Gmax, Fig 3.3D). Glibenclamide (100 nM) and gliclazide (5 µM) caused ~ 70% 
reduction in conductance, whilst tolbutamide (50 µM) treatment caused ~50% 
reduction. In addition the estimated membrane potential (when current = 0) was 




to no alteration with vehicle treatment, all three sulfonylureas significantly 
depolarised the membrane potential by ~ 5-15 mV (Fig 3.7Aii).  
Taken together, these results showed that sulfonylureas attenuated the 
maximum conductance density, observed at Run Up. Confirming that GT1-7 cells 
expressed functional KATP channels that are maximally activated by removal of 
intracellular nucleotides through pipette dialysis.  As Mg-ATP has been shown to 
modulate the effect of sulfonylureas on KATP channels, the effect of Mg-ATP (1 







Figure 3.1: Acute sulfonylurea exposure reduces currents evoked by a 
hyperpolarising voltage step in GT1-7 cells in the presence of 0 ATP.  
(Ai-Di) Pooled currents evoked using a voltage clamp protocol from -70 mV to -
120 mV (Protocol C, Table 2.4) prior to drug exposure (termed Run Up) and after 
the exposure of GT1-7 cells to either 0.1% DMSO (n=6, Veh, Ai), glibenclamide 
(n=5, 100 nM Glib, Bi), gliclazide (n=3, 5 µM Glic, Ci) or tolbutamide (n=3, 50 µM 
Tol, Di).  (Bii-Dii) Current-Voltage (I-V) relationships of steady state linear current 
density (last 10 ms) evoked using voltage clamp after the cell had been fully 
dialysed with 0 ATP (Run Up) and after the respective treatment and response 
plateaued (Drug) had been applied. Data represented as mean ± SEM. 
Quantitative analysis performed using a two-way ANOVA repeated measures 





Figure 3.2: Representative conductance traces obtained from GT1-7 cells 
treated with vehicle or sulfonylurea after full ATP washout. 
GT1-7 cells were patched using whole-cell patch clamp allowing the full dialysis 
of intracellular contents with a 0 ATP solution from the pipette. Voltage-clamp 
protocol was applied every 5 seconds from a hold of – 70 mV to a test of -120 
mV to evoke linear membrane currents. Conductance at each individual data 
point could then be quantified, allowing the visualisation of conductance changes 
during ATP washout, as well as after exposure to either Vehicle (0.1% DMSO, A) 
, glibenclamide (100 nM Glib, B), gliclazide (5 µM Glic, C) or tolbutamide (50 µM 
Tol, D). Each graph is a representative example of a single n per treatment group. 
KATP channel run-up can be defined as the length of the x-axis up until the point 











Figure 3.3: Acute sulfonylurea application attenuates maximal membrane 
conductance in the presence of 0 ATP in GT1-7 cells. 
(A) Cell capacitance (pF) values recording from GT1-7 cells prior to whole cell 
voltage clamp recordings, maximal KATP channel activation (Run-Up) and 
exposure to either 0.1% DMSO (n=6, Veh), glibenclamide (n=5, 100 nM Glib), 
gliclazide (n=3, 5 µM Glic) or tolbutamide (n=3, 50 µM Tol).. (B) Pooled length of 
drug exposure (minutes). (C) Pooled conductance densities (nS/pF) at maximum 
Run Up and after drug application in GT1-7 cells. (D) Conductance density 
observed after drug administration as a proportion of conductance density 
observed at maximal Run Up (G/Gmax). Data represented as mean ± SEM. 
Quantitative analysis performed using a One-way ANOVA with Dunnett 
correction (A, B and D). * P < 0.05 (Vs Veh), + P < 0.05 (Vs Glib), **** P < 0.001 









3.2.2 Acute sulfonylurea exposure significantly reduces KATP channel 
mediated membrane conductance in GT1-7 cells in presence of 1 
mM [Mg-ATP]i. 
Sulfonylureas are known to only be partial KATP channel antagonists in the 
absence of intracellular nucleotides (Proks et al., 2014). Therefore, to fully 
analyse the effect of the chosen sulfonylurea concentrations on the functionality 
of KATP channels expressed in GT1-7 cells, experiments were repeated in the 
presence of intracellular ATP. Mg2+-ATP was chosen due to its stimulatory 
activity, so any attenuation of the channel would be as previously described 
(Proks, de Wet, et al., 2010).   
The voltage-clamp protocol was initiated upon rupture of the membrane (Break 
In) and recordings were obtained every 5 seconds for the duration of the 
recording. This allowed the visualisation and quantification of membrane 
conductance changes throughout treatment. Once conductance values (nS/pF) 
stabilised, cells were treated with either 0.1 % DMSO (Veh; Fig 3.5A), 
glibenclamide (100 nM; Fig 3.5B), gliclazide (5 µM; Fig 3.5C) or tolbutamide (50 
µM; Fig 3.5D). Once no further change in membrane conductance was observed 
(termed Drug), treatment was allowed to wash off. Pooled current traces for all 
treatment groups were obtained for the three sweeps prior to drug administration 
(Run Up) and three sweeps once drug effect had stabilised (Fig 3.4Ai-Di). 
Compared to vehicle control treatment, all three sulfonylurea treatments caused 
a significant attenuation of the current evoked by hyperpolarising voltage steps 
compared to that observed at Run Up (Fig 3.4Aii-Dii). Currents were normalised 
to cell capacitance to standardise measurements between cells and between 




between treatment groups (Fig 3.6A). Furthermore, there was no significant 
difference between the treatment times of vehicle and glibenclamide (100 nM) or 
tolbutamide (50 µM) (Fig 3.6B). However, gliclazide (5 µM) treatment was 
observed to be significantly longer, compared to vehicle treatment (n=4-5, Veh 
1.7 ± 0.2 vs Glic 3.3 ± 0.7, P < 0.05, Fig 3.6B). 
To analyse the effect of sulfonylurea treatment on KATP channel conductance, 
linear fitting of both Run Up and Drug I-V curves (Fig 3.5A-Dii) was performed 
providing normalised conductance values for each treatment group (Fig 3.6C). 
Conductance after drug administration (Drug) was then reported as a fraction of 
maximal membrane conductance (Run Up). Compared to vehicle controls, all 
three sulfonylurea treatments significantly attenuated KATP mediated membrane 
conductance in the absence of intracellular ATP (n=4-5; Veh, 0.99 ± 0.02 vs Glib, 
0.14 ± 0.01 vs Glic, 0.15 ± 0.05 vs Tol, 0.18 ± 0.05 G/Gmax, Fig 3.6D). 
Glibenclamide (100 nM), gliclazide (5 µM) and tolbutamide (50 µM) caused ~ 80-
85% reduction in membrane conductance in the presence of 1 mM Mg-ATP, 
showing no significant difference in treatment effect between sulfonylurea 
treatment groups. In addition, utilising Ohms Law (V=IR) the estimated 
membrane potential was determined for each treatment group at Run Up and 
Drug (Fig 3.7Bi). Compared to no alteration with vehicle treatment, all three 
sulfonylureas significantly depolarised the membrane potential by ~40 mV (Fig 
3.7Aii). 
These data show that GT1-7 cells express functional KATP channels that are 
inhibited by sulfonylureas and their effect is augmented in the presence of Mg-
ATP (Fig 3.10), as has been previously described (Proks, De Wet, et al., 2010). 
In addition, these studies show that the concentrations of sulfonylureas utilised 




KATP channels. Consequently, these concentrations can be used in further 
experiments to assess the impacts of different sulfonylureas on KATP mediated 























Figure 3.4: Acute sulfonylurea reduces current evoked by hyperpolarising 
voltage step in the presence of Mg-ATP (1 mM) in GT1-7 cells. 
(Ai-Di) Pooled currents evoked using a voltage clamp protocol from -70 mV to -
120 mV (Protocol C, Table 2.4) prior to drug exposure (termed Run Up) and after 
the exposure of GT1-7 cells to either 0.1% DMSO (n=5, Veh, Ai), glibenclamide 
(n=5, 100 nM Glib, Bi), gliclazide (n=4, 5 µM Glic, Ci) or tolbutamide (n=4, 50 µM 
Tol, Di).  (Bii-Dii) Current-Voltage (I-V) relationships of steady state linear current 
density evoked using voltage clamp after the cell had been fully dialysed with 1 
mM Mg-ATP (Run Up) and after the respective treatment and response plateaued 
(Drug) had been applied. Data represented as mean ± SEM. Quantitative 
analysis performed using a two-way ANOVA repeated-measures with 





Figure 3.5: Represented conductance traces obtained from cells treated 
with sulfonylureas in the presence of Mg-ATP (1 mM) in GT1-7 cells. 
GT1-7 cells were patched using whole-cell patch clamp allowing the full dialysis 
of intracellular contents with a 1 mM Mg-ATP solution from the pipette. Voltage-
clamp protocol was applied every 5 seconds from a hold of – 70 mV to -120 mV 
to evoke linear membrane currents. Conductance at each individual data point 
could then be quantified, allowing the visualisation of conductance changes 
during ATP washout, as well as after exposure to either Vehicle (0.1% DMSO, A) 
, glibenclamide (100 nM Glib, B), gliclazide (5 µM Glic, C) or tolbutamide (50 µM 
Tol, D). Each graph is a representative example of a single n per treatment group. 
KATP channel run-up can be defined as the length of the x-axis up until the point 















Figure 3.6: Acute sulfonylurea application attenuates maximal membrane 
conductance in the presence of Mg-ATP (1 mM) in GT1-7 cells. 
(A) Cell capacitance (pF) values recording from GT1-7 cells prior to whole cell 
voltage clamp recordings, maximal KATP channel activation (Run-Up) and 
exposure to either 0.1% DMSO (n=5, Veh), glibenclamide (n=5, 100 nM Glib), 
gliclazide (n=4, 5 µM Glic) or tolbutamide (n=4, 50 µM Tol).. (B) Pooled length of 
drug exposure (minutes). (C) Pooled conductance densities (nS/pF) at maximum 
Run Up and after drug application in GT1-7 cells. (D) Conductance density 
observed after drug administration as a proportion of conductance density 
observed at maximal Run Up (G/Gmax). Data represented as mean ± SEM. 
Quantitative analysis performed using a One-way ANOVA with Dunnett 









Figure 3.7: Acute sulfonylurea exposure depolarises 
membrane potential of GT1-7 cells. 
Estimated membrane potential values were calculated 
using Ohms Law (V=IR). Current was at 0 pA and 
resistance was determined as 1/slope (1/Conductance 
(nS)). (A) Membrane potential values calculated from 
GT1-7 cells treated with sulfonylurea in the presence of 0 
ATP. (Ai)  Membrane potential values obtained at maximal 
KATP channel opening after ATP washout (Run Up) and 
after plateau of drug response (Drug) for Veh (n=6), Glib 
(n=5), Glic (n=3) and Tol (n=3). (Aii) Change in membrane 
potential observed after drug treatment. (B) Membrane 
potential values calculated from GT1-7 cells treated with 
sulfonylurea in the presence of 1 mM Mg-ATP. (Bii) 
Membrane potential values obtained at maximal KATP 
channel opening (Run Up) and after drug exposure (Drug) 
for Veh (n=5), Glib (n=5), Glic (n=4) and Tol (n=4). (Aii) 
Change in membrane potential observed after drug 
treatment. Data represented as mean ± SEM. Data 
analysed using Two-way ANOVA repeated measures with 
Bonferonni comparisons (Ai, Bi) or one way ANOVA with 
Tukey multiple comparisons (Aii, Bii). Vs Veh (** P < 0.01, 















Figure 3.8: Sulfonylurea effect is augmented by increasing [ATP]i in GT1-7 cells. 
G/Gmax values obtained after treatment of GT1-7 cells with either Vehicle (0.1% DMSO), glibenclamide (100 nM Glib), gliclazide 
(5 µM Glic) or tolbutamide (50 µM Tol) after dialysis with either 0 ATP or 1 mM Mg-ATP. Data represented as Mean ± SEM. 
Quantitative analysis performed using a two-way ANOVA with Bonferonni Multiple comparisons. ** P < 0.01, **** P < 0.0001 (0 






3.2.3 Short-term (24 hour) gliclazide exposure does not impact KATP 
mediated membrane conductance in GT1-7 cells 
In order to assess the impact of prolonged KATP channel blockade on membrane 
conductance density, the effect of 24 hours of continuous exposure of GT1-7 cells 
with either vehicle (0.1 % DMSO) or gliclazide (5 µM) was performed. Cells were 
seeded and cultured in 2.5 mM Glucose for 18-24 hours prior to the initiation of 
treatment and incubated for 24 hours prior to experimentation.  
Whole-cell patch-clamp and current clamp recordings were performed to 
investigate the effect of acute sulfonylurea application on membrane 
conductance density and membrane potential, respectively. External solution A 
(supplemented with 2.5 mM Glucose) and internal solution B were used for these 
experiments.  
Upon Break In and Run Up currents were evoked using a voltage-clamp protocol 
from -140 to -80 mV steps (Fig 3.9Ai, Aii). Compared to vehicle treated controls, 
24 hour gliclazide (5 µM) treatment caused no alteration in cell capacitance (n=6, 
Break In; 15.5 ± 1.2 vs 17.0 ± 0.5, Run Up; 16.8 ± 1.6 vs 19.6 ± 0.7 pF, Fig 3.9B) 
or evoked currents observed at Run Up (Fig 3.9C) Whilst not significant, gliclazide 
caused a slight increase in conductance density at Run Up (n=6; 1.48 ± 0.23 vs 
1.80 ± 0.24 nS/pF, Fig 3.9D), indicating a potential homeostatic regulation of KATP 
channel activity. In addition, no significant alteration in voltage activated currents 
were observed (Fig 3.9E). 
Furthermore, current clamp recordings were obtained between Break In and Run 
Up to observe ATP dialysis and its impact on the membrane potential in the two 
treatment groups (Fig 3.10A). No significant difference was observed in ATP 




membrane potential values obtained at the start (Break In) and end (Run Up) of 
the recording (Fig 3.10C).  
These data indicate that 24 hour gliclazide (5 µM) treatment does not confer any 
significant alteration on KATP channel mediated membrane conductance density 
in GT1-7 cells. However, tolbutamide (50 µM) also caused significant reductions 
in conductance density after acute exposure. Therefore, the effect of 24 hour 
tolbutamide (50 µM) on membrane conductance was next investigated. 
3.2.4 Short term (24 hour) tolbutamide exposure does not impact KATP 
channel mediated membrane conductance in GT1-7 cells 
External solution A (supplemented with 2.5 mM Glucose) and internal solution B 
(0 ATP) were used for these experiments.  
Once whole-cell had been established (Break In) and after full ATP dialysis 
through the pipette (Run Up), currents were evoked using a voltage-clamp 
protocol from -140 to -80 mV steps which were 100 milliseconds in duration and 
3 seconds apart (Fig 3.11Ai, Aii). Compared to vehicle (0.1 % DMSO) treated 
controls, 24 hour tolbutamide (50 µM) treatment caused no significant alteration 
in cell capacitance (n=8, Break In; 17.5 ± 1.2 vs 18.7 ± 0.8, Run Up; 17.4 ± 1.0 
vs 18.8 ± 1.3 pF, Fig 3.11B), indicating no effect of 24 hour treatment on cell size. 
In addition, no significant alteration was observed in evoked linear currents 
observed at Run Up (Fig 3.11C) or normalised membrane conductance at Run 
Up (n=8; 1.52 ± 0.12 vs 1.50 ± 0.20 nS/pF Fig 3.11D), suggesting no significant 
effect of treatment on KATP channel activity. No significant alterations in voltage 
activated currents, evoked by voltage steps from -80 mV to + 40 mV, and were 




Furthermore, current clamp recordings were obtained between Break In and Run 
Up to observe ATP dialysis and its impact on the membrane potential in the two 
treatment groups (Fig 3.12A). No significant difference was observed in ATP 
washout time (n=8; Veh 7.4 ± 0.2 vs Glic 7.8 ± 0.3 minutes, Fig 3.12B) or pooled 
membrane potential values obtained at the start (Break In) and end (Run Up) of 
the recording (Fig 3.12C).  
These data indicate that 24 hour tolbutamide (50 µM) treatment does not confer 










Figure 3.9: 24 hour gliclazide (5 µM) treatment causes no significant 
alteration membrane conductance of GT1-7 cells. 
(A) Using voltage clamp electrophysiology (Protocol A, Table 2.4), whole cell 
macroscopic currents were examined after the establishment of whole-cell 
configuration (termed Break In) and after the cell had been fully dialysed with 0 
ATP (termed Run Up) in cells incubated for 24 hours in the presence of either 
(Ai) Vehicle (0.1 % DMSO, Veh, n=6) or (Aii) gliclazide (5 µM, Glic, n=6). (B) Cell 
capacitance (pF) values recording prior to whole cell voltage clamp recordings at 
Break In and Run Up. (C) Current-Voltage (I-V) relationships of steady state linear 
current density evoked using voltage clamp after the cell had been fully dialysed 
with 0 ATP (Run Up) in cells pre-treated with Vehicle or gliclazide. (D) Pooled 
conductance densities (nS/pF) at maximum Run Up in GT1-7 cells pre-treated 
with Vehicle or gliclazide. (E) Current-Voltage (I-V) relationships of voltage-
activated leak-subtracted outward currents elicited using a voltage clamp at 
Break In in GT1-7 cells incubated with Veh or Glic for 24 hours. All data 
represented as mean ± SEM. Quantitative analysis performed using either a 
unpaired t-test (D) or Two-way ANOVA repeated measures with Bonferonni 





Figure 3.10: 24 hour gliclazide (5 µM) treatment causes no significant 
alteration in membrane potential after washout with 0 ATP in GT1-7 cells 
(A) Representative whole-cell current clamp recordings obtained from GT1-7s 
during dialysis with 0 ATP after pre-treatment for 24 hours with either 0.1% DMSO 
(Veh; n=6) or gliclazide (5 µM Glic, n=6). KATP channel run-up can be defined as 
the length of the x-axis. (B) Pooled duration of ATP dialysis for each treatment 
group. (C) Pooled membrane potential values obtained upon establishment of 
whole cell configuration (Break In) and after full ATP dialysis (Run Up). All data 
represented as mean ± SEM. Quantitative analysis performed using an unpaired 









Figure 3.11: 24 hour tolbutamide (50 µM) treatment causes no significant 
alteration to membrane conductance in GT1-7 cells. 
(A) Using voltage clamp electrophysiology (Protocol A, Table 2.4), whole cell 
macroscopic currents were examined after the establishment of whole-cell 
configuration (termed Break In) and after the cell had been fully dialysed with 0 
ATP (termed Run Up) in cells incubated for 24 hours in the presence of either 
(Ai) Vehicle (0.1 % DMSO, Veh, n=8) or (Aii) tolbutamide (50 µM, Tol, n=8). (B) 
Cell capacitance (pF) values recording prior to whole cell voltage clamp 
recordings at Break In and Run Up. (C) Current-Voltage (I-V) relationships of 
steady state linear current density evoked using voltage clamp after the cell had 
been fully dialysed with 0 ATP (Run Up) in cells pre-treated with Vehicle or 
tolbutamide. (D) Pooled conductance densities (nS/pF) at maximum Run Up in 
GT1-7 cells pre-treated with Vehicle or tolbutamide. (E) Current-Voltage (I-V) 
relationships of voltage-activated leak-subtracted outward currents elicited using 
a voltage clamp at Break In in GT1-7 cells incubated with Veh or Tol for 24 hours. 
All data represented as mean ± SEM. Quantitative analysis performed using 
either an unpaired t-test (D) or Two-way ANOVA repeated measures with 





Figure 3.12: 24 hour tolbutamide (50 µM) treatment causes no significant 
alteration in membrane potential after washout with 0 ATP in GT1-7 cells 
(A) Representative whole-cell current clamp recordings obtained from GT1-7s 
during dialysis with 0 ATP after incubation for 24 hours with either 0.1% DMSO 
(Veh; n=8) or tolbutamide (50 µM Tol, n=8). KATP channel run-up can be defined 
as the length of the x-axis. (B) Pooled duration of ATP dialysis for each treatment 
group. (C) Pooled membrane potential values obtained upon establishment of 
whole cell configuration (Break In) and after full ATP dialysis (Run Up). All data 
represented as mean ± SEM. Quantitative analysis performed using an unpaired 











3.2.5 Chronic (48 hour) glibenclamide (100 nM) exposure reduces 
maximal membrane conductance after drug washout in GT1-7 cells 
So far, results had indicated that the treatment of GT1-7 cells for 24 hours with 
sulfonylureas did not lead to any significant alterations in maximal KATP channel 
conductance or membrane potential after ATP washout. As such, it was decided 
to investigate the effect of longer term treatment.  
The extracellular bath solution (External solution A) contained 2.5 mM glucose 
and the electrode solution contained 135 mM KGluc with 0 ATP (Internal solution 
A).  The junction potential (JP) was calculated as -15 mV, as a result, all 
recordings have been JP corrected. GT1-7 cells were removed and placed under 
constant perfusion with NS for ~ 30 minutes prior to experiments to wash off of 
the drug. 
Upon rupture of the cell membrane (Break In) and after full ATP dialysis (Run 
Up), currents were evoked using a voltage-clamp protocol from -80 (JP: -94) to -
50 (JP:-64) mV steps which were 100 milliseconds in duration and 3 seconds 
apart (Fig 3.13Ai, Aii). 3 replicates voltage-clamp recordings were obtained for 
each time point. Compared to vehicle controls, 48 hour glibenclamide (100 nM) 
treatment was shown to cause no significant alteration in cell capacitance, 
recorded at either Break In or Run Up (n=13-15; Break In: 18.2 ± 1.0 vs 16.9 ± 
1.4, Run Up: 21.4 ± 1.5 vs 22.0 ± 2.3 pF, Fig 3.13B). However, compared to 48 
hour vehicle treatment, glibenclamide (100 nM) caused a significant reduction in 
normalised linear currents evoked by hyperpolarising voltage steps after full ATP 
dialysis (Fig 3.13C). In addition, glibenclamide (glibenclamide) was shown to 




and activation of KATP channels (n=13-15; Veh 1.00 ± 0.20 vs Glib 0.50 ± 0.08 
nS/pF, P < 0.05, Fig 3.13D).  
Furthermore, current clamp recordings were obtained between Break In and Run 
Up to observe ATP dialysis and its impact on the membrane potential in the two 
treatment groups (Fig 3.14Ai, Aii). No significant difference was observed in ATP 
washout time (n=13-15; Veh 5.3 ± 0.3 vs Glib 6.1 ± 0.4 minutes, Fig 3.14B) or 
pooled membrane potential values obtained at the end (Run Up) of the recording 
(Fig 3.14C). However, compared to vehicle treated controls, glibenclamide (100 
nM) treatment was observed to cause a significant depolarisation of GT1-7 
membrane potential observed upon Break In (n=13-15; -82.9 ± 2.9 vs -72.0 ± 3.6 
mV, P < 0.01, Fig 3.14C).  
At the time of experimentation, it was hypothesised that 15-25 minutes was 
sufficient to allow full glibenclamide wash off. However, following experiments 
indicated that this was insufficient (Fig 3.19D). Therefore, it was concluded that 
KATP channel conductance was measured in the presence of reduced 











Figure 3.13: 48 hour glibenclamide (100 nM) treatment significantly 
attenuates membrane conductance in GT1-7 cells. 
(A) Using voltage clamp electrophysiology (Protocol B, Table 2.4), whole cell 
macroscopic currents were examined after the establishment of whole-cell 
configuration (termed Break In) and after the cell had been fully dialysed with 0 
ATP (termed Run Up) in cells incubated for 48 hours with either (Ai) Vehicle (0.1 
% DMSO, Veh, n=13) or (Aii) glibenclamide (100 nM Glib, n=16). (B) Cell 
capacitance (pF) values recording prior to whole cell voltage clamp recordings at 
Break In and Run Up. (C) Current-Voltage (I-V) relationships of steady state linear 
current density evoked using voltage clamp after the cell had been fully dialysed 
with 0 ATP (Run Up) in cells pre-treated with Vehicle or glibenclamide. (D) Pooled 
conductance densities (nS/pF) at Break In and maximum Run Up in GT1-7 cells 
pre-treated with Vehicle or glibenclamide. (E) Current-Voltage (I-V) relationships 
of voltage-activated leak-subtracted outward currents elicited using a voltage 
clamp protocol at Break In in GT1-7 cells incubated for 48 hours with Veh or Glib 
(100 nM). All data represented as mean ± SEM. Quantitative analysis performed 
using an un-paired t-test (D) or Two-way ANOVA repeated measures with 





Figure 3.14: 48 hour glibenclamide (100 nM) treatment causes no alteration 
of membrane potential observed after ATP dialysis in GT1-7 cells. 
Representative whole-cell current clamp recordings obtained from GT1-7s during 
dialysis with 0 ATP after incubation for 48 hours with either (Ai) 0.1% DMSO 
(Veh; n=13) or (Aii) glibenclamide (100 nM, Glib, n=16). KATP channel run-up can 
be defined as the length of the x-axis. (B) Pooled membrane potential values 
obtained upon establishment of whole cell configuration (Break In) and after full 
ATP dialysis (Run Up). (C) Pooled duration of ATP dialysis for each treatment 
group. All data represented as mean ± SEM. Quantitative analysis performed 
using an unpaired t-test (C) or two-way ANOVA repeated measures with 










3.2.6 Chronic (48 hour) gliclazide (5 µM) exposure augments membrane 
conductance of GT1-7 cells after drug washout.  
Previous experiments suggested that 24 hour treatment of GT1-7 cells with 
gliclazide (5 µM) caused no significant alteration in KATP channel mediated 
membrane conductance. However, whilst not significant, gliclazide caused a 
modest increase in membrane conductance following drug wash off (Fig 3.9D). 
Therefore, to ascertain the effect of longer term (48 hour) treatment on membrane 
conductance, GT1-7 cells were treated with either vehicle (0.1 % DMSO) or 
gliclazide (5 µM) in 2.5 mM glucose supplemented medium for 48 hours.  
The extracellular bath solution (External solution A) contained 2.5 mM glucose 
and the electrode solution contained 135 KGluc with 0 ATP (Internal solution A). 
The junction potential (JP) was calculated as -15 mV. Therefore, all recordings 
have been JP corrected. GT1-7 cells were removed and placed under constant 
perfusion with NS for ~ 30 minutes prior to experiments to wash off of the drug, 
calculated to be viable to enable near full drug wash off (Fig 3.19D). 
Linear currents were evoked from vehicle and gliclazide treated GT1-7 cells upon 
Break In and Run Up using a voltage-clamp protocol from -140 to -80 mV, each 
step was 100 millisecond in duration and 3 seconds apart (Fig 3.15Ai, Aii). As 
was observed with 24 hour treatment, gliclazide (5 µM) treatment caused no 
significant alteration in cell capacitance compared with vehicle treated controls at 
neither Break In (n=8; Veh: 14.3 ± 1.3 vs Glic 12.6 pF, Fig 3.15B) nor Run Up 
(n=8; Veh 16.5 ± 1.5 vs Glic  13.9 ± 1.1 pF, Fig 3.15B). Interestingly however, in 
comparison with vehicle treated controls, the 48 hour treatment of GT1-7 cells 
with the KATP channel antagonist gliclazide (5 µM) increased current evoked by 




gliclazide treatment increased the maximal normalised membrane conductance 
of GT1-7 cells after full ATP dialysis by ~300% (n=8; Veh 0.68 ± 0.04 vs Glic 1.92 
± 0.33 nS/pF, P < 0.001, Fig 3.15D), indicating either increased KATP channel 
conductance or increased expression of channels.  Whilst alterations were 
observed in linear current profile and conductance, no significant alteration was 
observed in voltage activated outward current profile (Fig 3.15E).  
Current clamp recordings were obtained between Break In and Run Up to 
observe ATP dialysis and hyperpolarisation of the membrane potential (Fig 
3.16Ai, Aii). No significant difference was observed in ATP washout time (n=8; 
Veh 6.0 ± 2.0 vs Glic 5.6 ± 0.8 minutes, Fig 3.16B), indicating that incomplete or 
inconsistent ATP washout was not the cause of any alterations in membrane 
conductance observed. In addition, pooled membrane potential values obtained 
at the end (Run Up) of the recording were not significantly different in either 
treatment group (Fig 3.16C). However, compared to vehicle treated controls, 
gliclazide (5 µM) treatment was observed to cause a significant hyperpolarisation 
of GT1-7 membrane potential observed upon Break In (n=8; -79.1 ± 2.6 vs -92.1 











Figure 3.15: 48 hour 5 µM gliclazide exposure augments maximal 
membrane conductance after dialysis with 0 ATP in GT1-7 cells. 
(A) Using voltage clamp electrophysiology (Protocol A, Table 2.4), whole cell 
macroscopic currents using were examined after the establishment of whole-cell 
configuration (termed Break In) and after the cell had been fully dialysed with 0 
ATP (termed Run Up) in cells pre-treated for 48 hours with either (Ai) Vehicle (0.1 
% DMSO, Veh, n=8) or (Aii) gliclazide (5 µM, Glic, n=7). (B) Cell capacitance 
(pF) values recording prior to whole cell voltage clamp recordings at Break In and 
Run Up. (C) Current-Voltage (I-V) relationships of steady state linear current 
density evoked using voltage clamp after the cell had been fully dialysed with 0 
ATP (Run Up) in cells pre-treated with Vehicle or gliclazide. (D) Pooled 
conductance densities (nS/pF) at Break In and maximum Run Up in GT1-7 cells 
incubated for 48 hours with Veh or Glic. (E) Current-Voltage (I-V) relationships of 
voltage-activated leak-subtracted outward currents elicited using a voltage clamp 
at Break In in GT1-7 cells incubated for 48 hours with Veh or Glic (5 µM). All data 
represented as mean ± SEM. Quantitative analysis performed using Two-way 
ANOVA repeated measures with Bonferonni multiple comparisons (B, C, D, and 





Figure 3.16: 48 hour 5 µM gliclazide exposure depolarises membrane 
potential prior to full dialysis with 0 ATP in GT1-7 cells. 
Representative whole-cell current clamp recordings obtained from GT1-7s during 
dialysis with 0 ATP after incubation for 48 hours with either (Ai) Vehicle (0.1% 
DMSO, Veh, n=8) or (Aii) gliclazide (5 µM, Glic, n=7). KATP channel run-up can 
be defined as the length of the x-axis. (B) Pooled membrane potential values 
obtained upon establishment of whole cell configuration (Break In) and after full 
ATP dialysis (Run Up). (C) Pooled duration of ATP dialysis for each treatment 
group. All data represented as mean ± SEM. Quantitative analysis performed 
using an unpaired t-test (C) or two-way ANOVA repeated measures with 










3.2.7 Chronic (48 hour) tolbutamide (50 µM) exposure enhances maximal 
membrane conductance in GT1-7 cells after drug washout  
Linear currents were evoked from vehicle and tolbutamide (50 µM) treated GT1-
7 cells upon Break In and Run Up using a voltage-clamp protocol from -140 to -
80 mV, each step was 100 millisecond in duration and 3 seconds apart (Fig 
3.17Ai, Aii). No significant effect of treatment or ATP washout was observed on 
cell capacitance (Fig 3.17B), indicating that 48 hour treatment of GT1-7 cells with 
tolbutamide (50 µM) had no effect on cell size. However, tolbutamide treatment 
led to an increase in currents evoked by hyperpolarising voltage steps after full 
ATP dialysis (Fig 3.17C). Additionally, linear fitting of I-V curves showed that in 
comparison with vehicle treated controls, tolbutamide (50 µM) treatment 
augmented membrane conductance of GT1-7 cells at Run Up (n=4; 0.75 ± 0.12 
vs 1.51 ± 0.06 nS/pF, P < 0.01, Fig 3.17D). No effect of treatment was observed 
on voltage activated currents (Fig 3.17E). No significant difference was observed 
in membrane potential observed after full ATP washout between vehicle and 
tolbutamide (50 µM) treated cells (n=4, -92.2 ± 1.9 vs -93.3 ± 1.0 mV, P > 0.05, 
Fig 3.18B). Additionally, no difference was observed in the time taken for ATP 
washout between the treatment groups (n=4; Veh 10.4 ± 0.8 vs Tol 12.2 ± 0.5 
minutes, P > 0.05, Fig 3.18C), indicating that time of ATP washout had little to no 
effect on results acquired for membrane conductance density.  
Taken together, these results show that 48 hours continuous exposure of 
gliclazide (5 µM) and tolbutamide (50 µM), significantly augments linear 
membrane conductance of GT1-7 cells after ATP washout (Fig 3.15D, 3.17D). 






Figure 3.17: 48 hour tolbutamide (50 µM) exposure augments maximal 
membrane conductance after ATP dialysis in GT1-7 cells. 
(A) Using voltage clamp electrophysiology (Protocol A, Table 2.4), whole cell 
macroscopic currents were examined after the establishment of whole-cell 
configuration (termed Break In) and after the cell had been fully dialysed with 0 
ATP (termed Run Up) in cells pre-treated for 48 hours with either (Ai) Vehicle (0.1 
% DMSO, n=4) or (Aii) tolbutamide (50 µM, n=4). (B) Cell capacitance (pF) 
values recording prior to whole cell voltage clamp recordings at Break In and Run 
Up. (C) Current-Voltage (I-V) relationships of steady state linear current density 
evoked using voltage clamp after the cell had been fully dialysed with 0 ATP (Run 
Up) in cells pre-treated with Vehicle or tolbutamide. (D) Pooled conductance 
densities (nS/pF) at Break In and maximum Run Up in GT1-7 cells pre-treated 
with Vehicle or tolbutamide. (E) Current-Voltage (I-V) relationships of voltage-
activated leak-subtracted outward currents elicited using a voltage clamp at 
Break In in GT1-7 cells incubated for 48 hours with Veh or Tol (50 µM). All data 
represented as mean ± SEM. Quantitative analysis performed using Two-way 
ANOVA repeated measures with Bonferonni multiple comparisons (B, C, D, and 






Figure 3.18: 48 hour tolbutamide (50 µM) treatment causes no significant 
effect on cellular membrane potential during ATP washout in GT1-7 cells. 
Representative whole-cell current clamp recordings obtained from GT1-7s during 
dialysis with 0 ATP after incubation for 48 hours with either (Ai) Vehicle (0.1% 
DMSO, Veh, n=4) or (Aii) tolbutamide (50 µM Tol, n=4). KATP channel run-up can 
be defined as the length of the x-axis. (B) Pooled membrane potential values 
obtained upon establishment of whole cell configuration (Break In) and after full 
ATP dialysis (Run Up). (C) Pooled duration of ATP dialysis for each treatment 
group. All data represented as mean ± SEM. Quantitative analysis performed 
using an unpaired t-test (C) or two-way ANOVA repeated measures with 















Figure 3.19: Analysis of estimated wash off times for sulfonylureas in 
GT1-7 cells.  
(A-C) Representative examples of changes in conductance (nS/pF) in GT1-7 
cells using intracellular solution containing Mg-ATP (1 mM) after the initiation of 
wash off of (A) Vehicle (0.1% DMSO), (B) glibenclamide (100 nM) and (C) 
gliclazide (5 μM) after acute treatment. (D) For each cell (Veh (0.1% DMSO), n=5; 
Glib (100 nM), n=5; Glic (5 µM), n=4; Tol (50 µM), n=4) an exponential fit of the 
wash off curve was performed to establish an estimated time-point at which the 
effects of the drug would be > 95% removed, indicating near complete drug wash 
off. Mean time in minutes to reach adequate wash off is expressed above the 
bars.  Data represented as mean ± SEM. Quantitative Analysis performed using 





Sulfonylureas are an oral antidiabetic drug recommended as a second line 
treatment in patients with type 2 diabetes, most commonly prescribed after failure 
with the first line drug metformin (Christensen et al., 2016). Whilst initially 
beneficial, continuous treatment is associated with an increased risk of 
myocardial infarction and severe hypoglycaemia, compared to metformin therapy 
(Douros et al., 2018). In addition, prolonged treatment can cause secondary 
treatment failure in ~33% of patients (H. Wang et al., 2017), characterised by 
insulin secretory failure and the requirement of conjunct therapeutics to provide 
adequate glycaemic control. The impact of prolonged sulfonylurea therapy on 
insulin secretory capacity and glucose homeostasis has been previously 
described in both in vivo (Remedi & Nichols, 2008) and in vitro (Kawaki et al., 
1999; A. Takahashi et al., 2007) studies of β-cell physiology. Interestingly, 
however, continuous treatment of hypothalamic neurons with the KATP channel 
agonist NN414 (5 µM) causes a severe reduction in KATP channel activity 
(Haythorne et al., 2016), without altering channel expression (Craig Beall, 
Haythorne, et al., 2013), even after drug wash off.  Therefore, the aim of the 
current study was to investigate the impact of continuous KATP channel blockade 
with sulfonylureas in a homogenous population of glucose excited neurons. To 
do this, the mouse hypothalamic GT1-7 cell line was utilised as a model of 
glucose excited neurons and the adaptions to acute, short term and chronic 
sulfonylurea were examined in terms of electrical activity.  
GT1-7 cells have been previously shown to express Kir6.2/SUR1 containing KATP 
channels (C. Beall et al., 2012). However, it was important to confirm that KATP 
channel function could be measured “in house”, as well as characterise the 




clamp recordings were obtained from cells during dialysis with 0 ATP to 
maximally open KATP channels. Once full ATP washout had been achieved 
various sulfonylureas were applied, causing significant reductions in ATP-
sensitive K+ current (3.1). These data showed that the majority of the increase in 
current amplitude elicited by ATP washout is due to KATP channel activation in the 
absence of intracellular nucleotides (Fig 3.1-3.3). No significant differences were 
observed between the attenuation of conductance density caused by 
glibenclamide (Glib; 100 nM) and gliclazide (Glic; 5 µM). However, tolbutamide 
(Tol; 50 µM) indicted conductance attenuation was significantly lower than that 
observed with glibenclamide and gliclazide. Both glibenclamide and gliclazide 
concentrations (100 nM and 5 µM, respectively) used for these studies have been 
previously shown to cause maximal block of Kir6.2/SUR1 KATP channels 
(Gopalakrishnan et al., 2000; Lawrence et al., 2001), whereas the concentration 
of tolbutamide only elicits a ~60% reduction in KATP conductance, as has been 
previously described (Schwanstecher et al., 1994). However, in the presence of 
1 mM Mg-ATP all three caused maximal blockade of membrane conductance 
elicited by ATP dialysis, showing no significant difference between treatment 
groups (Fig 3.6). These data confirmed the effect of Mg-ATP on sulfonylureas, 
previously described for sulfonylurea-dependent KATP channel antagonism 
(Proks, de Wet, et al., 2010; Proks et al., 2014). Furthermore, these data showed 
that GT1-7 cells express functional KATP channels that can be activated by 
removal of intracellular nucleotides and blocked by sulfonylureas and that 
maximal KATP channel activation can be measured through ATP washout.  In 
addition, it showed that all three concentrations caused similar block of KATP 




inhibition. However, the roles for other intracellular factors (e.g. PIP2 and ROS) 
and metabolism (e.g. Mg-ADP) cannot be ignored.  
The impact of chronic sulfonylurea application, in particular glibenclamide, on β-
cell KATP channel function has been extensively studied and reported in the 
literature. Firstly, Takahashi et al showed that both glibenclamide (100 nM) and 
tolbutamide (300 µM) exposure for 3 days caused no significant alteration in 
single channel current or ATP-dependent inhibition of KATP channels, however, a 
significant reduction was observed in normalised peak membrane conductance 
with both treatments. These data indicate that chronic treatment reduces 
functional KATP expression in treated MIN6 β-cells (A. Takahashi et al., 2007). 
Furthermore, Kawaki et al treated MIN6 pancreatic β-cells for 14 days with 10 µM 
glibenclamide showed a significant reduction in KATP channel conductance and 
responsiveness to further pharmacological challenge, indicating either reduced 
KATP expression on reduced functionality (Kawaki et al., 1999). Taken together 
these data conclude that the chronic application of glibenclamide acts to 
significantly reduce KATP channel activity. Results from the current study are 
consistent with those reported in the literature. The incubation of GT1-7 cell for 
48 hours in euglycaemic conditions (2.5 mM glucose) with glibenclamide (100 
nM) caused a significant attenuation of maximal conductance density observed 
after drug “wash off” and ATP washout by ~ 50%. No alteration in capacitance 
values was observed before or after ATP washout, indicating no effect of chronic 
treatment on cell size or membrane surface area. Prior to experimentation, all 
cells were placed under constant perfusion for 15-20 minutes prior to recording 
to allow drug wash off and measurement of currents and conductance in the 
absence of glibenclamide. However, whilst the effects of chronic incubation with 




days) (Remedi & Nichols, 2008), the inhibition of wild type Kir6.2/SUR1 channels 
with glibenclamide (100 nM) has been previously shown to be nearly irreversible 
(Martin et al., 2017). This result is confirmed by the current study where these 
data  shown that full washout would take > 2 hours, much longer than was allowed 
in our experiments (~30 minutes). It can therefore be concluded that membrane 
conductance after chronic administration of glibenclamide was not adequately 
measured in the absence of the drug. Further experiments are required utilising 
a longer washout period to investigate the effect of chronic administration on KATP 
channel mediated membrane conductance. However, the impact of channel 
rundown must be taken into account. Furthermore, 24 hour treatment of isolated 
pancreatic islets with glibenclamide (100 nM) has been previously shown to 
greatly reduce insulin secretory responses to a maximal glibenclamide 
stimulatory concentration and glucose challenge, without impacting cellular 
insulin content (Gullo et al., 1991).  The reduction in response to further 
pharmacological challenge and reduced insulin secretory response after a 
glucose challenge indicates alterations to KATP channel functionality in response 
to change in intracellular nucleotide concentrations or by pharmacological 
inhibition, potentially due to increased basal conductance reducing the effectivity 
of the drug or intracellular nucleotides. Additionally, whilst glibenclamide has 
previously been shown to inhibit voltage dependent potassium currents in human 
cardiomyocytes (Schaffer et al., 1999), these data show no significant effect of 
48 hour glibenclamide treatment on voltage-activated outward currents, 
indicating no effect of Kv channels in GT1-7 cells.  
Glibenclamide is a potent KATP channel antagonist, possessing high binding 
affinity, binding non-specifically to the benzamido sites of both SUR1 and SUR2A, 




1999; Proks et al., 2002) However, other sulfonylureas, namely tolbutamide and 
gliclazide, bind specifically only to the sulfonylurea site of SUR1 due to their lack 
of the benzamido group and only the sulfonylurea moiety to being SUR. 
Therefore, a potential difference in effect of chronic (48 hr) treatment between 
different sulfonylureas was hypothesised. Incubation with glibenclamide (100 nM) 
for 24 hours reduces effectiveness of acute glibenclamide exposure, indicating 
alterations to KATP channel conductance (Gullo et al., 1991). Interestingly 
however, physiological concentrations of intracellular taurine have been found to 
inhibit native KATP channels (E. J. Park et al., 2004). Furthermore, intracellular 
taurine exposure enhances high affinity binding of glibenclamide, but not 
gliclazide or tolbutamide, through interactions with benzamido moiety-bind site 
on SUR (Lim et al., 2004; E. J. Park et al., 2004). These data potentially explain 
the results presented here, indicating an enhancement of high affinity binding with 
glibenclamide leading to prolonged channel inhibition. Further work is required to 
assess whether blockade of the cysteine sulfinic acid pathway, and thus taurine 
synthesis, reduces the impact of chronic glibenclamide exposure on channel 
activity.    
GT1-7 cells were treated for 24 hours with gliclazide (5 µM) and tolbutamide (50 
µM) and the effects on membrane conductance density was examined. After 24 
hour incubation, cells were placed under constant perfusion for ~30 minutes prior 
to experiments to ensure adequate wash off of the drug prior to recording, a 
timescale deemed adequate for both drugs (Fig. 3.9). Here these data show that 
the 24 hour exposure of GT1-7 cells to the sulfonylureas gliclazide (5 µM) and 
tolbutamide (50 µM) caused no significant alteration to maximum KATP mediated 
leak current conductance density. Maximum conductance density was 




to augment a sulfonylurea sensitive leak current (Haythorne et al., 2016; Shyr et 
al., 2019), proposed to be KATP mediated. In addition, no significant difference in 
cellular capacitance between treatment groups was observed, demonstrating no 
effect of treatment on membrane surface area. Tolbutamide has previously been 
shown to increase capacitance of β-cells following acute application (Mariot et 
al., 1998), due to increased insulin granule exocytosis. Therefore, whilst GT1-7 
cells are GnRH (Kim et al., 2006), 24 hour sulfonylurea treatment has no 
significant effect on cellular capacitance.  
KATP channel activity in hypothalamic neurons plays an important role in 
regulating cellular excitability and firing rate through alterations in the membrane 
potential. Increases in KATP channel activity and membrane conductance initiate 
cellular hyperpolarisation and a decrease in firing rate of glucose excited neurons 
(Fioramonti et al., 2004; Burdakov et al., 2005; C. Beall et al., 2012). 
Unsurprisingly, as no alterations in membrane conductance was observed after 
24 hours, indicating no alteration in KATP channel activation, no alteration of the 
membrane potential was observed between sulfonylurea or vehicle treated cells 
before or after ATP washout. Taken together, these data show that 24 hour 
stimulation with tolbutamide or gliclazide causes no significant alterations to KATP 
channel expression or activation by ATP withdrawal in GT1-7 cells.  
The impact of chronic (48 hour) tolbutamide (50 µM) and gliclazide (5 µM) 
treatment on maximal conductance density of GT1-7 cells was subsequently 
assessed.  As before, cells were placed under constant perfusion for ~30 minutes 
prior to experiments to ensure adequate wash off of the drug. Results confirmed 
that chronic tolbutamide (50 µM) and gliclazide (5 µM) caused a significant 
augmentation of maximal conductance density (Fig. 3.16 and 3.18, respectively), 




sulfonylurea treatment. However, no significant effect of either treatment was 
observed on membrane potential after ATP washout (Fig 3.16), demonstrating 
that whilst K+ permeability is increased through decreased resistance, maximal 
hyperpolarisation had been achieved (both were close to theoretical Ek). 
However, it is possible that treatment causes reduction in input resistance (by 
increasing KATP channel activation), which is missed when examining currents 
after the removal of intracellular nucleotides, may make further depolarization 
more difficult and thus limit the excitability of the cell.  The results presented here 
is in direct competition with previous reports suggesting that chronic sulfonylurea 
application induces a reduction in functional KATP channel expression (Kawaki et 
al., 1999; A. Takahashi et al., 2007). However, it can be hypothesised that this is 
due to incomplete washout in these previous studies in β-cells. It is important to 
understand if membrane conductance can be rescued after discontinuation of 
treatment for a period of time, as has been described previously with 
glibenclamide treatment (Remedi & Nichols, 2008). 
Regardless, the increase in membrane conductance observed with gliclazide and 
tolbutamide treatment are interesting. As this current study presents data 
containing whole-cell macroscopic currents and calculated membrane 
conductance densities, there are two possible explanations for the observed 
results. 1) Chronic sulfonylurea treatment induces alterations in single KATP 
channel function to increase conductance or open probability or 2) chronic 
sulfonylurea exposure increases surface KATP channel expression.  Both of which 
will be discussed in detail below.  
Firstly, these results suggest a potential homeostatic mechanism similar to that 
observed with the agonist NN414 (Haythorne et al., 2016), in which short term or 




able to rescue KATP channel activity, indicating a confirmation change brought 
about by NN414 exposure. It can therefore be proposed that a similar effect on 
channel activity is occurring with sulfonylurea treatment, yet in the opposite 
direction. 
Gliclazide blocks Kir6.2/SUR1 channels but not Kir6.2/SUR2A and Kir6.2/SUR2B, 
requiring the presence of SUR1 for inhibition. (Lawrence et al., 2001). The 
SUR2A-Y1206S mutation, which changes the SUR2A site to that found in SUR1, 
has been shown to confer gliclazide sensitivity to SUR2A. In addition, gliclazide 
abolishes the stimulatory effects of Mg-ADP and Mg-ATP on Kir6.2-G334D/SUR1 
channels, a mutation that renders the channel insensitive to nucleotide inhibition 
(Proks et al., 2014). Overall, these data show that gliclazide both reduces 
nucleotide binding to SUR1 and impairs the ability of nucleotide binding to 
translate into pore-opening. Tolbutamide is also specific to SUR1, requiring 
SUR1 transmembrane domains 14-16 for high affinity inhibition (Ashfield et al., 
1999). It remains to be investigated whether chronic tolbutamide and gliclazide 
binding significantly alter structure of SUR1 subunits, stabilising the open channel 
confirmation of the KATP channel. Furthermore, tolbutamide inhibitory effect is 
enhanced by intracellular nucleotides, which results from an impairment of their 
stimulatory action on SUR1 which unmasks their inhibitory effects on Kir6.2. 
Furthermore, both gliclazide and tolbutamide have been shown to induce 
conformational changes in Kir6.2 as a result of low-affinity binding to Kir6.2, rather 
than channel closure (Lippiat et al., 2002), indicating that prolonged exposure 
may induce significant alterations to channel physiology leading to the observed 
effect. 
In addition to nucleotides, a variety of other secondary mechanism act to 




nucleotide exchange factors (Epac1 and Epac2) mediate stimulatory actions of 
the second messenger cAMP in a PKA-independent manner. Epac2 has been 
previously demonstrated in vitro to interact with isolated nucleotide-binding fold-
1 (NBF-1) of the SUR1 receptor, mediating cAMP dependent inhibition of KATP 
channels through reduction in Mg-ADP dependent stimulation of KATP channel 
activity in both pancreatic β-cells (F. M. Gribble et al., 1997; G. Kang et al., 2008) 
and neurons (K. Zhao et al., 2013) . As such, sulfonylurea efficacy is reduced in 
Epac2 -/- mouse pancreatic islets, indicating that sulfonylurea sensitivity is linked 
to Epac2 activity (Leech et al., 2010). Furthermore, the sulfonylureas 
glibenclamide and tolbutamide (but not gliclazide) have also been shown to act 
cooperatively with cAMP to activate Epac2A (C. L. Zhang et al., 2009; T. 
Takahashi et al., 2013; H. Takahashi et al., 2015), stabilising its open activate 
state and increasing insulin secretion through a Rap1 dependent mechanism in 
β-cells. As such, as these data show increases in ATP sensitive membrane 
conductance with both gliclazide and tolbutamide after removal of the drug, it can 
be assumed that this increase is not due to alterations in Epac2 signalling brought 
about by chronic sulfonylurea administration. However, upregulation of Epac2 
signalling through sulfonylurea treatment may still play an important role in the 
diminished efficacy of long term sulfonylurea treatment on insulin secretion and 
glycaemic control. Further studies employing the use of primary β-cells are 
required to test this hypothesis.  
Phosphatidylinositol 4,5-biphosphate (PIP2) has been previously shown to 
simulate the activity of KATP channels by increasing channel open probability 
through increases in bursting behaviour and a decrease in ATP sensitivity 
(Baukrowitz et al., 1998; Shyng & Nichols, 1998; Rohács et al., 2003). Primarily 




concluded that PIP2 also decreases syntaxin-1A/SUR1 interactions that cause 
reductions in channel activity (T. Liang et al., 2014). Furthermore, acute PIP2 
exposure also abolished high affinity tolbutamide sensitivity (J C Koster et al., 
1999). It is therefore possible that the observed increases in membrane 
conductance observed is due to increased PIP2 association with the channel, 
increasing channel open probability and therefore conductance. An analysis of 
PIP2 expression and its association with KATP channels after chronic sulfonylurea 
treatment would have to be conducted to confirm this.  
The observed upregulation of membrane conductance induced by chronic 
gliclazide and tolbutamide may be due to alterations in single channel kinetics. 
The KATP channel is spontaneously active in the absence of ATP (termed intrinsic 
gating). It is characterised by bursts of short openings and closings separated by 
long, non-conducting inter-burst internals. With the addition of ATP, a marked 
reduction in burst duration and a prolongation of long closed states occurs. It can 
therefore be hypothesised that chronic sulfonylurea stimulation induced increase 
in membrane conductance is due to the increased conductance of single KATP 
channels, brought about by potential increases in mean open time, number of 
openings per burst or channel open probability. However, chronic glibenclamide 
treatment of MIN6 β-cells causes no significant alteration in single channel 
current or ATP responsiveness of KATP channels (Kawaki et al., 1999). As a result, 
further studies after chronic treatment are required to determine if alterations in 
single-channel kinetics are present.  
Secondly, whilst alteration in single channel conductance or gating may underlie 
the effects observed with gliclazide and tolbutamide treatment after 48 hour 
incubation, as seen with chronic NN414 induced KATP channel inactivation (Craig 




channel expression remains open. Both glibenclamide (5 µM) and tolbutamide 
(300 µM) exposure has been previously shown to rescue trafficking defects 
caused by mutations  in SUR1 and increase cell surface expression of KATP 
channels after 24 hours  (F. Yan et al., 2004; Martin et al., 2016), as well as that 
of the neonatal diabetes causing KCNJ11 mutant KATP channels (Lin et al., 2006). 
Glibenclamide promotes interactions between distal N-terminus of Kir6.2 and 
SUR1 (Devaraneni et al., 2015), demonstrating a pharmacological chaperoning 
mechanism that stabilises the heteromeric subunit interaction critical for channel 
biogenesis. Interestingly, glibenclamide (5 µM) treatment also increases the 
surface expression of WT Kir6.2/SUR1 channels by ~20% (Pratt et al., 2009) and 
the inhibition of the ubiquitin-proteasome-degradation pathway using MG-132 
increases KATP channel current density by ~ 40% (F. F. Yan et al., 2005), due to 
increased channel expression. These data suggest that sulfonylurea application 
can increase KATP expression after 24 hours exposure. However, most previous 
studies investigate the impact of sulfonylureas using saturating concentrations of 
drug, consequently lower concentrations (~IC50) may have a longer time course. 
In this study gliclazide and tolbutamide caused no significant alteration in whole-
cell membrane conductance, however, after 48 hours both caused significant 
augmentations of conductance density. Glibenclamide exposure for 48 hours 
caused significant reductions in channel conductance, however, this can be 
explained by high-affinity block and incomplete drug wash-off. Further studies are 
required to determine if 48 hour sulfonylurea exposure increases cell surface 
expression of KATP channels.  
Furthermore, the differences in effect observed after 24 and 48 hours may be in 
part due to drug concentration. As such, further work using higher concentrations 




conductance is observed after 24 hours. Assuming the increased conductance is 
indeed due to increased expression some estimations of channel expression can 
be attempted.  Wild-type Kir6.2/SUR1 single channel KATP channel conductance 
has previously been observed to be ~ 70 pS (Proks et al., 2001). It can be 
consequently hypothesised that 48 hour gliclazide (5 µM) and tolbutamide (50 
µM) treatment increases KATP channel expression from ~ 9 KATP/pF to ~ 27 
KATP/pF  and ~ 10 KATP/pF to ~ 21 KATP/pF, respectively.  
Lastly, glibenclamide has previously been shown to inhibit voltage dependent 
potassium currents in human cardiomyocytes (Schaffer et al., 1999). However, 
these data show no significant effect of short term or chronic sulfonylurea 
treatment on voltage-gated families of currents. 
Taken together these data show that chronic sulfonylurea exposure can lead to 
an increase in ATP sensitive K+ current and membrane conductance after 48 
hours treatment, providing a potential mechanism behind sulfonylurea treatment 
failure. Differences observed in the effects of tolbutamide and gliclazide, 
compared to glibenclamide, may also be attributed to their sites of interaction, or 
instead could be due to incomplete drug wash off. However, further studies 
investigating the effect of chronic sulfonylurea treatment on KATP channel 
membrane expression and single channel kinetics in GT1-7 cells must be 








Chapter 4  
Effect of KATP channel modulators on 






















Glucose metabolism is the major pathway of energy production in the mature 
brain (Mergenthaler et al., 2013). Therefore, glucose homeostasis is highly 
regulated to prevent large alterations in brain glucose concentration that may lead 
to damage. Pancreatic beta (β)-cells and hypothalamic glucose excited (GE) 
neurons are important in the detection of increases in glucose concentration in 
the periphery and brain, respectively. Working in concert with hypoglycaemia 
detecting GI neurons and pancreatic α-cells to control plasma glucose 
concentration. Cellular metabolism and KATP channel activity are intrinsically 
linked, with increases in glucose metabolism and associated ATP generation 
leading to reductions in KATP channel activity, membrane depolarisation, 
increasing insulin release or increased electrical activity in β-cells and GE 
neurons, respectively.   
In β-cells, mitochondrial generated ATP plays an important role in the regulation 
of KATP channel activity (A. Tarasov et al., 2004). However, other reports suggest 
that whilst glycolysis only produces only 20 of the ~30 net ATP molecules from 
the total oxidation of glucose, effective compartmentalisation may allow 
glycolytically derived ATP to play a more important role in fuelling processes at 
the plasma membrane, including KATP channel activity (C. Li et al., 2017). 
Consequently, whether a rise in cellular ATP, through oxidative metabolism, or 
compartmentalised ATP rise at the plasma membrane, through glycolysis, is 
more important in the regulation of KATP channel activity in glucose sensing cells 
is still unclear (Ainscow et al., 2002). Interestingly, inhibiting glycolysis in 
substantia nigra pars reticulata (SNr) neurons in the presence of alternative fuels 
lowered SNr firing to a slower sustained firing rate and the complete omission of 




SNr firing (Lutas et al., 2014). These data show that the regulation of neuronal 
activity and firing behaviour, through KATP channel modulation, may be an 
interplay between glycolysis and mitochondrial derived ATP. 
Using fluorescent biosensors, it has also been observed that stimulation of 
neuronal activity increases glucose oxidation and neuronal glycolytic output, 
above that of oxidative phosphorylation (Díaz-García et al., 2017), indicating that 
increased neuronal activity and membrane depolarisation can transiently 
increase metabolic rate. Potentially through increased ATP consumption by the 
Na+/K+ pump (Glitsch, 2001). A process that has been shown to increase KATP 
channel activity in several preparations (Kabakov, 1998; Haller et al., 2001; 
Tanner et al., 2011). 
Studies of islets isolated from the pancreas of KATP HI patients, caused by 
KCNJ11 (Kir6.2) and ABCC8 (SUR1) mutations, show significant differences in 
β-cell gene expression and fuel metabolism (C. Li et al., 2017), indicating that 
alterations in KATP channel activity may significantly impact cellular metabolism. 
In addition to increased glycolytic activity, cells also displayed an increased 
mitochondrial mass, oxygen consumption and ATP synthase expression, 
increasing production of ATP.  However, it has been suggested that these effects 
are not replicated in normal human islets after acute blockade of KATP channels 
(C. Li et al., 2017). However, acute pharmacological blockade still shows 
impaired glucose-stimulated insulin responses and increased response to amino 
acid exposure (C. Li et al., 2017). Chronic β-cell depolarisation through KATP 
channel in-activation would however lead to elevation of intracellular Ca2+ through 
membrane hyper excitability, causing potential changes in fuel sensing, fuel 




Whilst acute KATP channel inactivation through sulfonylureas has shown no effect 
on isolated islets, 18 hour exposure of clonal BRIN-BD11 β-cells to tolbutamide 
(100 µM), but not glibenclamide (1 µM), showed a significant reduction in the ratio 
of pyruvate flux through pyruvate carboxylase (PC, catalysing conversion to 
oxaloacetate)and pyruvate dehydrogenase (PDH; catalysing conversion to acetyl 
CoA), indicating a potential alteration in pyruvate cycling (Brennan et al., 2006). 
Pyruvate cycling in β-cells plays an important role in anaplerosis and associated 
increases in cellular NADP(H) content through cytosolic NADP-dependent 
isocitrate dehydrogenase (ICDc) also plays an important role in glucose-
stimulated insulin secretion (Ronnebaum et al., 2006). However, in neuronal 
populations pyruvate carboxylation may play an important role in the regeneration 
of glutamate (Hassel & Bråthe, 2000).  Pyruvate cycling can occur via the 
“pyruvate/malate cycle” which involves the PC-catalysed conversion of pyruvate 
into oxaloacetate, reduction to malate and its subsequent decarboxylation to 
pyruvate by cytosolic NADP-dependent malic enzyme (MEc). Alternatively, 
cycling may occur via the “pyruvate/citrate” or “pyruvate/isocitrate” cycles, where 
the first and last step is the same, but oxaloacetate is converted to citrate or 
isocitrate, which then leave the mitochondria for further transformation. 
Furthermore, isocitrate can be oxidized to α-ketoglutarate (αKG) via the cytosolic 
ICDc or mitochondrial NAD-dependent isocitrate dehydrogenase. A predicted 
product of all pyruvate cycling pathways is NADP(H), produced via MEc- or ICDc-
catalyzed reactions, playing an important role in glucose-stimulated insulin 
secretion. 
The aims of this chapter were to ascertain the effect of acute or chronic KATP 




controlled glucose concentrations. This will allow us to better ascertain the impact 





















4.2.1 Acute KATP channel modulator exposure significantly reduces 
ECAR in GT1-7 cells.  
Acute alteration in neuronal membrane potential, whether through the 
administration of pharmacological agents or through sustained increases in 
neuronal firing produce a large energy demand on the cell to re-establish the 
membrane potential. In addition, due to the important interaction between 
metabolism and cellular electrical excitability, it was hypothesised that the 
pharmacological modulation of KATP channels and resultant alteration in 
membrane potential and electrical excitability would alter basal metabolism, 
through alterations in calcium homeostasis (Gleichmann & Mattson, 2011). GT1-
7 cells were used to investigate this hypothesis.  
Real-time analysis of cellular respiration was investigated using the Seahorse 
XF-96 Extracellular Flux Analyser (Seahorse Bioscience, Copenhagen, 
Denmark). This allowed the concurrent measurement of Extracellular acidification 
rate (ECAR) and oxygen consumption rate (OCR) as indirect measures of 
glycolysis and mitochondrial respiration, respectively. ECAR is a measure of 
protons extrusion from the cell in the as a result of glycolysis, whilst OCR is a 
measure of dissolved oxygen concentration as a proxy for substrate flux through 
mitochondria.  
KATP channel conductance of hypothalamic neurons plateaus above 2.5 mM 
glucose (R. Wang et al., 2004) and intracellular [ATP] of hypothalamic neurons 
does not increase in response to glucose concentrations from 3 to 15 mM 
(Ainscow et al., 2002), indicating that near maximal metabolic rate and KATP 




were incubated for 1 hour prior to the assay in serum-free low buffered media 
(assay medium), supplemented with glucose (2.5 mM), L-glutamine (2 mM) and 
sodium pyruvate (2.5 mM), permitting maximal oxygen consumption. 
After short baseline period, wells were injected with KATP modulators (Vehicle 
(0.1% DMSO), glibenclamide (Glib, 100 nM), gliclazide (Glic, 5 µM), tolbutamide 
(Tol, 50 µM) and NN414 (NN, 5 µM)).  
Compared to vehicle controls, cells treated with KATP channel modulators 
displayed no significant difference in OCR (Fig 4.1Ai) compared to baseline after 
100 minutes of continuous drug exposure (n=22-28, Veh, 104.7 ± 0.3., Glib, 105.2 
± 0.4., Glic, 105.2 ± 0.6., Tol, 105.1 ± 0.2., NN, 104.1 ± 0.2 % Baseline, P > 0.05, 
Fig 4.1Aii). However, compared to vehicle controls, a significant reduction in 
basal ECAR was observed with the administration of the KATP channel 
antagonists gliclazide and tolbutamide, as well as the KATP channel agonist 
NN414 (n=22-28, 109.7 ± 0.8 vs 106.2 ± 0.8 vs 105.0 ± 1.1 vs 99.7 ± 0.8 % 
Baseline, respectively, P < 0.05, Fig 4.1Bii). Interestingly, increase in baseline 
ECAR measurements between the 1st and 3rd measurements was observed (Fig 
4.1Bi), potentially indicating a steady increase in glycolysis during the recording, 
an effects observed in vehicle and sulfonylurea treated cells (Fig 4.1). A 
significant artefact of injection was also observed, as well as significant 
differences in baseline ECAR prior to drug treatment (Table 4.1).   
Taken together, these data suggest that the acute modulation of KATP channels 






Figure 4.1: Acute Gliclazide (5 µM), Tolbutamide (50 µM) and NN414 (5 µM) 
cause significant reductions in ECAR, in GT1-7 cells  
(Ai - Bi) Analysis of alterations in OCR (Ai) and ECAR (Bi) upon the addition of 
either Vehicle (Veh, 0.1 % DMSO, n=28), Glibenclamide (Glib, 100 nM, N=2, 
n=26), Gliclazide (Glic, 5 µM, N=2, n=25), tolbutamide (Tol, 50 µM, N=2, n=22) 
or NN414 (NN, 5 µM, N=2, n=26) at the indicated time (Drug). Both OCR and 
ECAR are indicated as a percentage of the final baseline value prior to drug 
administration (3rd measurement). (Aii) Pooled OCR (% baseline) of last 3 
measurements for each treatment group (Bii) Pooled ECAR (% baseline) of last 
3 measurements for each treatment group. Assay Medium contained Glucose 
(2.5 mM), L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM). All data is a 
combination of two separate plates. Data represented as mean ± SEM of 2 
separate experiments (n) which contained multiple technical replicates (n). Data 
analysed using One-way ANOVA with Bonferonni multiple comparisons. * P < 
0.05, ** P< 0.01, *** P < 0.001.  Normalised to protein values recorded for each 


























































































Table 4.1: Normalised ECAR and OCR values recorded before and after 
exposure to pharmacological agents. 
A table representing the mean ± SEM values for ECAR (mpH/min) and OCR 
(pmol/min) values normalised to protein (µg) for baseline (Base, 3rd 
measurement), final (17th – 19th measurements) and the difference (Diff, Final 
– Baseline) recorded from cells treated with either Vehicle (Veh, 0.1 % DMSO, 
n=28), glibenclamide (Glib, 100 nM, n=26), gliclazide (Glic, 5 µM, n=25), 
tolbutamide (Tol, 50 µM, n=22) or NN414 (NN, 5 µM, n=26). Data analysis 
performed using One-way ANOVA with Bonferonni multiple comparisons. * P 




4.2.2 Acute KATP channel modulators do not affect basal metabolism in 
GT1-7 cells pre-incubated in 0.1 mM or 2.5 mM glucose. 
Pre-exposure of β-cells to sulfonylureas in the absence of exogenous fuels 
decreases glucose stimulated insulin secretion, potentially through interactions 
with key glycolytic enzymes (Arden et al., 2008), as has been described in liver 
(Kaku et al., 1995). As a result, GT1-7 cells were first pre-exposed to 
sulfonylureas under euglycaemic (2.5 mM glucose) or hypoglycaemic (0.1 mM 
glucose) conditions prior to glucose (2.5 mM) injections, to investigate the impact 
of KATP channel blockade on glucose stimulated glycolysis.  
Cells were incubated for 1 hour prior to the assay in serum-free seahorse media 
(assay medium), supplemented with glucose (0.1/ 2.5 mM), L-glutamine (2 mM) 
and sodium pyruvate (2.5 mM), ensuring maximal mitochondrial metabolism.  
After baseline measurements were taken to ascertain the basal ECAR values 
(Fig. 4.2B, 4.4B), sulfonylureas (glibenclamide (100 nM), gliclazide (5 µM) and 
tolbutamide (50 µM)) were then injected and the alterations in ECAR were 
observed. Effects of drug exposure on ECAR were calculated as the difference 
between the last recordings before glucose injection (9th measurement) 
compared to the last baseline recording (4th measurement).  
Compared to vehicle, gliclazide, caused a small but significant increase in 
glycolysis under hypoglycaemic conditions (n=18-19, -0.01 ± 0.06 vs 0.21 ± 0.07, 
P < 0.05, Δ mpH ECAR /min/μg, Fig 4.2C), compared to baseline. However, 
under euglycaemic conditions glibenclamide, gliclazide and tolbutamide 
significantly increase ECAR above that observed with vehicle (n=18, Veh 0.24 ± 
0.07  vs Glib 0.58 ± 0.06, Glic 0.52 ± 0.09, Tol 0.65 ± 0.06 Δ mpH ECAR /min/μg, 




injection on glycolysis in euglycaemic conditions (Fig 4.6A) are most probably 
due to increased glycolytic substrate availability and therefore higher basal 
glycolytic rate. 
No significant effect of sulfonylurea exposure was observed on glucose-
stimulated glycolysis after hypoglycaemic (n=18-19, Veh 10.39 ± 0.56 vs Glib 
10.24 ± 0.48, Glic 9.08 ± 0.46 and Tol 9.96 ± 0.50 Δ mpH ECAR /min/μg, P > 
0.05, Fig 4.2D) or euglycaemic incubation (n=18-19, Veh, 3.11 ± 0.18 vs Glib, 
3.09 ± 0.18., Glic, 3.32 ± 0.14., Tol, 2.91 ± 0.19 Δ mpH ECAR /min/μg, P > 0.05, 
Fig 4.4D). However, a non-significant trend towards attenuated glycolysis was 
observed with tolbutamide in both treatment conditions. Furthermore, the ΔECAR 
through glucose-stimulated glycolysis was much larger in cells incubated under 
hypoglycaemic conditions (Fig 4.6B), most probably due the much lower 
substrate availability prior to glucose administration in the aforementioned group 
and therefore their larger spare capacity.  
No significant differences between treatment groups were observed in OCR (Fig 
4.3A), at either baseline (n=18-19, P> 0.05, Fig 4.3B and 4.5B), after drug 
exposure (n=18-19, P > 0.05, Fig 4.3C and 4.5C) or after 2.5 mM glucose 






Figure 4.2: Acute gliclazide (5 µM) exposure significantly increases ECAR, 
but not response to glucose under hypoglycaemic conditions, in GT1-7 
cells.  
GT1-7 cells were pre-incubated in assay medium contained Glucose (0.1 mM)  
L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM), pH 7.4 @ 37°C.to reduce 
glycolytic rate and ATP generation. (A) ECAR (mpH/min/µg) values from GT1-7 
cells following sequential injections of Drug (Vehicle (Veh, 0.1 % DMSO, n=19), 
glibenclamide (Glib, 100 nM, n=18), gliclazide (Glic, 5 µM, n=18) and tolbutamide 
(Tol, 50 µM, n=18)) and glucose (Glu, 2.5 mM). (B) Pooled ECAR values 
calculated from the final baseline measurement (4th measurement) of each 
treatment group. (C) Pooled change (ΔECAR) in ECAR observed after drug 
administration compared to baseline. (D) Pooled ΔECAR after Glu administration. 
Data represented as mean ± SEM of 2 separate experiments (n) which contained 
multiple technical replicates (n). Data analysed using One-way ANOVA with 






Figure 4.3: Acute sulfonylurea exposure application does not impact basal 
activity metabolism or response to glucose under hypoglycaemic 
conditions, in GT1-7 cells.  
GT1-7 cells were pre-incubated in assay medium contained Glucose (0.1 mM)  
L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM), pH 7.4 @ 37°C to reduce 
glycolytic rate and ATP generation. (A) OCR (pmol/min/µg) values from GT1-7 
cells following sequential injections of Drug (Vehicle (Veh, 0.1 % DMSO, N=2, 
n=19), glibenclamide (Glib, 100 nM, N=2, n=18), gliclazide (Glic, 5 µM, N=2, 
n=18) and tolbutamide (Tol, 50 µM, N=2, n=18)) and glucose (Glu, 2.5 mM). (B) 
Pooled OCR values calculated from the final baseline measurement (4th 
measurement) of each treatment group. (C) Pooled change (ΔOCR) in ECAR 
observed after drug administration compared to baseline. (D) Pooled ΔOCR after 
Glu administration. Data represented as mean ± SEM of 2 separate experiments 
(N) which contained multiple technical replicates (n). Data analysed using One-









Figure 4.4: Acute sulfonylurea exposure significantly increases basal 
glycolysis, but not response to glucose under euglycaemic conditions, in 
GT1-7 cells.  
GT1-7 cells were pre-incubated in assay medium contained Glucose (2.5 mM)  
L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM), pH 7.4 @ 37°C to maintain 
glycolytic rate and ATP generation. (A) ECAR (mpH/min/µg) values from GT1-7 
cells following sequential injections of Drug (Vehicle (Veh, 0.1 % DMSO, N=2, 
n=20), glibenclamide (Glib, 100 nM, N=2, n=19), gliclazide (Glic, 5 µM, N=2, 
n=19) and tolbutamide (Tol, 50 µM, N=2, n=19)) and glucose (Glu, 2.5 mM). (B) 
Pooled ECAR values calculated from the final baseline measurement (4th 
measurement) of each treatment group. (C) Pooled change (ΔECAR) in ECAR 
observed after drug administration compared to baseline. (D) Pooled ΔECAR after 
Glu administration. Data represented as mean ± SEM of 2 separate experiments 
(N) which contained multiple technical replicates (n). Data analysed using One-






Figure 4.5: Acute sulfonylurea exposure application does not impact basal 
activity metabolism or response to glucose under euglycaemic conditions, 
in GT1-7 cells.  
GT1-7 cells were pre-incubated in assay medium contained Glucose (2.5 mM)  
L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM), pH 7.4 @ 37°C to maintain 
glycolytic rate and ATP generation. (A) OCR (pmol/min/µg) values from GT1-7 
cells following sequential injections of Drug (Vehicle (Veh, 0.1 % DMSO, N=2, 
n=20), glibenclamide (Glib, 100 nM, N=2, n=19), gliclazide (Glic, 5 µM, N=2, 
n=19) and tolbutamide (Tol, 50 µM, N=2, n=19)) and glucose (Glu, 2.5 mM). (B) 
Pooled OCR values calculated from the final baseline measurement (4th 
measurement) of each treatment group. (C) Pooled change (ΔOCR) in ECAR 
observed after drug administration compared to baseline. (D) Pooled ΔOCR after 
Glu administration. Data represented as mean ± SEM of 2 separate experiments 
(N) which contained multiple technical replicates (n). Data analysed using One-







Figure 4.6: Acute sulfonylurea effect is increased in euglycaemic conditions 
GT1-7 cells were incubated in assay medium containing 0.1 mM (Hypoglycaemic) or 2.5 mM (Euglycaemic) glucose prior to 
sequential exposure to Drug (Vehicle (0.1% DMSO, Veh, N=2 n=19-20), glibenclamide (100 nM, Glib, N=2 n=18), gliclazide (5 µM, 
Glic, N=2 n=18) or tolbutamide (50 µM, Tol, N=2, n=18)) and glucose (2.5 mM). (A-B) Pooled delta ECAR (ΔECAR) elicited by Drug 
injection (A) or glucose injection (B). Data represented as mean ± SEM of 2 separate experiments (N) which contained multiple 
technical replicates (n). Data analysed using a Two-way ANOVA with Bonferonni multiple comparisons. * P < 0.05, # P < 0.01 (0.1 






4.2.3 Acute gliclazide (5 µM) and tolbutamide (50 µM) exposure 
significantly increases glycolytic capacity in GT1-7. 
Previous experiments have shown conflicting results on the effect of 
sulfonylureas on ECAR of GT1-7 cells. Data has indicated both a significant 
decrease (Results 4.2.1) and a significant increase (Results 4.2.3) of ECAR upon 
acute exposure of sulfonylureas, suggesting different impacts on cellular 
glycolysis. To confirm the effect of sulfonylureas on glycolysis, a glycolysis stress 
test was conducted to GT1-7 cells following acute sulfonylurea application.  
Cells were incubated in assay media supplemented with L-glutamine (2 mM) and 
sodium pyruvate (2.5 mM), but no glucose, to slow/ shut off glycolysis, whilst 
maintaining cellular energetics through oxidative metabolism. Firstly, either 
Vehicle (0.1% DMSO), glibenclamide (100 nM), gliclazide (5 µM) or tolbutamide 
(50 µM) were injected into respective wells containing GT1-7 cells (Drug, Fig 
4.7A) to determine the acute effect of drug exposure. Next, to stimulate glycolysis, 
glucose (Glu, 2.5 mM, Fig 4.7A) was injected. Followed by Oligomycin (Oligo, 1 
µM, Fig 4.7A), an ATP synthase inhibitor, shifting energy production to glycolysis 
and revealing the maximal glycolytic capacity. Finally, 2-deoxyglucose (2-DG, 25 
mM, Fig 4.7A) was injected to inhibit glycolysis through competitive binding to 
hexokinase. Data was quantified as a percentage of the last baseline recording 
prior to drug injection (ΔECAR, 3rd Measurement, Fig 4.7A).  
To quantify the differences in glycolysis between control and sulfonylurea treated 
cells, the first measurement following the addition of glucose was compared to 
the last recording after drug injection. The delta ECAR (ΔECAR) at the first 
measurement after 2.5 mM glucose addition was reduced following sulfonylurea 




Veh 278.1 ± 22.2 vs Glib 261.7 ± 17.4 vs Glic 263.8 ± 17.9 vs Tol 255.3 ± 16.7, 
Fig 4.7C). Furthermore, ΔECAR after Oligomycin (1 µM) injection increased after 
sulfonylurea exposure compared to Vehicle control. However, similarly to the 
ΔECAR response to glucose, this effect was not significant (n=36-40, Veh 248.4 
± 14.6 vs Glib 273.8 ± 14.5 vs Glic 280.5 ± 14.2 vs 273.6 ± 14.2 % Baseline, P > 
0.05, Fig 4.7D). Interestingly, Oligomycin failed to upregulate glycolysis in GT1-7 
cells treated with Vehicle, however, glycolytic reserve (Glycolytic Capacity/ 
Glycolysis) was significantly increased following treatment with gliclazide and 
tolbutamide (n=36-40, Veh 98.19 ± 3.42, Glic 116.4 ± 4.17, Tol 115.8 ± 4.25, 
P<0.05). 2 - DG (25 mM) was then added to fully block glycolysis/inhibit ECAR.  
4.2.4 Acute sulfonylurea exposure increases spare capacity of 
oxidative metabolism in GT1-7 cells  
Glibenclamide treatment increases oxygen consumption in skeletal muscle 
(Skalska et al., 2005). Whilst the KATP channel opener diazoxide depolarises the 
mitochondrial membrane potential and decreases ATP synthesis in mitochondria 
isolated from the whole pig cortex (Busija et al., 2005). Therefore, whilst no effect 
was previously observed, a Mito stress test was used to investigate the effect of 
acute sulfonylurea treatment on mitochondrial activity. GT1-7 cells were 
incubated in serum free medium supplemented with 0.1 mM glucose. Whilst 
hypoglycaemic conditions would provide less substrate for oxidative 
phosphorylation, it was decided that the adequate KATP channel activation and 
hyperpolarisation of the membrane was required to investigate the effect of 
sulfonylurea exposure on mitochondrial activity.  
Firstly, either Vehicle (0.1% DMSO), glibenclamide (100 nM), gliclazide (5 µM) or 




Oligomycin (Oligo, 1 µM, Fig 4.8A) was injected onto the cells to inhibit ATP 
synthase and drive metabolism through the glycolysis. Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, 1 µM, Fig 4.8A) was then injected 
onto the cells to uncouple the mitochondrial membrane and disrupting the 
mitochondrial membrane potential. Therefore, electron flow through the electron 
transport chain is uninhibited and oxygen consumption reaches its maximum.  
Finally, a cocktail of Rotenone (complex I inhibitor) and Antimycin A (complex III 
inhibitor) are injected into the wells to shut down mitochondrial respiration 
(Rot/AA, 0.9 µM, Fig 4.8A). Data is presented as a percentage of the last baseline 
recording prior to drug injection (3rd Measurement, Fig 4.8A) and changes 
represented as delta OCR (ΔOCR).  
No significant of acute drug exposure observed on ΔOCR, however, a non-
significant trend toward increased ΔOCR was observed with both glibenclamide 
and tolbutamide treatment compared to vehicle (n=16-20, Veh 0.71 ± 0.26, Glib 
1.51 ± 0.24, Glic 1.16 ± 0.15, Tol 1.46 ± 0.19 ΔOCR, P > 0.05, Fig 4.8B). To quantify 
the differences in ATP production between control and sulfonylurea treated cells, 
the first measurement following the addition of oligomycin was compared to that 
recorded at baseline. The ΔOCR decrease produced by oligomycin addition, 
corresponding to OCR responsible for ATP production, was not altered by 
sulfonylurea treatment compared to control (n=16-20, Veh 39.98 ± 2.31, Glib 
33.33 ± 4.24, Glic 38.24 ± 4.01, Tol 34.35 ± 3.58 ΔOCR, P > 0.05, Fig 4.8E).  No 
significant effect of treatment was observed on proton leak (Fig 4.8F) or non-
mitochondrial oxygen consumption (Fig 4.8C), However, tolbutamide treatment 
caused a significant increase in spare respiratory capacity, compared to vehicle 







Figure 4.7: Acute sulfonylurea exposure does not impact glycolysis, in GT1-
7 cells. 
(A) ECAR measurements from GT1-7 cells incubated in assay medium contained 
L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM), pH 7.4 @ 37°C, following 
sequential injections of Drug (Vehicle (0.1% DMSO, Veh, N=4, n=36), 
glibenclamide (100 nM, Glib, N=4, n=40), gliclazide (5 µM, Glic, N=4, n=40) or 
tolbutamide (50 μM; Tol, N=4, n=40)), glucose (2.5 mM; Glu), Oligomycin (1 μM; 
Oligo) and 2-Deoxyglucose (25 mM; 2-DG). (B-D) Delta ECAR (ΔECAR) values 
calculated for: (B) Acute Drug Effect, (C) Glycolysis and (D) Glycolytic Capacity. 
All data represented as mean ± SEM of 4 separate experiments (N) which 
contained multiple technical replicates (n). Data analysis performed using One-
way ANOVA with Bonferonni’s multiple comparisons (B) or Kruskal-Wallis test 






Figure 4.8: Acute tolbutamide (50 µM) exposure significantly increases 
mitochondrial spare respiratory capacity in GT1-7 cells. 
(A) OCR measurements from GT1-7 cells incubated in assay medium contained 
L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM), pH 7.4 @ 37°C, following 
sequential injections of Drug (Vehicle (0.1% DMSO, Veh, N=2, n=20), 
glibenclamide (100 nM, Glib, N=2, n=16), gliclazide (5 μM, Glic, N=2, n=16) or 
Tolbutamide (50 μM, Tol, N=2, n=16)), Oligomycin (1 μM; Oligo), FCCP (1 μM) 
and Rotenone Antimycin A (0.9 μM; Rot/AA) in medium supplemented with 
glucose (0.1 mM). (B-F) Pooled OCR/ ΔOCR values for respiratory parameters: 
(B) Acute Response (Acute Drug Effect), (C) Non Mitochondrial: Non-
Mitochondrial respiration, (D) Spare Capacity: Spare respiratory capacity, (E) 
ATP Production and (F) Proton Leak. All data represented as a percentage of the 
last baseline (% baseline) measurement prior to drug injection (3rd 
measurement). All data represented as Mean ± SEM of 2 separate experiments 
(N) which contained multiple technical replicates (n). Data analysed using One-
way ANOVA with Bonferonni’s multiple comparisons test (B, C) or Kruskal-Wallis 




4.2.5 Acute KATP channel opener exposure causes no significant 
alterations to glycolysis in GT1-7 cells. 
Cells were incubated in assay media supplemented with L-Glutamine (2 mM) and 
sodium pyruvate (2.5 mM). 
Sequential injections of Drug (Vehicle (Veh, 0.1% DMSO), NN414 (NN, 5 µM) 
and Diazoxide (Diaz, 100 µM)), Glucose (Glu, 2.5 mM), Oligomycin (Oligo, 1 µM) 
and 2-Deoxyglucose (2-DG, 25 mM) were applied to analyse key parameters of 
glycolytic function (Fig 4.9A).   
The Δ ECAR observed after injection of either NN414 or diazoxide was not 
significantly different from that observed with vehicle treatment (n=40-42, Veh -
1.75 ± 2.25, 5 µM NN 1.05 ± 2.57, Diaz 0.82 ± 2.37 %, P> 0.05, Fig 4.9B). 
Additionally, no significant difference was observed in Δ ECAR from baseline at 
the first measurement after the injection of glucose (n=40-42, Veh  268.9 ± 17.36 
vs NN 268.0 ± 20.8 vs Diaz 272.6 ± 16.9 ΔOCR %, P > 0.05, Fig 4.9C) or the Δ 
ECAR from the first measurement after 2.5 mM glucose at the highest value 
recorded after oligomycin administration (n=40-42, Veh 273.2 ± 13.0 vs NN 267.5 
± 17.2 vs 262.5 ± 14.9, P > 0.05, Fig 4.9D). These results indicate that the 
exposure to KATP channel openers to GT1-7 cells has no impact on glycolysis or 
glycolytic capacity in GT1-7 cells. In addition, these results also confirm previous 
results that the administration of Oligomycin failed to upregulate glycolysis in 







4.2.6 Acute KATP channel openers cause no significant alterations to 
mitochondrial activity in GT1-7 cells.  
Cells were incubated in assay media supplemented with glucose (2.5 mM). 
Sequential injections of Drug (Vehicle (Veh, 0.1% DMSO), NN414 (NN, 5 µM) 
and Diazoxide (Diaz, 100 µM)), Oligomycin (Oligo, 1 µM), FCCP (1 µM) and a 
cocktail of Rotenone and Antimycin A (Rot/AA, 0.9 µM)) were applied to analyse 
key parameters of mitochondrial function (Fig 4.10A).   
Data are presented as a percentage of the last baseline recording prior to drug 
injection (3rd Measurement, Fig 4.8A) and changes thereafter represented as 
delta OCR (ΔOCR). Firstly, acute exposure of NN414 and diazoxide showed no 
significant alteration in OCR in comparison with vehicle controls (n=16-19, (Veh) 
0.2 ± 0.2, (NN) -0.2 ± 0.2, (Diaz) 0.1 ± 0.2) ΔOCR %, P>0.05, Fig 4.10A). 
Additionally, no difference was observed in the effect of oligomycin, showing no 
significant effect of acute exposure on ATP production (n=16-19, (Veh) 28.6 ± 
4.2, (NN) 32.4 ± 4.4, (Diaz) 27.10 ± 4.3 ΔOCR, Fig 4.10E). In comparison with 
vehicle controls, 100 µM Diazoxide treatment caused a decrease in the spare 
respiratory capacity, however, this effect was not significant (n=16-19, 69.1 ± 2.1 
vs 63.0 ± 2.0 ΔOCR, Fig 4.10D). No significant alterations were also observed in 
non-mitochondrial metabolism (Fig 4.10C) or proton leak (Fig 4.10F), between 
the three treatment groups. Lastly, whilst not significant, Fig 4.10B illustrates 
large differences between replicate experiments, thought to be due to differences 
in degassing prior to initiation of the assay. 
Taken together, these results indicate that the acute treatment of GT1-7 cells with 






Figure 4.9: Acute KATP channel openers do not significantly affect key 
parameters of glycolysis in GT1-7 cells. 
(A) ECAR measurements from GT1-7 cells incubated in assay medium contained 
L-Glutamine (2 mM) and Sodium Pyruvate (2.5 mM), pH 7.4 @ 37°C, following 
sequential injections of Drug (Vehicle (0.1% DMSO, Veh, N=2, n=42), NN414 (5 
µM, NN, N=2, n=40) or diazoxide (100 µM, Diaz, N=2, n=40)), glucose (2.5 mM, 
Glu), oligomycin (1 μM, Oligo) and 2-deoxyglucose (25 mM, 2-DG). (B-D) Delta 
ECAR (ΔECAR) values calculated for: (B) Acute Drug Effect, (C) Glycolysis and 
(D) Glycolytic Capacity. All data represented as mean ± SEM of 4 separate 
experiments (N) which contained multiple technical replicates (n). All data 
represented as a percentage of the last baseline (% baseline) measurement prior 
to drug injection (3rd measurement). Data analysis performed using One-way 
ANOVA with Bonferonni’s multiple comparisons (B) or Kruskal-Wallis test with 







Figure 4.10: Acute KATP channel openers cause no significant effect on key 
parameters of mitochondrial activity in GT1-7 cells. 
(A) OCR measurements from GT1-7 cells incubated in assay medium contained 
Glucose (2.5 mM), pH 7.4 @ 37°C,following sequential injections of Drug (Vehicle 
(0.1% DMSO, Veh, N=2, n=19), NN414 (5 µM, NN, N=2, n=16) or diazoxide (100 
µM, Diaz, N=2, n=16)), oligomycin (1 μM, Oligo), FCCP (1 μM) and a cocktail of 
Rotenone Antimycin A (0.9 μM, Rot/AA) in medium supplemented with glucose 
(0.1 mM). (B-F) Pooled OCR/ ΔOCR values for respiratory parameters: (B) Acute 
Response (Acute Drug Effect), (C) Non Mitochondrial: Non-Mitochondrial 
respiration, (D) Spare Capacity: Spare respiratory capacity, (E) ATP Production 
and (F) Proton Leak. All data represented as a percentage of the last baseline 
(% baseline) measurement prior to drug injection (3rd measurement). All data 
represented as mean ± SEM of 2 separate experiments (N) which contained 
multiple technical replicates (n). Data analysed using One-way ANOVA with 
Bonferonni’s multiple comparisons test (B, C) or Kruskal-Wallis test with Dunn’s 




4.2.7 Acute KATP channel modulators do not significantly alter 
mitochondrial oxygen consumption in INS-1 cells 
Previous work concluded that the acute exposure of glibenclamide to human 
islets did not cause any alterations in fuel metabolism comparable to those 
caused by in-activating KATP channel mutations (C. Li et al., 2017). Similarly, the 
impact of acute KATP channel modulators on GT1-7 cells had shown no significant 
effect on either glycolysis or oxidative phosphorylation. However, to further 
confirm these results, experiments were repeated on another KATP channel 
expressing cell type, the rat insulinoma (INS-1) 823/13 pancreatic β-cell. 
INS-1 cells were seeded at a density of 30,000 cells/ well 18 – 24 hrs prior to 
experiments in plating medium supplemented with 10 mM glucose. Cells were 
incubated for 1 hour in serum free assay medium containing either 0.5 mM for 
acute exposure to sulfonylureas (glibenclamide (100 nM), gliclazide (5 µM) and 
tolbutamide (50 µM)) or 5.0 mM glucose for acute exposure to KATP channel 
openers (NN414 (5 µM) and diazoxide (100 µM)). Metabolism and ATP 
production is a key determinant of KATP channel activity (Frances M. Ashcroft et 
al., 1984), as a result different glucose concentrations were utilised to increase 
or decrease basal KATP channel activity prior to drug exposure. This was 
performed to provide the largest response for each treatment group in regards to 
KATP channel activity.  
Firstly, wells were injected after the 3rd measurement with Drug (Vehicle (0.1% 
DMSO), sulfonylureas (Fig 4.12A) or KATP channel openers (Fig 4.12B). After 
which, cells were sequentially exposed to oligomycin (1 µM, Oligo), FCCP (1 µM) 
and Rotenone/ Antimycin A (0.9 µM, Rot/AA), to investigate the effect of acute 




All data was quantified as the change in OCR from baseline (prior to drug 
administration). Compared to vehicle controls, INS-1 cells pre-treated for 1 hour 
with 0.5 mM glucose showed no significant change in OCR upon exposure of 
cells to sulfonylureas, however a trend towards increase was observed with 
glibenclamide exposure (n = 22-29, Veh -0.27 ± 0.24, Glib 0.37 ± 0.35, ΔOCR P 
> 0.05, Fig 4.11B).  Similarly, compared to vehicle controls, glibenclamide caused 
a small non-significant increase in OCR (n=24-30, 26.7 ± 2.2 vs 32.7 ± 2.4 ΔOCR, 
P > 0.05, Fig 4.11D). No significant differences between treatment groups was 
observed in ATP production or proton leak. However, whilst no significant 
difference was observed in non-mitochondrial respiration, 1/3 of experiments had 
much larger non-mitochondrial respiration both in raw values (pmol/min/μg), as 
well as that normalised to baseline (Fig 4.11C). However, unlike sulfonylureas, 
both NN414 and diazoxide significantly reduced OCR upon acute exposure to 
INS-1 cells (n=24-30, Veh 0.22 ± 0.41, NN -2.22 ± 0.49, Diaz -1.08 ± 0.33, P > 
0.05, Fig 4.12B). Furthermore, compared to vehicle controls, NN414 causes 
significant reductions in ΔOCR related to ATP production (n=24-30, 41.3 1.5 vs 
34.8 1.8 ΔOCR, Fig. 12E). No significant effect of either NN414 or diazoxide was 
observed on non-mitochondrial respiration (Fig 4.12C) or spare respiratory 
capacity (Fig 4.11D and 4.12D). The impact of NN414 and diazoxide are 
consistent with previous reports on the effect of KATP channel openers on 
mitochondrial activity (Busija et al., 2005), albeit less pronounced. Taken 
together, these results provide evidence showing that the acute blockade (~25 
minutes) of KATP channel activity in immortalised pancreatic β-cells has no 
significant impact on mitochondrial oxygen consumption. Whilst acute KATP 
channel activation can acutely decrease oxygen consumption, as well as that 





Figure 4.11: Acute sulfonylurea exposure causes no significant alteration 
in mitochondrial activity, in INS-1 cells. 
(A) OCR (% Baseline) measurements obtained from INS-1 cells incubated in 
assay medium contained Glucose (2.5 mM), pH 7.4 @ 37°C, following sequential 
injections of Drug (Vehicle (0.1% DMSO, Veh, N=3, n=29), glibenclamide (100 
nM, Glib, N=3, n=24), gliclazide (5 μM, Glic, N=3, n=22) or Tolbutamide (50 μM, 
Tol, N=3, n=24)), Oligomycin (1 μM, Oligo) FCCP (1 μM) and Rotenone Antimycin 
A (0.9 μM, Rot/AA) in medium supplemented with glucose (0.5 mM). (B-F) Pooled 
values for the key respiratory parameters: (B) Acute Response (Acute Drug 
Effect), (C) Non Mitochondrial (Non-Mitochondrial respiration), (D) Spare 
Capacity (Spare respiratory capacity), (E) ATP Production and (F) Proton Leak.  
All data represented as a percentage of the last baseline (% baseline) 
measurement prior to drug injection (3rd measurement). Data represented as 
mean ± SEM of 3 separate experiments (N) which contained multiple technical 
replicates (n). Data analysed using Kruskal-Wallis test with Dunn’s multiple 





Figure 4.12: Acute KATP channel openers have no significant impact on 
mitochondrial activity, in INS-1 cells. 
(A) OCR measurements (% Baseline) from INS-1 cells incubated in assay 
medium contained Glucose (2.5 mM), pH 7.4 @ 37°C, following sequential 
injections of Drug (Vehicle (0.1% DMSO, Veh, N=2, n=30), NN414 (5 μM, NN, 
N=2, n=24) or Diazoxide (100 μM, Diaz, N=2, n=24)), Oligomycin (1 μM; Oligo), 
FCCP (1 μM) and a cocktail of Rotenone and Antimycin A (0.9 μM, Rot/AA) in 
medium supplemented with glucose (5.0 mM). (B-F) Pooled values for key 
respiratory parameters: (B) Acute Response (Acute Drug Effect), (C) Non-
Mitochondrial (Non-Mitochondrial respiration), (D) Spare Capacity (Spare 
respiratory capacity), (F) ATP Production and (E) Proton Leak. All data 
represented as a percentage of the last baseline (% baseline) measurement prior 
to drug injection (3rd measurement). Data represented as mean ± SEM of 2 
separate experiments (N) which contained multiple technical replicates (n). Data 
analysed using Kruskal-Wallis test with Dunns multiple comparison test (B-F). * 




4.2.8 Acute sulfonylurea exposure modulates intracellular calcium 
levels 
So far, acute KATP channel blockade showed no significant alterations in 
mitochondrial metabolism or glycolysis, as has been previously shown (C. Li et 
al., 2017). However, Increases in intracellular free-calcium exerts a deleterious 
effect on glycolysis and cellular viability (Glass-Marmor et al., 1999a). The effect 
of KATP channel modulation on intracellular calcium concentration was 
investigated using the Fura-2 AM ratiometric calcium dye (ThermoFisher 
Scientific).  
GT1-7 cells were treated for ~15 minutes with either vehicle (0.1% DMSO), 
glibenclamide (100 nM), gliclazide (5 μM), tolbutamide (50 μM), NN414 (5 μM), 
diazoxide (100 μM) and KCl (30 mM). KCl was utilised as a positive control for 
alterations in cellular excitability through changes in the membrane potential.  
Administration of sulfonylureas; glibenclamide, gliclazide and tolbutamide act to 
slightly increase baseline calcium when compared to vehicle controls. 
Conversely, exposure to the KATP channel agonist NN414 (5 µM) caused a 
reduction in intracellular calcium concentration. In addition, as was expected, the 
administration of 30 mM KCl (causing a membrane potential depolarisation of  ~ 
+60 mV) causes an increase in baseline calcium compared to vehicle. This shows 
that the observed changes with KATP channel modulation were most likely through 
alterations to cellular excitability. 
These data show that the administration of KATP channel modulators to GT1- 7 
cells acts to alter intracellular calcium concentrations through alterations in 
membrane excitability. Due to the previously observed deleterious effects of 




et al., 1999a). As well as the observed increases in basal oxygen consumption 
and mitochondrial mass observed with heterozygous expression of in activating 
KATP channel mutations (C. Li et al., 2017). It was decided to next examine the 
effects of chronic KATP channel modulation on both mitochondrial activity and 














4.2.9 Chronic (48 hour) glibenclamide (100 nM) treatment significantly 
reduces basal glycolysis in GT1-7 cells 
Acute sulfonylurea exposure had shown reduction in glycolysis, however, further 
detailed analysis of key glycolytic parameters showed no effect of acute 
Figure 4.13: Alterations in intracellular calcium concentrations observed 
after KATP channel modulation in GT1-7 cells. 
GT1-7 cells were loaded with Fura-2 AM (4 μM) and treated with either vehicle 
(0.1% DMSO, Veh, N=1, n=10), glibenclamide (100 nM; Glib, N=1, n=12), 
gliclazide (5 μM; Glic, N=1, n=12), tolbutamide (50 μM; Tol, n=1, n=12), NN414 
(5 μM; NN, N=1, n=12), Diazoxide (100 μM; Diaz, n=1, N=12) or KCl (40 mM; 
KCl, N=1, n=12) in External E (supplemented with 0.1 mM glucose) for 30 
minutes. Emission values at 510 nm were then obtained after excitation at 340 
nm and 380 nm (denoting calcium-bound Fura 2 and calcium-free Fura 2, 
respectively) every 3 s for 27 s. 340/380 ratios for each replicate (8 per treatment 
group) was then averaged. Data represented as mean ± SEM of 1 experiment 





sulfonylurea exposure on glycolysis. However, sulfonylurea administration 
increased baseline calcium of GT1-7 cells, as previously reported  (Lebrun et al., 
1982). Furthermore, neuronal stimulation has been shown to increase glucose 
metabolism, proposed to be due to increases in intracellular calcium (Bak et al., 
2009). However, raised intracellular-free calcium can exert deleterious effects on 
glucose metabolism (Glass-Marmor et al., 1999a).  Therefore, it was decided to 
investigate the impact of continuous KATP channel blockade on glycolysis and 
whether there presented any longer lasting effects once drug has washed off and 
channel is active. 
GT1-7 cells were treated for 48 hours in euglycaemic medium with either Vehicle 
(0.1% DMSO), glibenclamide (100 nM), gliclazide (5 μM) or tolbutamide (50 μM).  
Cells were incubated for 1 hour prior to analysis in assay medium with 2 mM L-
Glutamine and 2.5 mM sodium pyruvate to slow glycolysis, whilst maintaining 
cellular energetics through oxidative metabolism.  
Sequential injections of glucose (2.5 mM), oligomycin (1 µM) and 2-DG (25 mM) 
were used to calculate key glycolytic parameters.  
To quantify the differences in glycolysis between control and 48 hour sulfonylurea 
treated cells, the first measurement following the addition of glucose was 
compared to that recorded at baseline (5th Measurement – 4th measurement, Fig 
4.14A). Compared to vehicle treated controls, the ΔECAR at the first 
measurement after 2.5 mM glucose addition was significantly reduced in GT1-7 
cells treated with glibenclamide (100nM) for 48 hours (n=46, 4.3 ± 0.2 vs 3.7 ± 
0.1 mpH/min/μg, p < 0.05, Fig 4.14B). However, no effect was observed with 
either gliclazide (5 μM) or tolbutamide treatment (50 μM). Chronic sulfonylurea 




(n=46, Veh 5.4 ± 0.2 vs Glib 4.8 ± 0.2 vs Glic 5.0 ± 0.3 vs Tol 4.9 ± 0.2,  P > 0.05, 
Fig 4.14C). No significant alteration was observed in non-glycolytic acidification 
(4.14D) after 48 hour sulfonylurea treatment. These data show that 48 hour 
treatment with sulfonylureas induces alterations in glucose stimulated glycolysis, 
potentially through increased intracellular calcium. However, loss-of-function 
KATP channel mutations, decreasing channel activity, can increase basal oxygen 
consumption in β-cells (C. Li et al., 2017), indicating that a reduction in KATP 














Figure 4.14: Chronic glibenclamide (100 nM) exposure attenuates 
glycolysis in GT1-7 cells. 
(A) ECAR measurements (mpH/min/μg) were obtained from GT1-7 cells in assay 
medium containing L-Glutamine (2 mM) and Sodium pyruvate (2.5 mM),  pH 7.4 
@ 37°C, following sequential injections of glucose (2.5 mM; Glu), Oligomycin (1 
μM; Oligo) and 2-Deoxyglucose (25 mM; 2-DG) after exposure for 48 hours to 
either vehicle (0.1% DMSO, Veh, N=2, n=46), glibenclamide (100 nM, Glib, N=2, 
n=46), gliclazide (5 μM, Glic, N=2, n=46) or tolbutamide (50 μM, Tol, N=2, n=46). 
(B-D) Pooled calculated values for key glycolytic parameters: (B) Glycolysis, (C) 
Glycolytic Capacity and (D) Non-glycolytic Acidification. Data represented as 
mean ± SEM of 2 separate experiments (N) which contained multiple technical 
replicates (n). Data analysed using One-way ANOVA with Bonferonni’s multiple 











4.2.10 Chronic (48 hour) glibenclamide (100 nM) treatment increases 
spare respiratory capacity in GT1-7 cells.  
Experiments concluded that the acute modulation of KATP channel activity did not 
significantly impact mitochondrial activity in either GT1-7 cells or INS-1 cells. 
These results confirmed previous observations from isolated human islets that 
showed acute sulfonylurea application did not significantly impact fuel 
metabolism (C. Li et al., 2017). However, the effect of continuous application had 
thus far not been addressed. As a result, both GT1-7 and INS-1 cells were 
employed to investigate the effect of chronic sulfonylurea application on 
mitochondrial oxygen consumption.   
GT1-7 cells and INS-1 cells were seeded at a density of 10,000 cells/well in 
respective plating medium and incubated for 18-24 hours prior to treatment in a 
96 well seahorse plate. This concentration of cells ensured the desired 
confluency by time of experimentation. Cells were then incubated in the presence 
of Vehicle (0.1 % DMSO), glibenclamide (100 nM), gliclazide (5 µM), tolbutamide 
(50 µM) or High KCl (30 mM) for 48 hours prior to experimentation. High KCl 
treatment was employed as a positive control for the effect of continuous 
membrane depolarisation on fuel metabolism, independent of sulfonylureas or 
KATP activity. Distinguishing of the direct effect of sulfonylureas compared to their 
subsequent effect on membrane potential due to KATP channel inactivation.  After 
chronic cell treatment, cells were washed in 2X PBS to ensure the adequate 
removal of any remaining drug.  
Cells were incubated for 1 hour prior to experimentation in serum-free medium 





Whilst 48 hour glibenclamide treatment cause no significant alteration to basal 
OCR of GT1-7 cells, a trend towards increase was observed (24.9 ± 1.8 vs 31.2 
± 2.5 mpH/min/μg, Fig 4.15C).  Similarly, compared to vehicle, glibenclamide 
caused a non-significant increase in non-mitochondrial respiration (n=21-22, Veh 
9.1 ± 0.6 vs Glib 11.3 ± 0.9, P = 0.096, Fig 4.15B). In comparison with vehicle 
controls 48 hours glibenclamide treatment also significantly increased maximal 
OCR (48.73 ± 3.6 vs 63.0 ± 5.3 pmol/min/µg, P < 0.05, Fig 4.15D), ATP 
production (16.1 ± 1.2 vs 20.9 ± 1.6 pmol/min/µg, P < 0.05, Fig 4.15F) and spare 
respiratory capacity (23.9 ± 1.9 vs 31.8 ± 2.8 pmol/min/µg, P < 0.05, Fig 4.15G). 
No significant effect of membrane depolarisation with KCl was observed on any 
key parameter. Compared to vehicle controls (Fig 4.15B-G) 
In INS-1 cells, no significant impact of chronic sulfonylurea treatment was 
observed on basal OCR (Fig 4.16C), maximal OCR (Fig 4.16D), spare respiratory 
capacity (Fig 4.16G), ATP production (Fig 4.16F) or proton leak (Fig 4.16E). 
However trends towards increase were observed with glibenclamide, compared 
to control, in non-mitochondrial oxygen consumption (n=24, Veh 5.9 ± 0.5 vs Glib 
6.9 0.6 pmol/min/μg, P>0.05, Fig 4.16B).  
This may be due to treatment in hyperglycaemic conditions (~10 mM glucose), 
compared with euglycaemic conditions used in GT1-7 cell plating medium (2.5 
mM glucose). As a result, there would be limited KATP channel activity under basal 
conditions, therefore less chance for sulfonylureas or 30 mM KCl to have any 
additional impact. However, whilst results were not significant, glibenclamide 
(100 nM) treatment showed a trend towards increasing maximal OCR (n = 24, 
26.7 ± 3.9 vs 30.1 ± 4.3 pmol/min/µg, P = 0.91, Fig 4.16D), spare respiratory 
capacity (n =24, 10.5 ± 2.1 vs 12.8 ± 2.4 pmol/min/µg, P = 0.87, Fig 4.16G) and 




cells was observed to be much lower than that observed in GT1-7 cells (GT1-7 
23.9 ± 1.9 vs INS-1 10.5 ± 2.1 pmol/min/µg), potentially due to differences in 
response to FCCP observed between replicates in each cell type (GT1-7: (1st) 
27.1 ± 2.5 vs (2nd) 21.3 ± 2.43; INS-1: (1st) 1.1 ± 0.3 vs (2nd) 19.9 ± 1.4 





















Figure 4.15: Chronic glibenclamide significantly increases spare 
respiratory capacity and ATP production, in GT1-7 cells. 
(A) OCR measurements (pmol/min/µg) were obtained from GT1-7 cells in assay 
medium containing Glucose (2.5 mM),  pH 7.4 @ 37°C, following sequential 
injections Oligomycin (1 μM, Oligo), FCCP (1 μM) and a cocktail of Rotenone and 
Antimycin A (0.9 μM, Rot/AA) after 48 hours exposure, in plating medium 
supplemented with glucose (2.5 mM), to either vehicle (0.1% DMSO, Veh, N=2, 
n=22), glibenclamide (100 nM, Glib, N=2, n=21), gliclazide (5 μM, Glic, N=2, 
n=22), Tolbutamide (50 μM, Tol, N=2, n=22) or potassium chloride (30 mM, KCl, 
N=2, n=20). (B-F) Pooled values for key respiratory parameters: (B) Non 
Mitochondrial (Non-Mitochondrial respiration), (C) Basal (Basal respiration), (D) 
Maximal (Maximal respiratory capacity), (E) Proton Leak, (F) ATP Production and 
(G) Spare Capacity (Spare respiratory capacity). All data represented as mean ± 
SEM of 2 separate experiments (N) which contained multiple technical replicates 
(n). Data analysis performed using One-way ANOVA with Bonferonni’s multiple 





Figure 4.16: Chronic sulfonylurea causes no significant alteration in 
mitochondrial activity, in INS-1 cells. 
(A) OCR measurements (pmol/min/µg) were obtained from INS-1 cells in assay 
medium containing Glucose (5 mM),  pH 7.4 @ 37°C, following sequential 
injections Oligomycin (1 μM, Oligo), FCCP (1 μM) and a cocktail of Rotenone and 
Antimycin A (0.9 μM, Rot/AA) after 48 hours exposure, in plating medium 
supplemented with glucose (10 mM), to either vehicle (0.1% DMSO, Veh, N=2 
n=24), glibenclamide (100 nM, Glib, N=2, n=24), gliclazide (5 μM, Glic, N=2, 
n=23), tolbutamide (50 μM, Tol, N=2 n=23) or potassium chloride (30 mM, KCl, 
N=2 n=23). (B-F) Pooled calculated values for key respiratory parameters: (B) 
Non Mitochondrial (Non-Mitochondrial respiration), (C) Basal (Basal respiration), 
(D) Maximal (Maximal respiratory capacity), (E) Proton Leak, (F) ATP Production 
and (G) Spare Capacity (Spare respiratory capacity). All data represented as 
mean ± SEM of 2 separate experiments (N) which contained multiple technical 
replicates (n). Data analysis performed using One-way ANOVA with Bonferonni’s 






Cellular metabolism and KATP channel activity are intrinsically linked, with 
alterations in glucose metabolism and respective changes in intracellular 
nucleotide concentration acting to modulate activation of KATP channels (A. 
Tarasov et al., 2004; Craig et al., 2008a). This link is important for the regulation 
of insulin secretion from β-cells and in the control of hypothalamic neuron firing 
rate (Michael L. J. Ashford et al., 1990; Evans et al., 2004; Acosta-Martínez & 
Levine, 2007). Therefore, any mutations that impact KATP channel activity in CNS 
centres can have downstream effects on whole-body glycaemic control. In mouse 
models of Kir6.2 gain-of-function mutations induced neonatal diabetes, insulin 
secretion and glycaemic control is severely diminished, leading to 
hyperglycaemia (J C Koster et al., 2000). Acute hyperglycaemia caused marked 
increases in β-cell carbohydrate metabolism and glucose stimulated ATP 
production. (Brereton et al., 2016), an effect reversed by culture in low glucose 
or low glucose plus gliclazide. Furthermore, in mouse and human islets 
expressing loss-of-function mutation (in-activating) KATP channels, fuel 
responsiveness has been shown to shift from glucose to amino acids, potentially 
due to elevated [Ca]2+ (C. Li et al., 2017). In addition, islets expressing KATP 
inactivating mutations have increased basal rate of oxygen consumption and 
mitochondrial density compared to healthy controls (C. Li et al., 2017).  
Pancreatic β-cell specific expression of KATP channels containing the V59M 
activating mutation display significant dysregulation of major metabolic pathways. 
However, chronic culture of INS-1 β-cells in hyperglycaemic conditions also 
induces reduction in mitochondrial metabolism and ATP synthesis (Haythorne et 




modulate cellular metabolism. However, whether modulation of KATP channel 
function can modulate cellular metabolism directly is unclear. 
Acute exposure to KATP channel modulators causes no significant 
alterations to glycolysis. 
Action potential firing frequency of glucose sensing neurons of the ventromedial 
hypothalamus can be increased by tolbutamide (200 µM), even in euglycaemic 
conditions (Song & Routh, 2005). Additionally, electrical neuronal stimulation 
causes transient increases in cytosolic NADH:NAD+ and glycolytic rate in 
individual neurons (Díaz-García et al., 2017), suggesting that acute sulfonylurea 
application can increase glycolytic rate of GT1-7 cells through modulation of 
cellular excitability. Furthermore, in cardiomyocytes KATP channels have been 
found to physically associate with various glycolytic enzymes, in which enzymatic 
activity of adolase and pyruvate kinase functionally modulate KATP channels 
(Hong et al., 2011a).  In addition, in SH-SY5Y the regulation of pyruvate kinase 
activity acts to directly reduce KATP channel conductance (Mele et al., 2012). 
However, whether this is due to a direct interaction or reduced ATP generation is 
not yet known. These data show that KATP channels form a complex with glycolytic 
enzymes in multiple cells types, potentially facilitating glucose metabolism and 
KATP channel inhibition. Whether the modulation of KATP channels affects 
enzymatic function or localisation is the role of future studies.  
It was found that the acute administration of sub-maximal KATP channel 
antagonists’ glibenclamide (100 nM), gliclazide (5 μM) and tolbutamide (50 μM) 
under euglycaemic conditions significantly increased basal glycolysis in GT1-7 
cells (~5% > baseline), an effect that is diminished under hypoglycaemic 




and therefore glycolytic flux in hypoglycaemic states, reducing ability for 
upregulation of glycolysis to be visualised. The exposure to rat myocardium to 
tolbutamide in euglycaemic conditions significantly increases glycolysis through 
activation of phosphofructokinase (Kramer et al., 1983), increasing glycolytic flux. 
However, no significant alteration in glucose stimulated glycolysis after 1 hour pre 
incubation with 0.1 mM or 2.5 mM glucose was observed, indicating that whilst 
sulfonylurea application may modestly increase glycolysis upon acute exposure, 
that this does not impact glucose stimulated or maximal glycolytic flux.  
Key parameters of glycolysis are assessed through the ECAR, a measurement 
of the acidification of the medium as a proxy for glycolytic output. This means that 
changes to pH, brought about through injections, can skew interpretations of the 
data. Previous work has described that sulfonylureas are weak acids, Gliclazide 
(5.8 pKa), Tolbutamide (5.43 pKa) and Glibenclamide (5.3 pKa) (Newton & Kluza, 
1978; Jondhale et al., 2012). Therefore, administration of medium without re-
establishing a correct pH would lead to a significant but small decrease in pH of 
the culture medium, represented as a small but significant increase in ECAR. 
However, whilst improbable, the potential direct effect of sulfonylureas cannot be 
ignored.   
KATP channel agonist exposure decreases mitochondrial activity in β-cells 
but not neurons.  
Acute KATP channel blockade in healthy human islets showed no significant 
impact on β-cell gene expression or fuel metabolism (C. Li et al., 2017). However, 
in SUR1 -/- islets, lacking functional KATP channel expression, the GABA shunt, 
requiring glucose metabolism, is decreased by ~75%, most probably due to 




synthesis (C. Li et al., 2008). This is coupled with an elevation in glucose 
oxidation and pyruvate cycling in low glucose conditions (C. Li et al., 2008). The 
GABA shunt is a closed-loop process with the dual purpose of producing and 
conserving the supply of GABA, as well as channelling L-glutamate into the TCA 
cycle. The first step is the transamination of α-ketoglutarate by GABA α-
oxoglutrate transaminase into L-glutamic acid. Glutamic acid decarboxylase 
(GAD) catalyses the decarboxylation of L-glutamic acid to form GABA, only 
appearing to be expressed in cells that use GABA as a neurotransmitter, such as 
GABAergic neurons. Once released into the synaptic cleft, GABA taken back up 
into nerve terminals is re-cycled, however, GABA in glia (e.g. astrocytes) is 
metabolised to succinic semialdehyde by GABA transaminase (GABA-T). This 
can then be oxidised by succinic semi-aldehyde dehydroganse (SSADH) into 
succinic acid where is can re-enter the TCA cycle, closing the loop. Ultimately, 
GABA can be recovered through conversion in glia to L-glutamine, transfer back 
to neurons where it is converted to glutamate which re-enters the GABA shunt 
(glutamate-glutamine shuttling, for a review see here (Hertz, 2013)). 
Furthermore, unlike in adult brain, in islet β-cells, GABA produces membrane 
depolarisation and Ca2+ influx leading to PI3K/ Akt-dependent growth and survival 
pathway (Soltani et al., 2011). Interestingly, GT1-7 cells also express functional 
GABAA receptors with GABA inducing dose dependent membrane depolarisation 
and increased calcium oscillations (Mellon et al., 1990; T. G. Hales et al., 1992; 
Tim G. Hales et al., 1994; C. Zhang et al., 2007), similar to that observed in β-
cells. Furthermore, high glucose conditions decrease both content and release of 
islet GABA through increased GABA catabolism and entry into the Krebs cycle 
through the GABA shunt. This leads to an increase in ATP and ATP/ADP ratio, 




et al., 2010). Therefore, reduction of KATP channel expression or activity in β-cells, 
and potentially GnRH neurons (such as GT1-7 cells) may negatively impact cell 
mass and function. Tolbutamide has been shown to decrease pyruvate flux 
through PC, indicating a potential deleterious effect on pyruvate cycling (Brennan 
et al., 2006). However, as these data show no evidence, in INS-1 or GT1-7 cells, 
that sulfonylureas significantly impact mitochondrial oxygen consumption or 
glycolysis. However, impacts on insulin/ transmitter release or anaplerosis 
mechanisms requires further investigation.  
Diazoxide (KATP agonist) has been shown to  reduce the mitochondrial membrane 
potential and therefore ATP synthesis in mitochondria isolated from the whole pig 
cortex (Busija et al., 2005), an effect inhibited with glibenclamide. In addition, 
diazoxide (0.1 – 1 mM) significantly decreases the mitochondrial membrane 
potential and ATP production of isolated β-cell mitochondria (Grimmsmann & 
Rustenbeck, 1998). It is shown in this current study that NN414 exposure caused 
significant reductions in basal OCR and ATP production linked oxygen 
consumption in INS-1 β-cells, as has been shown previously with other KATP 
channel openers (Busija et al., 2005). However, whilst diazoxide also produced 
an acute reduction of oxygen consumption in INS-1 cells, no impact was 
observed on any other parameter, unlike its effect observed in cardiac cells 
(Holmuhamedov et al., 1999; Riess et al., 2008).  
Diazoxide and its analogues inhibit complex II of the electron transport chain, 
reducing mitochondrial oxygen consumption (Riess et al., 2008). Potentially 
explain the observed effects. However, NN414 activates KATP channels with a 
much higher potency than diazoxide (Dabrowski et al., 2003), indicating the 




Are the effects observed due to MitoKATP modulation? 
MitoKATP channels have been proposed in both skeletal and cardiac tissue, aiding 
preconditioning to ischemia and hypoxia through modulation of the mitochondrial 
membrane potential (Mironova et al., 2004). Glibenclamide exposure causes 
mitochondrial swelling, increased mitochondrial membrane potential and 
increased respiratory rate in skeletal muscle (Skalska et al., 2005). However, both 
gliclazide and tolbutamide have no effect (Sato et al., 2006), potentially explaining 
the lack of effect observed after chronic treatment in GT1-7 cells. In addition, in 
intact cardiac myocytes, KATP channel opener causes mitochondrial membrane 
depolarisation/decrease (Holmuhamedov et al., 1999). Further to its role in 
muscle, MitoKATP activation has been proposed to trigger for the development of 
ischemic tolerance in the brain (Horiguchi et al., 2003). Pre-treatment with 
mitoKATP openers significantly reduces infarct volume and protects against 
neuronal death in rat venous ischemia (Nakagawa et al., 2005), as well as 
reduces neuronal damage after transient focal cerebral ischemia (Mayanagi et 
al., 2007). Whilst, in these same studies, inactivation of mitoKATP, using 
sulfonylureas, augment the effects of ischemia and increases neuronal damage. 
These data indicate the presence of a mitochondrial-expressed KATP channels 
that play an important role in neuronal protection under ischemic or hypoxic 
conditions. As previously mentioned, diazoxide reduces the mitochondrial 
membrane potential and therefore ATP synthesis in mitochondria isolated from 
the whole pig cortex (Busija et al., 2005), an affect blocked by glibenclamide 
application. However, it can be assumed that due to the heterogeneity of the 
brain, including neurons, astrocytes, oligodendrocytes and microglia, that 
mitoKATP containing mitochondria may not be derived from neurons but may 




has confirmed the presence of mitoKATP in astrocytes (J. Wang et al., 2013), 
whilst little to no evidence suggests their presence in neurons. In addition, several 
laboratories have questioned the existence of the mitoKATP, a viewpoint 
summarized in (Garlid & Halestrap, 2012). 
Interestingly, as no significant effect of sulfonylureas on OCR was observed, 
suggests that either they have no effect (Riess et al., 2008) or that these channels 
may remain closed at rest, much like cardiac mKATP channels. This is supported 
by the attenuation of mitochondrial oxygen consumption upon acute application 
of KATP channel openers to INS-1, but not GT1-7 cells, potentially through 
mitoKATP channel activation.  
Much more work is required to unpick this hypothesis, potentially investigating 
the effect of acute KATP channel modulation on mitochondrial membrane potential 
of isolated mitochondria from primary β-cells and hypothalamic GE neurons.  
Chronic KATP channel antagonist exposure potentiates oxygen 
consumption in GT1-7 cells 
Chronic NN414 application significantly attenuates KATP channel conductance in 
GT1-7 neurons. However, no significant effect is observed on glucose 
metabolism in treated cells. Chronic exposure to glibenclamide has been shown 
to significantly increase intracellular calcium concentration (Kawaki et al., 1999). 
Increases in cytosolic calcium in β-cells has been shown to potentiate oxidative 
metabolism (Wiederkehr & Wollheim, 2008). Furthermore, attenuated maximal 
glycolysis or glycolytic reserve has been hypothesised with increases in 
intracellular free-calcium brought about by sulfonylureas exposure (Glass-
Marmor et al., 1999a).  Furthermore, the functional inactivation of KATP channels 




mitochondrial mass in β-cells, potentially through increases in calcium influx. 
However, if these changes are the direct effect of the mutation or the downstream 
consequence of hyperinsulinemia are not certain (C. Li et al., 2017). In contrast, 
it is shown here that chronic KATP channel antagonism caused no significant 
alteration in INS-1 cell mitochondrial activity treated in euglycaemic conditions, 
confirming that the pharmacological blockade of KATP channels has no impact on 
mitochondrial respiration of pancreatic β-cells (C. Li et al., 2017).  
However, in hypothalamic GT1-7 cells a significant increase in maximal 
respiration is observed, as well as increases in ATP production in cells treated 
for 48 hours with glibenclamide (100 nM). In addition, glibenclamide treatment 
also significantly attenuated the glycolytic response to glucose (2.5 mM) 
exposure. Administration of glibenclamide increases action potential firing in 
dentate granule neurons, indicating that acute KATP channel blockade even in 
cells with a low basal KATP channel activity (MartÍnez-François et al., 2018). 24 
hour exposure of cardiac cells to glibenclamide impairs oxygen consumption and 
ATP synthase activity through inhibition of mitochondrial complexes I, II and III 
(Salani et al., 2017). In addition, previous work has shown that chronic 
glibenclamide (100 nM) exposure decreases membrane conductance density in 
GT1-7 cells by ~50% (Chapter 3), hypothesised to increase membrane 
excitability and calcium influx. Mitochondrial calcium accumulation increases ATP 
synthesis in the mitochondria, through depolarisation of the mitochondrial 
membrane potential (Jouaville et al., 1999). In addition, increases in intracellular 
free-calcium exerts a deleterious effect on glycolysis and cellular viability (Glass-
Marmor et al., 1999a). Furthermore, depolarisation of the membrane potential 
with sulfonylureas in the absence of exogenous fuels, such as glucose, has been 




administration (Schulze et al., 2017). It can therefore be concluded based on 
these findings that chronic glibenclamide exposure increases mitochondrial ATP 
synthesis, whilst reducing glucose oxidation through glycolysis, potentially as a 
consequence of increased intracellular calcium (Kawaki et al., 1999). 
Furthermore, glibenclamide exposure causes mitochondrial swelling, decreased 
mitochondrial membrane potential and increased respiratory rate in skeletal 
muscle (Skalska et al., 2005), an effect not observed with either gliclazide and 
tolbutamide (Sato et al., 2006), potentially aiding to explain the differences 
observed between sulfonylureas.  
Data presented in chapter 3 also shows that gliclazide and tolbutamide, but not 
glibenclamide acts to significantly increase KATP channel conductance after drug 
wash-off. However, this is shown to be due to the high-binding affinity of 
glibenclamide and continued presence during the recordings. This therefore 
suggests that the continuous glibenclamide application in GT1-7 cells during the 
assay acts to significantly alter mitochondrial oxygen consumption and inhibit 
glycolysis, potentially through increased membrane excitability and raised 
intracellular calcium. 
Impact of raised intracellular calcium  
Our preliminary data shows that the acute exposure of sulfonylureas, or direct 
membrane potential depolarisation with KCl acts to increase intracellular calcium 
of GT1-7 cells. Whist the administration of KATP channel openers decrease 
intracellular calcium. These data confirm that modulation of KATP channel activity 
can significantly alter intracellular calcium concentration (Henquin, 2000), most 
probably through KATP-dependent alterations in membrane excitability. However, 




intracellular calcium through release from intracellular stores in β-cells 
(Grimmsmann & Rustenbeck, 1998), this is deemed not to play a role here due 
to the much lower concentration and low effect of much higher concentrations. 
Furthermore, chronic glibenclamide (100 nM) treatment in β-cells significantly 
increases cellular calcium concentration even after drug wash off.  
Interestingly, increases in cytosolic calcium in β-cells has been shown to 
potentiate oxidative metabolism (Wiederkehr & Wollheim, 2008). In addition, 
functional inactivation of KATP channels in pancreatic islets has been shown to 
produce increases in basal mitochondrial respiration and increases in 
mitochondrial mass in β-cells. However, if these changes are the direct effect of 
the mutation or the downstream consequence of hyperinsulinemia are not certain 
(C. Li et al., 2017). In addition, in a mouse model of neonatal diabetes with 
hyperactive KATP channels, increased glycogen accumulation and increased 
apoptosis of β-cells were observed (Brereton et al., 2016), however, this was 
produced in part by hyperglycaemia, rather than a direct effect of the KATP 
mutation on cellular metabolism. However, it is shown here that chronic KATP 
channel antagonism caused no significant alteration in INS-1 cell mitochondrial 
activity, confirming that the pharmacological blockade of KATP channels has no 
impact on mitochondrial respiration of pancreatic β-cells (C. Li et al., 2017). 
However, significant increases in ATP production and maximal respiration are 
observed in GT1-7 cells chronically treated with glibenclamide. Potentially 
highlighting different responses between these two cell types.  
Glibenclamide exposure has also increases ROS production through the PKC 
dependent activation of NAD(P)H oxidase in MIN6 β-cells, causing loss of 
mitochondrial membrane potential and reduction in ATP production (Tsubouchi 




abolishes the increase in NADPH/ NADP+ ratio upon glucose stimulation in 
mouse pancreatic islets, potentially due to mild mitochondrial depolarisation and 
reduction in oxidative phosphorylation (Panten & Rustenbeck, 2008).  These 
results suggest that chronic sulfonylurea incubation should diminish, not enhance 
mitochondrial activity. However, in these and other studies of the effects of 
sulfonylureas on mitochondria, much higher concentrations are applied than are 
used in the current study, potentially amplifying toxic rather than beneficial effects 
of sulfonylurea exposure. 
KATP channel inactivation has been shown to increase amino acid usage as 
metabolic substrate for oxidative metabolism above that of glucose (C. Li et al., 
2017). KATP channel inactivation and resultant continuous membrane 
depolarisation would augment ATP consumption, requiring additional substrates 
to maintain the high rates of oxidative metabolism. This may therefore explain 
results observed herein, in which chronic KATP channel inactivation and 
membrane depolarisation may increase usage of additional substrates to 
increase oxygen consumption. Sulfonylureas also significantly inhibit the 
myocardial CPT-1 isoform (CPT-1b; (G. A. Cook, 1987)), however, its effect on 
other isoforms have yet to be examined. If similar, it would suggest that 
sulfonylureas may limit fatty acid metabolism in treated cells through reduced 
fatty acid uptake into mitochondria. Further work is required to investigate if 
chronic glibenclamide exposure (or KATP channel antagonism) alters fuel 
selectivity of treated cells.   
Differences between INS-1 and GT1-7 cell responses  
The reasons for the cell type differences in the impact of chronic sulfonylurea 




ATP production or spare capacity were observed in INS-1 cells, they followed the 
same trends as that observed GT1-7 cells. In addition, under euglycaemic 
conditions vehicle treated GT1-7 cells have a significantly higher basal and ATP 
production linked oxygen consumption and per µg protein compared to INS-1 
cells. However, no difference is observed in their coupling efficiency, indicating a 
similar coupling of oxidation to phosphorylation in both cell types. This data 
indicates that whilst these two cell types are similar, GT1-7 cells are much more 
metabolically active than INS-1 cells under basal conditions, as to be expected 
from a neuronal cell due to increased Na+/K+ ATPase activity under euglycaemic 
conditions. Furthermore, whilst the same concentrations of oligomycin, FCCP 
and Rot/AA were used for both cell types to reduce variability between 
experiments when assessing mitochondrial function, a titration of drug 
concentration is required prior to further experiments to establish if 
concentrations used here are achieving maximal results.  It is also important to 
consider that GT1-7 cells and INS-1 cells are derived from mouse and rat, 
respectively. Whilst both rodent cells therefore share many similarities, there are 
isoform expression differences observed between the two species (Arden et al., 
2008) which may alter the impact of particular treatments in ways that are not 
immediately apparent. In addition, care must be taken in the extrapolation of 
results observed in mouse and rat cells to hypothesised outcomes in human.  
Overall in this chapter it is concluded that acute KATP channel modulator exposure 
has little to no significant impact on cellular metabolism. However, interestingly 
chronic exposure with glibenclamide for 48 hours causes significant alterations 
to both glucose stimulated increases in glycolysis and oxygen consumption 




this is due to KATP channel inactivation or direct impacts of glibenclamide on 




Chapter 5  
Impact of memantine exposure on 































3,5 –Dimethyl-1-adamantanamine hydrochloride (memantine) is most commonly 
known as potent moderate affinity, non-competitive antagonist of N-methyl-D-
Aspartate (NMDA) receptor channels (Bormann, 1989; H. S. Chen & Lipton, 
1997). Its inhibitory effects on NMDA receptors are well described, shown to 
display both voltage dependence and fast kinetics, as well as modulation by Mg2+ 
concentration (Kotermanski & Johnson, 2009; Glasgow, 2017). As such, 
memantine is a common therapeutic agent used for the treatment of moderate to 
severe Alzheimer’s disease (Reisberg et al., 2003), in which it has shown to 
improve cognitive function and reducing behavioural disturbances (Kishi et al., 
2017). However, there is now an accumulating body of evidence in the literature 
that memantine may not be entirely selective for the NMDA receptor.  
Whilst NMDA receptors comprise the main target of memantine (EC50 ~ 5-12 µM), 
other mechanisms of action have been reported in the literature. These include 
reduced action potential firing in cultured neurons (Netzer & Bigalke, 1990), 
reduced release of prolactin from anterior pituitary cells through high affinity 
interactions with D2 High receptors (Seeman et al., 2008) and increasing mean 
closed time of transfected Kir2.1 channels in RAW 264.7 cells (Tsai et al., 2013). 
In addition, memantine (10 nM) pre-treatment has been shown to inhibit the 
induction of dynamic allodynia in spare nerve injury, an effect tightly correlated 
with the blockade of microglial Kir2.1 and subsequent microglial activation (Y. 
Chen et al., 2019). However, in the interest of this chapter, evidence suggests 
that memantine may also interact with, and reduce the conductance of ATP-
sensitive potassium (KATP) channels. memantine application (30 µM and 100 µM)  
increases the spontaneous firing rate of midbrain slice dopaminergic neurons, an 




was prevented in neurons dialysed with high concentrations of ATP. Additionally, 
more recent reports showed that 10 nM memantine exposure caused significant 
reductions in transfected Kir6.1/SUR1 and Kir6.2/SUR1 KATP channel 
conductance, as well as, pinacidil (KATP channel agonist) sensitive enhancements 
of long-term potentiation and CAMKII activity in APP23 mouse hippocampus (S. 
Moriguchi et al., 2016). Conversely, memantine (1 µM) has also been shown to 
have no significant effect on pancreatic KATP channel (Kir6.2/SUR1) current, or 
insulin secretion in response to increased glucose concentrations in isolated 
islets (Imai et al., 2018). Whilst the literature on the effect of memantine on KATP 
channels is minimal, these studies present a wide variety of effective and 
ineffective concentrations. Both 10 nM and 100 µM memantine have been shown 
to significantly reduce KATP channel current by ~50%, whereas, 1 µM memantine 
was also shown to have no effect on pancreatic KATP channel mediated current 
or downstream mechanisms. Therefore, the effect of memantine on KATP 
channels is still unclear.  
Neonatal diabetes caused by gain-of-function KCNJ11 mutations, causes 
permanent diabetes due to reduced insulin secretion from pancreatic β-cells 
(Gloyn et al., 2004). In addition, due to its widespread expression throughout the 
CNS (Karschin et al., 1997), in severe impairment of normal channel activity leads 
to reductions in brain development, memory deficits and cognitive impairment 
(Gloyn et al., 2006), a condition known as Developmental delay and Epilepsy in 
Neonatal Diabetes (DEND). KCNJ11 mutations are associated with much lower 
visual-integration score (Shah et al., 2012), as well as increased risks for delays 
in learning, emotional and behavioural development, ADHD and sleep problems 
(Landmeier et al., 2017; Bowman et al., 2019). These symptoms are 




reducing its ability to regulate the firing activities of a variety of neuronal 
populations (Lemak et al., 2014).   
The use of oral sulfonylurea therapy has been shown to improve glycaemic 
control to patients, limiting the impact of diabetes on health (Bowman et al., 
2018). However, long term sulfonylurea exposure has thus far showed minimal 
impact on cognitive scores present in NDM (Bowman et al., 2018). This is likely 
because of limited sulfonylurea brain permeability. At therapeutic concentrations, 
the CNS efflux rate of tolbutamide is faster than the influx rate, leading to low 
brain concentrations of tolbutamide (Takanaga et al., 1998). In addition, the 
systemic subcutaneous administration of glibenclamide fails to achieve 
detectable levels in the cerebrospinal fluid (CSF) or brain tissue of treated rats, 
even with high plasma concentrations (Lahmann et al., 2015). Furthermore, one 
hour after intracranial injection of glibenclamide, the plasma concentration was 
twice that observed in the CSF, demonstrating that glibenclamide is rapidly 
exported from the CSF.  Taken together, these results potentially explain the low 
impact of sulfonylurea application on cognitive scores of neonatal diabetes 
patients. However, increased blood-brain-barrier (BBB) permeability with 
magnetic resonance brain imaging has been detected in patients with type 2 
diabetes (Starr et al., 2003), indicating that hyperglycaemic conditions may 
increase BB permeability to therapeutics. Consequently, results from studies 
examining the brain permeability of sulfonylureas in healthy animals, may be 
incomplete due to this observed effect of diabetes on the BBB. 
Therefore, at present, current KATP-targeted therapeutics are not suitable for 
treating DEND symptoms, providing little to no alleviation of neurological 
symptoms. In addition, sulfonylureas have reduced inhibitory impact on mutant 




expression of KCNJ11 PNDM mutant channels (Lin et al., 2006), thereby limiting 
the effectiveness. As such, the translational impact of memantine as a brain 
permeable KATP channel antagonist is undeniable. The aims of this chapter are 
hence to investigate the concentration response of neuronal KATP channels to 
memantine, a known CNS penetrant and active therapy, aiming to providing 



























5.2 Results  
5.2.1 Acute memantine application attenuates maximal KATP channel 
mediated membrane conductance in GT1-7 cells 
To determine the antagonist effect of memantine on KATP channels the KATP 
channel expressing GT1-7 hypothalamic cell line was used for all studies in this 
chapter. 
To examine the effect of acute memantine application on KATP channel 
conductance and membrane potential of GT1-7 cells, whole-cell patch-clamp 
recordings were performed (n=5-12). The extracellular bath solution (External A, 
Table 2.3) contained 2.5 mM glucose and the electrode solution (Internal A, Table 
2.3) contained 0 ATP, opening/activating KATP channels and allowing the 
measurement of maximal membrane conductance. All recordings have been 
junction potential (JP) corrected as the JP brought about by external and internal 
solutions was calculated as -14 mV.  
Currents were evoked by a voltage-clamp protocol from -120 (JP: -134) to -60 
(JP: -74) mV steps which were 100 milliseconds in duration and steps were 
spaced 3 seconds apart (Fig. 5.1Ai, Bi, Ci and Di).  This voltage-clamp protocol 
was applied at three time points to determine conductance density: Upon rupture 
of the membrane (Break In), when intracellular ATP had been dialysed (Run Up) 
and after drug effect had plateaued (Drug). Run Up was defined when the 
membrane potential, had reached a steady state hyperpolarisation ~7-10 minutes 
after the membrane had been ruptured (Fig 5.2Ai, Bi, Ci and Di). Once Run Up 
was achieved, indicating maximal conductance density, treatments of either 0.1% 
DMSO (Veh) or memantine (1-100 µM) were applied until the membrane had 




voltage-clamp was once again performed to investigate the effect of acute 
exposure on maximal KATP  channel conductance density. The application of Veh, 
1 µM and 10 µM memantine caused no significant alteration to the membrane 
potential of GT1-7 cells after ATP washout (Veh; -95.6 ± 0.6 mV vs -94.4 ± 1 mV, 
1 µM; -93.1 ± 0.7 mV vs -92.2 ± 0.9 mV, 10 µM; -96.0 ± 1.0 mV vs -94.3 ± 1.2 
mV, Fig 5.2 E). However, the application of 100 µM memantine caused a 
significant depolarisation (-95.3 ± 0.8 mV vs -61.4 ± 4.8 mV, Fig 5.2 E), an 
increase of +35.8 ± 4.7 mV (Fig. 5.2 F, P<0.001).  
To assess whether this increase in membrane potential was due to a decrease 
in leak conductance, the membrane conductance (nS/pF) was quantified from 
steady state currents normalised to cell capacitance (Fig 5.1F) recorded in 
voltage-clamp (Fig 5.1 Aii, Bii, Cii and Dii). To best assess the impact of treatment 
on conductance (nS/pF) the data has been represented as conductance (Drug)/ 
maximal conductance (Run Up) (G/Gmax) (Fig. 5.1G). Veh (Fig 5.1A), 1 µM 
memantine (Fig 5.1B) and 10 µM memantine (Fig 5.1C) caused no significant 
alteration to linear membrane conductance density (n = 6-12, 0.86 ± 0.13 vs 0.85 
± 0.03 vs 0.75 ± 0.10 G/Gmax, Fig 5.1G). However, compared to Veh controls (Fig 
5.1A), 100 µM memantine (Fig 5.1D) caused a significant reduction in the linear 
conductance density (n=5-6, 0.86 ± 0.13 vs 0.20 ± 0.12 G/Gmax, Fig 5.1G). In 
addition, whilst only 100 µM memantine caused significant alterations to linear 
conductance density at negative potentials and membrane potential, acute 
memantine (1 - 100 µM) exposure significantly inhibited the activation of outward 
voltage-activated currents in GT1-7 cells (Fig 5.3). An effect more potent than 
that on leak currents and membrane conductance (Fig 5.1, 5.2).  
Taken together, these data confirm that memantine (100 µM) significantly 





Figure 5.1: Memantine (100 µM) attenuates linear current increase caused 
by 0 ATP perfusion in GT1-7 cells. 
(Ai- Di) Whole cell macroscopic currents were examined after the cell had been 
fully dialysed with 0 ATP (Run Up) and after the respective treatment and 
response plateaued (Drug) had been applied (Veh, n=6; 1 µM, n=5; 10 µM, n=12; 
100 µM, n=5). (Aii –Dii) Current-Voltage (I-V) relationships of steady-state linear 
current density evoked using voltage clamp after the cell had been fully dialysed 
with 0 ATP (Run Up) and after the respective treatment and response plateaued 
(Drug) had been applied. (E) Cell capacitance (pF) values recorded prior to whole 
cell voltage clamp recordings at Run Up and Drug time points. (F) Pooled 
conductance densities (nS/pF) at maximum Run Up and after drug application in 
GT1-7 cells. (G) Conductance density observed after drug administration as a 
proportion of conductance density observed at maximal Run Up (G/Gmax). 
Statistical analysis was performed using two-way ANVOVA repeated measures 
with Dunnett multiple comparisons (Aii-Dii, E) and one-way ANOVA with Tukey 






Figure 5.2: Memantine (100 µM) application depolarises GT1-7 cells fully 
dialysed with 0 ATP.  
(Ai- Di) Representative whole-cell current clamp recordings of GT1-7 cells in 
each treatment group during dialysis with 0 ATP. KATP channel run-up can be 
defined as the length of the x-axis. (Aii – Dii) Representative whole cell current 
clamp recordings of GT1-7 cells exposed to either: 0.1% DMSO (Aii), 1 µM 
memantine (Bii), 10 µM memantine (Cii) and 100 µM memantine (Dii). (E) 
Junction potential corrected mean membrane potential (mV) values recorded 
prior to (Run Up) and after (Treatment) drug exposure. (F) Mean Δ membrane 
potential recorded after respective drug treatment. All data represented as mean 
± SEM. Data analysis performed using a 2 way ANOVA with Dunnett multiple 
comparisons (E) or One way ANOVA with Dunnett multiple comparisons (F). * 











Figure 5.3: Memantine attenuates voltage-activated outward currents in 
GT1-7 cells. 
Current-Voltage (I-V) relationships of voltage-activated leak-subtracted outward 
currents elicited using a voltage clamp after the cell had been fully dialysed with 
0 ATP (Run Up) and after treatment with (A) 0.1% DMSO (Veh; n=6), (B) 1 µM 
memantine (n=5), (C) 10 µM memantine (n=12) and (D) 100 µM memantine 
(n=5). Data expressed as mean ± SEM. analysed using two-way ANOVA 
















5.2.2 Short-term memantine exposure attenuates maximal KATP channel 
mediated membrane conductance in GT1-7 cells. 
As previous results indicated, memantine (100 µM) reduced maximal 
conductance density and depolarisation of the membrane potential when applied 
without the inhibitory effect of intracellular nucleotides. As such, the effect of 
memantine exposure prior to ATP washout and KATP channel activation was 
examined by exposing GT1-7 cells to 15-20 minutes of either 0.1% DMSO (Veh) 
and memantine (1-100 µM) in External Solution. At the end of this period cells 
were examined using whole cell patch clamp recording (n=12-27), under constant 
perfusion with respective memantine concentration. 
Whole cell patch-clamp recordings were performed to assess the impact of 
memantine exposure on families of leak and voltage-activated currents, as well 
as allowing the wash out of internal ATP with 0 ATP to maximally open KATP 
channels, as previously described. The extracellular bath solution (External A, 
Table 2.3) contained 2.5 mM glucose and the electrode solution contained 140 
mM KCl with 0 ATP (Internal solution B, Table 2.3). The junction potential was 
calculated as + 2.6 mV and all recordings have been junction potential corrected. 
GT1-7 cells were placed in the recording chamber 15-20 minutes prior to 
recording under constant perfusion with either Vehicle (Veh; 0.1% DMSO) or 
memantine (1-100 µM). Currents were evoked by a voltage-clamp protocol from 
-140 to -80 mV steps which were 100 milliseconds in duration and 3 seconds 
apart upon Break In and at Run Up (Fig 5.4Ai, Aii, Aiii and Aiv). The maximal 
conductance density, observed at Run Up, was significantly attenuated in cells 
pre-exposed to and in the constant presence of memantine (100 µM), compared 




However, the maximal conductance density of cells pre-exposed with memantine 
(1 µM and 10 µM), observed at Run Up, did not differ significantly from Veh (n= 
12-27, 1.0 ± 0.1 vs 0.8 ± 0.1 vs 1.1 ± 0.1 nS/pF, respectively, Fig 5.4G).  
In comparison with Vehicle treatment (Fig 5.5Ai) , the pre-exposure of cells with 
1 µM memantine (Fig 5.5Aii) and 10 µM memantine (Fig 5.5Aiii) caused no 
significant difference in membrane potential observed at Break In (n = 12-24, -
35.7 ± 1.0 vs -40.9 ± 4.2 vs -33.97 ± 0.8 mV, respectively , Fig 5.5B) or Run Up 
(n = 12-24, -82.7 ± 1.9 vs -80.1 ± 1.4 vs -80.31 ± 1.8 mV, respectively Fig 5.5B). 
However, 100 µM memantine (Fig 5.5Aiv) pre-exposure reduced the maximal 
hyperpolarisation caused by ATP washout and KATP channel activation (Veh, -
82.7 ± 1.9 vs 100 µM -70.4 ± 2.5 mV, P<0.001, Fig 5.5B). Additionally, no 
significant difference was observed in either cell capacitance (Fig 5.4B) or the 
time required to hyperpolarize on ATP washout (Fig 5.5C), indicating that the 
effects observed were due to memantine exposure and not incomplete ATP 
dialysis.  Concentration-dependant effects on voltage-activated outward currents 
were also observed (Fig 5.6). 
To summarise the findings so far with memantine exposure, application of 
memantine (100 µM) prior or post KATP channel activation causes an attenuation 
of linear conductance density and a depolarisation of the membrane potential of 
GT1-7 cells. However, no significant effect was observed with memantine (1-10 
µM). Furthermore, a more potent effect of memantine was observed on voltage-
gated outward currents, seen by significant attenuations observed with 






Figure 5.4: Acute memantine exposure attenuates maximal membrane 
conductance during dialysis with 0 ATP in GT1-7 cells. 
(Ai-Aiv) Pooled families of currents evoked using a voltage-clamp protocol stated 
in “Materials and Methods”. Whole cell macroscopic currents were examined 
upon establishment of whole-cell configuration (Break In) and after the cell had 
been fully dialysed with 0 ATP (Run Up) in the presence of 0.1% DMSO (Veh, 
n=27), 1 µM memantine (n=5), 10 µM memantine (n=12) and 100 µM memantine 
(n=5). (B) Cell capacitance (pF) values obtained from cells prior to initiation of 
voltage-clamp protocol at Run Up. (C) Current-voltage relationships of average 
steady state current observed with increasing voltage steps normalised to cell 
capacitance at Run Up. (D) Pooled conductance densities (nS/pF) at maximum 
Run Up. Data expressed as mean ± SEM. Data analysed using one-way ANOVA 
with Bonferonni multiple comparisons (B, D) or two-way ANOVA repeated 
measures with Bonferonni multiple comparisons (C). * P < 0.05, ** P < 0.01, *** 





Figure 5.5: Acute memantine exposure prevents maximal washout during 
dialysis with 0 ATP in GT1-7 cells. 
(Ai-Aiv) Representative whole-cell current clamp recordings obtained from GT1-
7s during dialysis with 0 ATP after pre-treatment and continuous exposure with 
either 0.1% DMSO (Veh; n=27) or memantine (1 µM, n=12; 10 µM, n=14; 100 
µM, n=8). KATP channel run-up can be defined as the length of the x-axis. (B) 
Average membrane potential values obtained upon establishment of whole cell 
configuration (Break In) and after full ATP dialysis (Run Up) (C) Average duration 
of ATP dialysis for each treatment group. Data analysed using two way ANOVA 
repeated measures with Bonferonni correction (B) and One-way ANOVA with 

















Figure 5.6: Effect of Memantine (1 - 100 µM) exposure on voltage activated 
outward currents in GT1-7 cells prior to ATP dialysis. 
Voltage-activated currents evoked from a clamped potential ranging from -80 to 
+40 mV, from a holding potential of -70 mV. All recordings obtained upon 
establishment of the whole cell configuration after pre-treatment with either 0.1% 
DMSO (Veh; n=27) or Memantine (1 µM, n=12; 10 µM, n=14; 100 µM, n=8) and 
leak subtracted. Statistical analysis performed using a two-way ANOVA repeated 




5.2.3 Acute intracellular memantine exposure does not significantly 
suppress maximal KATP channel mediated membrane conductance 
in GT1-7 cells. 
Previous results had indicated that in the absence of intracellular ATP, 100 µM 
memantine was the lowest concentration tested that significantly attenuated KATP 
channel driven leak conductance whether applied extracellularly to the open or 
closed channel. As such, the effect of memantine exposure directly to the 
intracellular portion of the membrane was performed by dialysing cells with a 
pipette solution containing either 0.1% DMSO (Veh) or memantine (1-100 µM). 
At the end of this period cells were examined using whole cell patch clamp 
recording (n=10-14).  
Whole cell patch-clamp recordings were performed to assess the impact of 
memantine exposure on families of leak and voltage-activated currents, as well 
as allowing the dialysation of internal ATP with 0 ATP to maximally open KATP 
channel. The electrode solution contained 140 mM KCl with 0 ATP (pipette 
solution B). The junction potential was calculated as +2.6 mV and all recordings 
have been junction potential corrected. 
Currents were evoked by a voltage-clamp protocol from -140 to -80 mV steps 
which were 100 milliseconds in duration and 3 seconds apart upon Break In and 
at Run Up (Fig 5.7Ai, Aii, Aiii, and Aiv). Firstly, compared to Veh controls (Fig 
5.6Aii), the exposure of GT1-7 cells to 1 µM (Fig 5.6Bii), 10 µM (Fig 5.6Cii) or 100 
µM memantine (Fig 5.6Dii) applied through the patch pipette caused no 
significant alteration in the membrane potential recorded at either Break In (n=10-
14, (Veh) -33.97 ± 1.05 vs (1 µM) -36.34 ± 2.06 vs (10 µM) -40.57 ± 2.68 vs (100 




µM) -79.16 ± 1.78 vs (10 µM) -81.77 ± 0.61 vs (100 µM) -81.71 ± 1.03 mV, Fig 
5.6D). In addition, compared to Vehicle controls (Fig 5.6Ai) application of neither 
1 µM (Fig 5.6Bi), 10 µM (Fig 5.6Ci) nor 100 µM memantine (Fig 5.6Di) 
intracellularly was observed to have any significant impact on the maximal 
conductance density observed after ATP dialysis (n =10-14, (Veh) 0.98 ± 0.06 vs 
(1 µM) 0.93 ± 0.8 vs (10 µM) 1.08 ± 0.07 vs (100 µM) 0.79 ± 0.9 nS/pF, Fig 5.7C). 
No change was observed between treatments in cell capacitance (n=10-14, (Veh) 
17.69 ± 1.83 vs (1 μM) 16.79 ± 1.26 vs (10 μM) 18.17 ± 1.43 vs (100 μM) 16.46 
± 0.94 pF, Fig 5.7A), or the time required to hyperpolarize on ATP washout were 
observed (n=10-14, (Veh) 7.04 ± 0.59 vs (1 μM) 7.72 ± 0.97 vs (10 μM) 6.88 ± 
0.80 vs (100 μM) 8.35 ± 0.82 minutes, Fig 5.7E), indicating that the effects 
observed were due to memantine exposure and not incomplete ATP dialysis. 
These data suggest that the direct application of memantine (1-100 µM) to the 
intracellular portion of the membrane, during ATP dialysis, causes no significant 
attenuation of maximal conductance density and no significant impact on 
membrane potential of GT1-7 cells.  Therefore, memantine acts extracellularly to 
block KATP channels. Furthermore, no significant effect was observed on voltage-
activated outward currents upon intracellular memantine concentration (Fig 5.9). 
Thus far, all experiments had been conducted in the presence of 0 ATP, allowing 
for maximal KATP channel activation. However, whilst efficacious to measure 
effects on maximal membrane conductance, to better understand the effects of 
memantine on KATP channel activity the effect of memantine exposure cells with 







Figure 5.7: Representative recordings from GT1-7 cells dialysed with 0 ATP 
and memantine 
GT1-7 cells were pre-treated for ~ 15-20 minutes prior to experimentation in 
continuous presence of treatment (Ai- Di) Families of currents evoked using a 
voltage-clamp protocol from -140 mV to -80 mV. Whole cell macroscopic currents 
were examined upon establishment of the whole cell configuration (Break In) and 
after the cell had been fully dialysed with 0 ATP(Run Up) in the presence of either 
0.1% DMSO (Veh, n=14) or memantine (1 µM, n=11; 10 µM, n=15 and 100 µM, 
n=10). (Aii-Dii) Representative whole-cell current clamp recordings of GT1-7 
cells in each treatment group during dialysis with 0 ATP in the presence of either 
0.1 % DMSO (Aii) or memantine (1-100 µM; Bii-Dii). KATP channel run-up can be 





Figure 5.8: Acute intracellular memantine exposure has no effect on 
maximal membrane conductance in GT1-7 cells. 
(A) Cell capacitance values obtained after full dialysis with 0 ATP (termed Run 
Up) and concurrent intracellular application of either 0.1% DMSO (Veh; n=14) or 
memantine (1 µM, n=11; 10 µM, n=15 and 100 µM, n=10).  (B) Current-voltage 
relationships of linear current observed at Run Up from clamp potentials ranging 
from -140 to -80 mV (C) Pooled conductance densities from each treatment group 
at Run Up. (D) Pooled membrane potential values obtained upon Break In and at 
Run Up. (E) Pooled duration of ATP dialysis in each treatment group. Statistical 
analysis performed using a two-way ANOVA repeated measures with Bonferonni 
multiple comparisons (panel B, D) or one-way ANOVA with Bonferonni multiple 








Figure 5.9: Effect of intracellular memantine (1 - 100 µM) exposure on 
voltage activated outward currents in GT1-7 cells after ATP dialysis. 
Voltage-activated currents evoked from a clamped potential ranging from -80 to 
+40 mV, from a holding potential of -70 mV. All recordings obtained upon Run Up 
after the intracellular exposure of cells to either 0.1% DMSO (Veh; n=14) or 
memantine (1 µM, n=11; 10 µM, n=15; 100 µM, n=10) and leak subtracted. 
Statistical analysis performed using a two-way ANOVA repeated measures with 



















5.2.4 Acute memantine application attenuates KATP channel mediated 
membrane conductance in presence of Mg-ATP in GT1-7 cells 
Previous experiments indicated that exposure of a high concentration of 
memantine to the extracellular portion of the membrane elicited inhibition of the 
KATP channel upon removal of stimulatory ATP. However, it was hypothesised 
that the high drug affinity and concentration-response observed previously (S. 
Moriguchi et al., 2016) may be due to interactions between memantine and ATP 
binding affinity. Therefore, the effect of memantine on KATP channel activity in the 
presence of fixed intracellular ATP was examined. 
Whole cell patch-clamp recordings were performed to assess the impact of 
memantine exposure on families of leak and voltage-activated currents, as well 
as allowing the dialysation of internal ATP with 1 mM Mg-ATP. The extracellular 
bath solution contained 2.5 mM glucose and the electrode solution contained 1 
mM Mg-ATP (pipette solution C). All recordings have been junction potential (JP) 
corrected, JP = -14 mV.  
Currents were evoked by a voltage-clamp protocol holding potential of -70 (JP: -
84.6) and stepping to -120 (JP: -134.6) mV. Each step was 300 milliseconds in 
duration and 5 seconds apart (Fig 5.10A). The voltage-clamp protocol was either 
applied upon Break In or when the membrane potential had been observed to 
stabilise in current clamp. Recordings were obtained every 5 seconds for the 
duration of the recording allowing the visualisation and quantification of 
conductance changes throughout treatment.  
Firstly, once current amplitude (pA) had stabilised (Run Up) GT1-7 cells were 
exposed to 0.1% DMSO (Veh) (Fig. 5.10Bii), 10 µM memantine (Fig 5.10Cii) or 




achieved all cells were exposed to 1 µM Glibenclamide as a positive control. 
Average steady state currents were then obtained at each time point (termed; 
Run Up, Treatment and Glibenclamide) to allow quantification of conductance 
density (Fig 5.10Bi, 5.10Ci and 5.10Di, respectively). Cell capacitance between 
treatments was not significantly different (Veh, 18.1 ± 0.6, 10 µM, 17.0 ± 0.8, 100 
µM, 16.2 ± 1.5 pF, P>0.05, Fig 5.11C). No significant differences were observed 
between Run Up and Veh treatment at step voltage (-35.47 ± 8.16 vs -35.51 ± 
8.05 pA/pF, respectively, P>0.05, Fig 5.11Ai) or 10 µM memantine treatment (-
31.91 ± 5.21 vs -27.30 ± 4.46 pA/pF, respectively, P>0.05, Fig 5.11Aii). However, 
100 µM memantine caused a significant reduction in steady state current 
compared to that observed at Run Up (-20.31 ± 3.16 vs -5.81 ± 0.94 pA/pF, 
P<0.0001, Fig 5.11Aiii). In all treatment groups glibenclamide (1 µM) significantly 
reduced steady state current compared to that observed at Run Up (Veh, Δ 
+23.88 ± 6.70, 10 µM, Δ +20.64 ± 5.70, 100 µM, Δ +14.35 ± 2.96 pA/pF, P<0.001, 
Fig 5.11Ai, Aii and Aii, respectively). Conductance densities (nS/pF) after 
treatment and Glibenclamide exposure were quantified, prior to normalising to 
maximal conductance (deemed to be at Run Up). Compared to vehicle controls, 
memantine (100 µM) was shown to cause a significant reduction in membrane 
conductance (Veh, 0.96 ± 0.06 vs 100 µM 0.22 ± 0.07 G/Gmax, P<0.001, Fig 
5.11B). Conversely, memantine (10 µM) caused a slight decrease in membrane 
conductance, however, not a significant decrease (Veh, 0.96 ± 0.06 vs 10 µM 
0.80 ± 0.02 G/Gmax, P=0.133, Fig 5.11B). A similar result to that observed after 
maximal opening of KATP channels using 0 ATP.  
No significant difference was observed between the treatment times for Veh and 
100 µM memantine (2.5 ± 1.2 vs 3.8 ± 0.3 minutes, respectively, p>0.05, Fig 




longer period of time (2.5 ± 1.2 vs 4.6 ± 0.6 minutes, respectively, P>0.05, Fig 
5.11D).  This is not deemed to have a significant impact on results, as memantine 





Figure 5.10: Acute Memantine exposure after dialysis with Mg-ATP (1 mM) 
(A) Representative example of the voltage clamp protocol utilised to observed the effects of either 0.1% DMSO (Veh; n=9) or memantine (10 µM, 
n=6; 100 µM, n=6) treatment on maximal membrane conductance density after dialysis with Mg-ATP (1 mM), prior to application of the KATP 
channel blocker glibenclamide (1 µM).  (Bi) Pooled current evoked by the voltage-clamp protocol (panel A) after maximal dialysis with Mg-ATP 
(termed Run Up), after treatment with 0.1% DMSO and post glibenclamide exposure. (Bii) Representative trace of conductance density as a 
fraction of maximal conductance (deemed to be at Run Up) in cells treated with Veh.  (Ci) Pooled current evoked by the voltage-clamp protocol 
(panel A) after maximal dialysis with 1 mM Mg-ATP (termed Run Up), after treatment with 10 µM memantine and post glibenclamide exposure. 
(Cii) Representative trace of conductance density as a fraction of maximal conductance (deemed to be at Run Up) in cell s treated with 10 µM).  
(Di) Pooled current evoked by the voltage-clamp protocol (panel A) after maximal dialysis with 1 mM Mg-ATP (termed Run Up), after treatment 
with 100 µM memantine and post glibenclamide exposure. (Dii) Representative trace of conductance density as a fraction of maximal 





Figure 5.11: Acute memantine (100 µM) exposure after dialysis with Mg-ATP 
(1 mM) significantly attenuates membrane conductance.  
(Ai-iii) Pooled Current-Voltage (I-V) relationships of steady state linear current 
density evoked using voltage clamp (Fig 5.10A) after the cell had been fully 
dialysed with 1 mM Mg-ATP (Run Up), after the respective treatment and 
response plateaued ( or memantine) had been applied and after exposure to a 
high affinity KATP channel blocker glibenclamide (1 µM). (B) Pooled conductance 
density values obtained after treatment with either 0.1% DMSO (Veh; n=9) or 
memantine (10 µM, n=6; 100 µM, n=6) and glibenclamide (1 µM), presented as 
a fraction of maximal conductance (G/Gmax). (C) Pooled capacitance values 
obtained upon establishment of whole-cell voltage clamp. (D) Pooled duration of 
treatment application. Statistical analysis performed using a two-way ANOVA 
repeated measures with Bonferonni multiple comparisons (Ai, Aii, Aiii, B and C) 
or one-way ANOVA with Bonferonni multiple comparisons (D).  * P < 0.05, **** P 























Figure 5.12: The effect of acute memantine exposure (10-100 µM) is not 
impacted by intracellular ATP concentration  
Reductions in G/Gmax observed after acute exposure of GT1-7 with Vehicle 
(0.1% DMSO) and Memantine (10-100 µM) after dialysis with either 0 ATP or 1 
mM Mg-ATP. Data expressed as Mean ± SEM. Analysed using two-way ANOVA 




5.2.5 Short-term memantine exposure attenuates KATP channel mediated 
membrane conductance in presence of Mg-ATP in GT1-7 cells 
As previous results indicated, memantine (100 µM) reduced maximal KATP 
channel conductance and depolarised the membrane potential when applied to 
maximally open KATP channels in the absence of intracellular nucleotides. As 
such, the effect of memantine exposure for 20 minutes prior to ATP dialysis and 
KATP channel activation was examined by exposing GT1-7 cells to either 0.1% 
DMSO (Veh), memantine (1-100 µM). At the end of this period cells were 
examined using whole cell patch clamp recording (n=6-16).  
Whole cell patch-clamp recordings were performed to assess the impact of 
memantine exposure on families of leak and voltage-activated currents. The 
extracellular solution (External A) contained 2.5 mM glucose and the electrode 
solution contained 1 mM Mg-ATP (internal solution C). All recordings have been 
JP corrected, -14 mV.  
To investigate the impact of treatment on conductance density of KATP channels, 
currents were evoked by a voltage-clamp protocol from -120 (JP: -134) to -60 
(JP: -74) mV steps which were 100 milliseconds in duration and 3 seconds apart 
upon Break In and at Run Up (Fig 5.13Ai-Di). In addition, whole-cell current-clamp 
recordings (~6-10 minutes) were performed during dialysis of intracellular ATP to 
visualise steady state hyperpolarisation of the membrane potential (Fig.5.13Aii – 
Dii).  
Compared to vehicle controls, cells pre-exposed to either 10 µM or 100 µM 
memantine had a significant attenuation of KATP channel mediated membrane 
conductance density (0.45 ± 0.5 vs 0.23 ± 0.1 (P<0.05) vs 0.08 ± 0.01 (P<0.001) 




µM) caused a mean depolarisation of ~ 10 mV (-78.7 ± 1.3 vs -66.1 ± 9.4 and -
68.8 ± 4.8 mV, respectively, Fig 5.14D), this was not statistically significant 
(P>0.05).   
In addition, no significant difference was found in cell capacitance observed at 
Run Up (16.7 ± 0.9 vs 14.0 ± 1.5 vs 13.1 ± 2.0 vs 16.5 ± 1.7 pF, respectively, 
P>0.05, Fig. 14A) or time to washout (6.7 ± 0.3 vs 6.3 ± 0.5 vs 6.4 ± 0.5 vs 6.6 ± 
0.2 minutes, respectively, p>0.05, Fig 5.14E).  
In summary, these data indicate that 1 mM intracellular Mg-ATP increases the 
antagonist effect of memantine on KATP channel conductance. As Mg-ATP is 
stimulatory, the effects observed may indicate that memantine decreases KATP 













Figure 5.13: Pre-exposure of memantine significantly attenuates evoked 
currents in the presence of Mg-ATP in GT1-7 cells. 
(Ai-Di) Families of currents evoked using a voltage-clamp protocol stated in 
“Materials and Methods”. Whole cell macroscopic currents were examined after 
the cell had been fully dialysed with 1 mM Mg-ATP (Run Up) and after the 
respective treatment and response plateaued (Drug) had been applied (Veh; 
n=16 , 1 µM; n=6,  10 µM; n=5, and 100 µM; n=6). Data represented as mean ± 
SEM. (Aii-Dii) Representative whole-cell current clamp recordings of GT1-7 cells 
in each treatment group during dialysis with Mg-ATP (1 mM) in the presence of 
either 0.1 % DMSO (Aii) or memantine (1-100 µM; Bii-Dii). KATP channel run-up 





Figure 5.14: Pre-exposure of memantine decreases maximal conductance 
density in the presence of 1 mM Mg-ATP in GT1-7 cells. 
(A) Capacitance values recorded from GT1-7 cells after full ATP dialysis (Run 
Up). (B) Current voltage relationships obtained from GT1-7 cells at Run Up after 
pre-treatment and continuous exposure with 0.1% DMSO (Veh, n=16), 1 µM 
memantine (n=6), 10 µM memantine (n=6) or 100 µM memantine (n=6). (C) 
Membrane conductance density observed for each treatment group at Run Up. 
(D) Mean membrane potential values obtained at the start (Break In) and end 
(Run Up) of ATP dialysis for cells pre-treated with Veh or memantine (1-100 µM). 
(E) Time taken for full ATP dialysis and no further alteration in membrane 
potential. Data analysed using one-way ANOVA with Dunnett’s multiple 
comparisons (A, C and E) or Two-way ANOVA repeated measures with 




5.2.6 Chronic (48 hour) memantine exposure does not significantly 
suppress KATP channel mediated membrane conductance after 
drug washout in GT1-7 cells.  
Previous studies have shown that the long term application of memantine can 
improve long term memory in a KATP channel dependent manner (S. Moriguchi et 
al., 2016), suggesting some long term effect of memantine application. 
Furthermore, previous work (Shown in Chapter 3) suggest that 48 hour 
continuous antagonism with characteristic blocker, sulfonylureas, can augment 
KATP channel conductance in GT1-7 cells upon wash off. Therefore, to better 
understand the impact of memantine treatment on KATP channel activity, the 
impact of continuous application (48 hours) and whether the prolonged exposure 
with lower concentrations lead to significant attenuation or augmentation of the 
KATP channel conductance was investigated. GT1-7 cells were incubated in the 
presence of either vehicle (Veh, 0.1% DMSO) or memantine (1-100 µM) for 48 
hours prior to experimentation. 
The extracellular bath solution (External solution A) contained 2.5 mM glucose 
and the electrode solution contained 0 ATP (Internal solution B). All recordings 
have been JP corrected, +2.6 mV. 
GT1-7 cells were placed in the recording chamber under constant perfusion with 
NS for 15 – 30 minutes prior to experimentation, this was to ensure the adequate 
removal of memantine prior to recording. Currents were evoked by a voltage-
clamp protocol from -140 to -80 mV steps which were 100 milliseconds in duration 
and 3 seconds apart upon Break In and at Run Up (Fig 5.14Ai, Aii, Aiii, and Aiv). 
Compared to Vehicle controls, neither 1 µM, 10 µM nor 100 µM memantine 




hours of continuous exposure (1.2 ± 0.1 vs 1.3 ± 1.2 vs 1.2 ± 0.2 vs 0.6 ± 0.2 
nS/pF, respectively, P > 0.05, Fig 5.15D), In addition, no significant alterations 
were observed in capacitance values obtained at either Break In or Run Up (Fig 
5.15C). However, there was a trend towards a decrease in conductance with 
increasing concentration which whilst non-significant, may have impacted results 
for conductance density.  
In addition, cells treated with either Veh or memantine (1-100 µM) no significant 
difference was observed in time to ATP washout (Fig 5.15B) or membrane 
potential observed at either Break In (-33.0 ± 1.6 vs -31.4 ± 0.8 vs -30.3 ± 1.5 vs 
-30.9 ± 0.8 mV, respectively, P > 0.05, Fig 5.16Ci) or Run Up (-77.4 ± 1.0 vs -
79.4 ± 1.9 vs -73.5 ± 3.6 vs -78.4 ± 2.5 mV, respectively, P > 0.05, Fig 5.16Cii), 
indicating that the effects observed on conductance density are not due to 
differences in ATP dialysation. Furthermore, these data suggest that continuous 
application of memantine had no impact on maximal membrane conductance and 
ATP-washout induced membrane hyperpolarisation, unlike previously reported 
with sulfonylureas (Chapter 3). In addition, no significant alteration in normalised 
voltage-activated currents were observed between the treatment groups (Fig. 
5.20Aii).  
Taken together, these results suggest that chronic memantine exposure has no 
lasting effects on membrane conductance density after wash-off, however, a 
trend towards a decrease was observed (Fig 5.15D). Previous results had 
suggested a more pronounced effect with pre-exposure of memantine compared 
to acute application (Section 5.2.5 vs 5.2.4). As such, it was important to next 
investigate if chronic memantine exposure and continued exposure throughout 





Figure 5.15: Chronic memantine application (48 hours) causes no 
significant effect on membrane conductance density in GT1-7 cells.  
(Ai-Aiv) Whole cell macroscopic currents were examined immediately after cell 
membrane was ruptured Break In and after the cell had been fully dialysed with 
0 ATP (Run Up) (Veh, n=24, 1 µM, n=5, 10 µM, n=13, 100 µM, n=4). (B) Current-
Voltage (I-V) relationships of steady state linear current evoked using voltage 
clamp protocol after the cell had been fully dialysed with 0 ATP (Run Up). (C) Cell 
capacitance (pF) values recorded upon Break In and Run Up. (D) Pooled 
conductance densities at maximum run up of GT1-7 cells exposed to memantine, 
or 0.1% DMSO Vehicle, for 48 hours (n = 4-24). All data represented as mean ± 
SEM. Analysed using Two-way ANOVA repeated measures with Bonferonni 
multiple comparisons Correction (B, C) and One-way ANOVA with Dunnett’s 





Figure 5.16: Chronic memantine exposure causes no alteration in 
membrane potential after ATP Washout in GT1-7 cells 
(A) Representative whole-cell current clamp recordings of GT1-7 cells exposed 
to 48 hours of either 0.1% DMSO (Ai), 1 µM memantine (Aii), 10 µM memantine 
(Aiii) or 100 µM memantine (Aiv) as it is dialysed with 0 ATP. KATP channel run-
up can be defined as the length of the x-axis. (B) Average washout time for GT1-
7 cells dialysed with 0 ATP (n= 4-24). (Ci) Pooled membrane potential (mV) 
values obtained from GT1-7 cells at the beginning of dialysis. (Cii) Pooled 
membrane potential (mV) values obtained from GT1-7 cells after full dialysis and 
plateau of the membrane potential. All data represented as mean ± SEM. 
Statistical analysis performed using a One-way ANOVA with Dunnett’s multiple 




5.2.7 Chronic (48 hour) memantine and continuous exposure 
significantly attenuates KATP channel mediated membrane 
conductance in GT1-7 cells.  
In the previous experiment memantine had been adequately washed off prior to 
experimentation, eliciting no statistically significant effect on either KATP channel 
conductance or membrane potential after ATP washout. It was now decided to 
investigate if the continuous exposure to memantine after chronic (48 hour) 
treatment impacted the outcome. GT1-7 cells were treated with either vehicle 
(Veh, 0.1% DMSO) or memantine (1-100 µM) and incubated for a further 48 hours 
prior to experimentation, as described previously. 
The extracellular bath solution (External solution A) contained 2.5 mM glucose 
and the electrode solution contained 0 ATP (Internal solution B). All recordings 
have been JP corrected, +2.6 mV. 
GT1-7 cells were placed in the recording chamber under constant perfusion with 
corresponding chronic treatment (0.1% DMSO, or memantine (1-100 µM) for 15 
– 30 minutes prior to experimentation. Currents were evoked by a voltage-clamp 
protocol from -140 to -80 mV steps which were 100 milliseconds in duration and 
3 seconds apart upon rupture of the membrane (Break In) and at Run Up (Fig 
5.17Ai, 5.17Aii, 5.17Aiii, 5.17Aiv). Compared to vehicle control, only 100 µM 
caused a significant attenuation of maximal KATP channel conductance density 
(1.08 ± 0.12 vs 0.20 ± 0.04 nS/pF, respectively, P < 0.0001, Fig 5.17D). In 
addition, significant reductions in cell capacitance at both Break In  ((Veh) 17.0 ± 
0.8 vs (100 µM) 10.7 ± 0.7 pF, P < 0.001, Fig 5.17C) and Run Up ((Veh) 20.4 ± 
1.3 vs (100 µM) 11.2 ± 0.9 pF, P < 0.001, Fig 5.17C) were observed. Therefore, 




alterations in cell capacitance may affect the observed impact of the effect of 
memantine on maximal KATP channel conductance. 
Additionally, in comparison with vehicle controls, chronic memantine exposure 
(1-100 µM) caused no significant effect on membrane potential (mV) observed 
upon Break In (Fig 5.18Ci). However, compared to vehicle, memantine (100 µM) 
was also shown to cause a depolarisation of the membrane potential observed 
at Run Up (-76.3 ± 1.4 vs -56.8 ± 2.6 mV, respectively, P < 0.05, Fig 5.18Cii), 
thought to be due to significant reduction of membrane conductance density. 
Furthermore, differences were observed in ATP washout time between vehicle 
and memantine (1 μM) treated cells (n=8-14; Veh: 7.3 ± 0.3 vs 1 µM: 8.9 ± 0.6 
minutes, P < 0.05, Fig 5.18B). 
Comparative analysis of the effect of chronic memantine on membrane 
conductance showed that there was no significant effect of continued memantine 
exposure compared to wash-off in terms of whole-cell conductance (Fig 5.19A) 
or conductance density (Fig 5.19B) in GT1-7 cells. 
Taken together, these results conclude that chronic memantine application has 
no significant effect on membrane conductance, unless continuously applied. 
However, comparisons between raw membrane conductance values and 
conductance density values obtained from both memantine washout and 
continuous memantine studies showed no significant difference within treatment 
groups (Fig 5.19). Indicating that whilst memantine (100 µM) causes a significant 
reduction compared with Vehicle controls when applied continuously after 48 
hours chronic treatment (Fig 5.15D), this is not significantly different from the 






Figure 5.17: Continuous memantine exposure after chronic (48 hr) 
treatment reduced maximal membrane conductance density, in GT1-7 cells. 
(Ai-Aiv) Whole cell macroscopic currents were examined immediately after 
Break In and Run Up (Veh, n=14, 1 µM memantine, n=8, 10 µM memantine, n=5, 
100 µM memantine, n=6). (B) Current-Voltage (I-V) relationships of steady state 
linear current evoked using voltage clamp protocol after the cell had been fully 
dialysed with 0 ATP (Run Up). (C) Cell capacitance (pF) values recorded upon 
Break In and Run Up. (D) Pooled conductance densities at maximum run up of 
GT1-7 cells exposed to memantine, or 0.1% DMSO Vehicle, for 48 hours (n = 6-
14). All data represented as mean ± SEM. Analysed using Two-way ANOVA 
repeated measures with Bonferonni multiple comparisons (B, C) and One-way 






Figure 5.18: Continuous memantine exposure after chronic (48 hr) 
treatment depolarises GT1-7 cells following dialysis with 0 ATP in GT1-7 
cells. 
(A) Representative whole-cell current clamp recordings of GT1-7 cells exposed 
to 48 hours + continuous application of either 0.1% DMSO (Ai), 1 µM memantine 
(Aii), 10 µM memantine (Aiii) or 100 µM memantine (Aiv) as it is dialysed with 0 
ATP. KATP channel run-up can be defined as the length of the x-axis. (B) Average 
washout time for GT1-7 cells dialysed with 0 ATP (n= 6-14). (Ci) Pooled 
membrane potential (mV) values obtained from GT1-7 cells at Break In. (Cii) 
Pooled membrane potential (mV) values obtained from GT1-7 cells after full 
dialysis and plateau of the membrane potential (Run Up). All data represented as 
mean ± SEM. Statistical analysis performed using a One-way ANOVA with 
Bonferonni multiple comparisons (B) or Dunnett’s multiple comparisons (Ci and 





Figure 5.19: Continuous application of memantine has no effect on 
membrane conductance inhibition produced by chronic memantine 
treatment in GT1-7 cells. 
(A, B) Pooled whole-cell conductance (A) and pooled conductance densities (B) 
observed at maximum run up of GT1-7 cells exposed to memantine (Mem), or 
0.1% DMSO Vehicle (Veh), for 48 hours (n = 6-14), after drug wash off (-) or 
under continuous treatment exposure (+). All data represented as mean ± SEM. 






Figure 5.20: Chronic memantine exposure attenuates macroscopic voltage activated currents in GT1-7 cells. 
(A) Whole cell macroscopic currents were examined after 15-20 min of drug washout under constant perfusion and recorded 
immediately after cell membrane was ruptured. I-V relationships were constructed for raw current recordings (Ai), as well as those 
normalised to cell capacitance (Aii).  (B) Whole cell macroscopic currents were examined in the constant presence of treatment drug 
(Veh or memantine (1-100 µM)) under constant perfusion and recorded immediately after cell membrane was ruptured. I-V 
relationships were constructed for raw current recordings (Bi), as well as those normalised to cell capacitance (Aii).  All data 
represented as mean ± SEM. Data analysed using two-way ANOVA repeated measures Bonferonni correction. Veh + vs 100 µM+; * 





A recent report (S. Moriguchi et al., 2016) demonstrated that memantine (10 nM) 
inhibits KATP channels in hippocampal neurons leading to improvements in 
contextual memory, as has also been shown with the canonical blocker 
tolbutamide (Betourne et al., 2009). In addition, memantine (30-100 µM) blocks 
KATP mediated currents in dopaminergic neurons of the rat substantia nigra pars 
compacta (Giustizieri et al., 2007), where they control bursting behaviour and 
novelty-induced exploration (Schiemann et al., 2012).  
As the main KATP channel isoform expressed in hippocampal neurons and 
dopaminergic neurons of the substantia nigra is Kir6.2/SUR1 (Karschin et al., 
1997; Zawar et al., 1999; Thomzig et al., 2005; Schiemann et al., 2012), the same 
isotype expressed throughout hypothalamic neurons (T Miki et al., 2001), it was 
hypothesised that memantine may also be able to inhibit hypothalamic KATP 
currents. However, not all studies have replicated these findings (Giustizieri et 
al., 2007; S. Moriguchi et al., 2016) or have used widely different concentrations. 
In addition, a recent study reported that memantine (1 µM) does not inhibit 
pancreatic KATP channel-mediated currents or alter insulin secretion or blood 
glucose levels (Imai et al., 2018).  
Due to the widely different concentrations used and reported in different cell types 
(10 nM; (S. Moriguchi et al., 2016), 100 µM; (Giustizieri et al., 2007) and 1µM; 
(Imai et al., 2018)), the aim of the current study was to investigate the inhibitory 
effect of memantine on KATP channel activity and membrane conductance.  
To do this, the mouse hypothalamic GT1-7 cell line was utilised as a model of a 
of GE neurons expressing KATP channels comprised of Kir6.2 and SUR1. This 




exposure to be easily determined. Whilst NMDA receptor expression has been 
previous described in GT1-7 cells (Spergel et al., 1994), membrane conductance 
was measured below the membrane potential required for removal of Mg2+ block 
of NMDA receptor (Kampa et al., 2004). In addition, no external stimulation of 
NMDA receptors was applied, e.g. glutamate. Therefore, any observed effects of 
memantine inhibition on membrane conductance are unlikely due to effects on 
NMDA receptors. In addition, whilst memantine has previously been shown to 
inhibit other Kir channels, namely Kir2.1 (Tsai et al., 2013). Expression of these 
channels have not previously been described in GT1-7 cells. Taken together, in 
addition to the observed increase in hyperpolarising current conductance elicited 
by ATP washout, these data indicate that the KATP channel-current is the main 
component observed in these studies.   
In the current study, acute exposure of memantine (100 μM) to open KATP 
channels after ATP dialysis caused a significant (~75%) attenuation of maximal 
membrane conductance density compared to vehicle treatment. This is 
compared to the ~1% and ~13% attenuation observed with 1 μM and 10 μM 
memantine treatment, respectively (Fig 5.1). This observed attenuation of 
membrane conductance density with memantine (100 µM)  in the absence of 
intracellular nucleotides was similar to that observed with the sulfonylureas 
glibenclamide and gliclazide (Fig 3.1), indicating that this is most likely due to the 
blockade of activated Kir6.2/SUR1 KATP channels (Proks et al., 2014).  
However, further investigation of the impact of memantine exposure, in which 
cells were pre-treated with memantine (1-100 µM), the effectiveness of 100 µM 
memantine to attenuate maximal conductance density was reduced (~62% 
reduction compared to vehicle). It is hypothesized that the difference observed in 




power between the two studies, stochastic noise or due to differences in 
intracellular solution used (Internal A vs Internal B). However, this requires further 
study to clarify. 
Regardless, this present study confirms previous reports that memantine (100 
μM) inhibits KATP channel mediated membrane conductance, similar to previous 
observations on dopaminergic neurons (Giustizieri et al., 2007). Furthermore, 1 
µM and 10 µM caused no significant attenuation of membrane conductance, as 
has been previously described in  previous reports on the effect of memantine (1 
µM) on Kir6.2/SUR1 expressing pancreatic β-cells (Imai et al., 2018). 
Well characterised KATP channel antagonists, sulfonylureas, inhibit KATP through 
high affinity binding to intracellular ATP-binding domains on SUR1 and the low 
affinity inhibition of Kir6.2, preventing ATP dependent channel activation (Ashfield 
et al., 1999; Winkler et al., 2007). Results from this study showed no significant 
effect of intracellular memantine application on membrane conductance density 
(Fig 5.6). These data indicated that memantine has no effect on KATP channel 
activation when applied to the intracellular side of the membrane, similar to that 
seen with its effects on NMDA receptors (Parsons et al., 2008). In addition, the 
effect of memantine on membrane conductance density was due to interaction 
with the extracellular portion of the channel, unlike most characteristic KATP 
channel blockers, namely sulfonylureas (Proks et al., 2014).  
The Kir6.2ΔC channel is commonly used to assess the impacts of 
pharmacological agents or endogenous compounds on Kir6.2 alone. Kir6.2ΔC 
involves the deletion of the last 26-36 amino acids of Kir6.2, removing the ER 
retention signal, allowing it to be expressed in the absence of SUR1 (Tucker et 




confirm whether memantine induced blockade is driven through interactions with 
SUR1 (Proks et al., 2002), as with sulfonylureas, or Kir6.2, or a combination of 
both. 
Whilst helpful to measure maximal conductance, removal of intracellular 
nucleotides can impact the efficacy of KATP channel antagonists (e.g. 
sulfonylureas) (Proks et al., 2014). In addition, Mg-nucleotides are required for 
the stimulation of the KATP channel by KATP channel openers such as Diazoxide 
(Larsson et al., 1993). Indicating that the presence of intracellular nucleotides can 
enhance, or is required for, the effect of pharmacological agents on the KATP 
channel. Therefore, the effect of memantine exposure on membrane 
conductance was assessed in the presence of the stimulatory nucleotide Mg-ATP 
(1 mM). Data presented herein suggests that the antagonistic effect of acute 
memantine is not enhanced by intracellular nucleotide concentration (Fig 5.12). 
However, memantine pre-exposure prior to KATP channel activation in the 
presence of 1 mM Mg-ATP enhances its inhibitory effect by ~ 10-fold.  
ATP interaction with the channel open state destabilises the channel and 
promotes channel closure (Craig et al., 2008a). Furthermore, sulfonylurea drugs 
inhibit activation of KATP channel through action of Mg-nucleotides, increasing the 
inhibitory power of ATP on Kir6.2. 
Whilst results thus far had indicated that the application of memantine only 
caused significant effects >10 µM in the absence of intracellular nucleotides, this 
was contradictory to what had been described previously (S. Moriguchi et al., 
2016). In which, both cells and animals had been treated for an extended period 
of time prior to analysis of evoked currents. As such, in this current study GT1-7 
cells were pre-treated with memantine and maximal membrane conductance was 




memantine (1-100 µM; Fig 5.16) to investigate the effect of chronic treatment on 
membrane conductance. Our results showed that 48 hour memantine (1-100 µM) 
exposure had no significant effects on membrane conductance density after 
wash-off of the drug, however, there was a tend towards significance. However, 
the chronic exposure and continuous treatment with memantine (100 µM) 
showed a significant reduction of membrane conductance, similar to that 
observed after acute exposure. No significant alterations were observed in the 
presence of memantine (1-10 µM). These data, taken with previous studies on 
the effects of memantine exposure on dopaminergic neurons (Giustizieri et al., 
2007) and pancreatic β-cells (Imai et al., 2018) show that only concentrations > 
10 µM are sufficient to significantly block Kir6.2/SUR1  KATP channels.  Further 
experiments are required to clarify if memantine (100 µM) significantly attenuates 
conductance after wash off. As shown in chapter 3, chronic treatment with 
glibenclamide also induced reductions in membrane conductance after chronic 
treatment, however, this was determined to be due to incomplete drug wash off. 
Due to the low binding affinity of memantine compared to glibenclamide (100 µM 
vs 100 nM) it is unlikely that incomplete drug wash off is the cause of the observed 
reduction in conductance. The effect of memantine on membrane conductance 
following chronic treatment requires further investigation.  
These data also showed a significant effect of treatment on cell capacitance, 
indicating that chronic and continuous memantine treatment > 10 µM significantly 
reduces cell size observed at Run Up (Fig 5.16), an affect not observed if drug 
was washed off prior to experimentation (Fig 5.14), albeit with the same 
observable concentration effect and trend towards significance. The observed 
reductions in capacitance with increasing drug concentration are interesting. The 




as well as the speed at which signals propagate. Cellular capacitance is 
unaffected by transmembrane protein content  (Gentet et al., 2000), indicating 
that this is not an effect due to alterations in protein expression. Furthermore 
whilst alterations in internal pressure and transient stressing of the membrane 
during recording may alter membrane capacitance, systematic errors of this type 
would affect results from all treatment groups equally, as well as recordings from 
acute or pre-exposure to memantine. 
Chronic high dose NMDA-antagonism has been previously been shown to cause 
axonal degeneration (Ellison, 1994; Bueno et al., 2003), leading to reductions in 
cell membrane surface area. Furthermore, targeted knockout of NMDARs from 
neurons significantly decreases cellular capacitance (Hou & Zhang, 2017). As 
such, it is probable that the chronic high dose (>10 µM) memantine exposure, 
and respective NMDA antagonism rather than its effects on KATP channels, lead 
to significant reductions in cell capacitance. Further experiments are required to 
clarify this hypothesis.  
Taken together, the results from this current study also provided increased 
evidence that that memantine (10 nM), previously reported as a potent KATP 
channel antagonist (S. Moriguchi et al., 2016), is insufficient to decrease 
Kir6.2/SUR1 KATP mediated current. Moriguchi et al investigated the impact of 
memantine treatment on KATP channel activity both used hyperpolarising and 
depolarising steps in neuro 2A cells, a cell line previously shown to display 
pronounced voltage activated outward currents (X. Y. Qiu et al., 2016). Therefore 
investigating the effect of memantine on both KATP channels and voltage-
activated Kv channels. As has been shown, the effect on the latter is pronounced 




previous reports have potentially instead shown its impact on Kv currents (S. 
Moriguchi et al., 2016), rather than solely due to inhibition of KATP channels.  
Furthermore, no significant effect of either memantine (10 nM) or tolbutamide (10 
µM), a known KATP channel blocker  (Trube et al., 1986), was observed on current 
density at hyperpolarising potentials and in the presence of the KATP channel 
activating Mg-ATP. This begs the question of functional expression of 
Kir6.2/SUR1 subunits in the neuro2A cells and their activation state during the 
recordings. As such, the data presented by Moriguchi et al (2016) on the potent 
effect of memantine on KATP, is at best inconclusive and at worst misleading.  
Taken together, these data indicate that memantine, a CNS penetrant drug with 
a clinically demonstrated safety profile (Hardan et al., 2019), is a brain permeable 
weak KATP channel blocker that exhibits greater activity at Kv channels. However, 
whilst interesting for its potential beneficial effect of reducing the over-activity of 
KATP channel mutants responsible for DEND neonatal diabetes, it is currently 
unclear from these current studies whether memantine would be efficacious at 
therapeutically relevant doses. For example, infusion of rats with clinically 
relevant doses leads to accumulation of memantine in the plasma and CSF of 
approximately 1 µM (Misztal et al., 1996; Hesselink et al., 1999), a concentration 
shown to affect the function of NMDA receptor function in vitro in the absence of 
Mg2+, as well as various other targets. In addition, serum levels of memantine in 
humans with the usual daily maintenance dose of 20 mg (Reisberg et al., 2003) 
are with the range of 0.5 µM to 1 µM (Kornhuber & Quack, 1995). Results from 
the current study, however, suggest that memantine concentrations <10 µM are 
insufficient to cause reductions in membrane conductance of KATP channel 
expressing neurons either in the presence, or absence, of intracellular 




Memantine (< 100 µM) was also insufficient to cause any significant alteration to 
membrane conductance following chronic treatment, indicating no significant 
effect of chronic treatment on channel activity. In this regard, the concentration of 
memantine in the brain is not significantly affected by duration of treatment 
(Kornhuber & Quack, 1995), indicating that even with chronic treatment 
concentrations would not significantly increase, bringing in further doubt into the 
impact of memantine application on KATP channel conductance in vivo.  
In terms of translatability, human and mouse KCNJ11 display substantial genetic 
identities with each other (Donley et al., 2005), with Kir6.2 from both species 
showing no observable differences in ATP sensitivity or drug response in in vitro 
studies. However, mutations in KATP channels that cause hyperinsulinemia in 
humans, do not do so in mice (Shimomura et al., 2013). The reason for the 
difference between the mouse model and human phenotype is as yet unclear. 
Potentially due in part to an as yet undetermined compensatory mechanism, 
rather than differences in KATP channel activity. Therefore, results from this study 
can be translated to effects on human KATP channels.  
Further to the potential of memantine as a neonatal diabetes treatment option. 
Diabetes Mellitus is associated with cognitive impairment, proposed to be due, in 
part, to blood-brain-barrier dysfunction and leakage. Evidence from both in vivo 
and in vitro studies have shown that blood brain barrier integrity in conditions of 
hyperglycaemia is compromised (Pooja Naik, 2014). More recent results from 
mouse models suggest that prolonged hyperglycaemia doesn’t cause pericyte 
loss and increased permeability of the BBB (Mäe et al., 2018). Regardless, if 
integrity of the BBB is compromised in hyperglycaemia this may increase 
bioavailability of memantine, or sulfonylureas, to treat neurological conditions. 




normoglycaemic conditions or after treatment with antioxidants (C. L. Allen & 
Bayraktutan, 2009). As such, treatment options will eventually be victims of their 
own success. In addition, surface KATP channel expression has been shown to 
be diminished with KCNJ11 mutations (Lin et al., 2006), an effect that can be 
rescued with sulfonylurea treatment (Partridge et al., 2001), implicating that the 
use of sulfonylureas may be compromised for neonatal diabetes therapy due to 
the potential for increased expression of mutant subunits. At time of writing, to 
our knowledge there is no evidence in the literature that memantine increases 
KATP channel expression, mutant or otherwise, suggesting that memantine may 
prove to be a more effectual treatment than sulfonylureas for neonatal diabetes 
therapy. However, due to the high concentration required for channel blockade, 
memantine is currently not an effectual treatment option. Medicinal chemistry 














Chapter 6  





























6.1 Chronic Sulfonylurea treatment augments membrane conductance 
of GT1-7 cells 
Several studies have investigated the chronic impact of sulfonylureas on 
membrane conductance of β-cells, showing a decrease in membrane 
conductance due to either reduced KATP channel expression (Kawaki et al., 1999; 
A. Takahashi et al., 2007) or a reduction in channel open probability (Gullo et al., 
1991; Remedi & Nichols, 2008).  These data are used to explain the diminished 
effects of acute sulfonylurea on β-cell activity following chronic treatment, as well 
as the reason for progressive sulfonylurea failure in T2D treatment (H. Wang et 
al., 2017). Interestingly, chronic treatment of GT1-7 cells with NN414, a KATP 
channel agonist, induces a significant attenuation of single KATP channel 
conductance (Craig Beall, Haythorne, et al., 2013; Haythorne et al., 2016), 
severely hindering glucose sensing even in the absence of drug. In the current 
study these data show that 48 hour incubation with gliclazide and tolbutamide, 
KATP channel antagonists, significantly augments KATP channel conductance in 
GT1-7 cells, an opposite effect to that observed with NN414. However, chronic 
treatment with glibenclamide caused a significant attenuation of membrane 
conductance and depolarisation of the membrane potential. This was likely due 
to incomplete drug wash-off of glibenclamide during experiments, a feature 
previously described due to its high binding affinity and benzamino and 
sulfonylurea moieties (Martin et al., 2017).  
Whilst in some respects preliminary, this observation brings into question the 
results of previous studies on the effect of chronic glibenclamide on β-cell 
membrane conductance (Gullo et al., 1991; Kawaki et al., 1999; A. Takahashi et 




an attenuation of current are observing this in the continued presence of the 
pharmacological agent. Regardless, results indicate that chronic antagonism of 
KATP channel activity with gliclazide and tolbutamide significantly increases the 
total conductance available from these channels in drug free conditions in GT1-
7 cells. However, whether this is due to increased expression or due to an 
increase in channel open probability is yet to be determined, potentially using 
single KATP channel recordings under controlled nucleotide levels to investigating 
channel gating kinetics after chronic sulfonylurea treatment.  
These results potentially explain the increased rates of sulfonylurea failure after 
long term treatment, suggesting that long term treatment increases total KATP 
channel conductance, and thus requires higher concentrations of sulfonylurea to 
reduce the active KATP channel population to the therapeutically required level. 
Furthermore, whilst this was conducted in GT1-7 cells, minor differences are 
observed between hypothalamic neurons and β-cells (Mele et al., 2012). As a 
result it would be interesting to determine whether this effect persists in different 
cell types, including primary pancreatic β-cells. Single channel analysis is 
required to understand whether chronic gliclazide and tolbutamide alter KATP 
channel open probability under well controlled nucleotide levels. Furthermore, it 
would be interesting to determine whether the observed between gliclazide/ 
tolbutamide and glibenclamide are due to their sites of interaction. The impact of 
higher concentrations of sulfonylurea for shorter treatment periods may also be 




6.2 Chronic KATP modulation significantly alters cellular metabolism of 
GT1-7 cells  
KATP channel modulation using either antagonists or agonists has previously been 
shown to impact glucose metabolism in cardiac tissue (Sato et al., 2006; Riess 
et al., 2008) and pancreatic β-cells (Brennan et al., 2006).  These data have 
shown that acute KATP channel blockade causes no significant alteration in 
glycolysis or mitochondrial function in either β-cells or hypothalamic neurons, 
results that contrast with that previously observed. However, these data do show 
that the KATP channel agonist NN414 significantly decreases oxygen consumption 
rate and ATP production in β-cells, but not in hypothalamic neurons, confirming 
previous observations on the effect of KATP channel agonists on mitochondrial 
function. Interestingly these data illustrate that the chronic KATP channel 
antagonism with glibenclamide induces increases in ATP production and spare 
respiratory capacity, whilst decreasing glycolysis in treated GT1-7 cells. No effect 
of gliclazide, tolbutamide or high KCl was observed indicating that this effect was 
most probably due to the continued presence of glibenclamide due to it high- 
affinity binding to KATP channels (Martin et al., 2017), induced continued cellular 
depolarisation. Therefore, whilst gliclazide and tolbutamide caused significant 
increases in membrane conductance, this has no significant impact on cellular 
metabolism. 18 hour treatment with both glibenclamide and tolbutamide 
decreases pyruvate carboxylase/ pyruvate dehydrogenase ratio in β-cells, 
reducing insulin secretion upon glucose challenge (Brennan et al., 2006). 
Furthermore, glibenclamide increases the percentage of Acetyl-CoA derived from 
glucose following chronic treatment (Brennan et al., 2006). These data suggest 




continued exposure to sulfonylureas may also impact glucose metabolism, which 
may also contribute to the phenomena of sulfonylurea failure.   
6.3 Memantine is a low-affinity KATP antagonist 
Memantine and its effect on KATP channels has been the subject of various 
studies over the past few years. These data show that memantine significantly 
attenuates KATP channel mediated membrane conductance > 10 μM in GT1-7 
cells, through binding to an extracellular binding site; Inducing KATP channel 
blockade similar to that observed with glibenclamide (1 μM). Furthermore, these 
data demonstrate that the addition of ATP significantly increases the inhibitory 
effect of memantine. Under drug-free experimental conditions, cells chronically 
exposed to memantine have decreased linear membrane conductance compared 
to control treated cells, albeit not significantly. This effect is unlike that observed 
with the sulfonylureas tolbutamide and gliclazide, indicating a potentially different 
mechanism of action of channel blockade. These data confirm previous 
observations on the effect of memantine on Kir6.2/SUR1 KATP channels 
(Giustizieri et al., 2007; Imai et al., 2018). However, our results put into doubt the 
results presented by Moriguchi and colleagues (2016) in which memantine at 
circa 10 nM is proposed to be a close to the maximally effective concentration. 
Data presented here indicates that memantine >1 μM significantly attenuate 
voltage-gated outward currents, most probably through inhibition of Kv channels 
(Lowinus et al., 2016), therefore limiting the validity of the report by Moriguchi in 
which KATP channel currents were examined at +40 mV in a Kv expressing cell 
line. In my opinion, Moriguchi et al (2016), through poor experimental design, 




presented misleading conclusions contrary to observations presented here and 
elsewhere (Giustizieri et al., 2007; Imai et al., 2018).  
Whilst memantine is CNS permeant, unlike sulfonylureas, the concentration 
attainable (at circa 1 µM) compared to the observed concentration-response is 
deemed not beneficial for treatment of DEND due to its potential off-target effects 
at that concentration range (Bormann, 1989; Seeman et al., 2008; Tsai et al., 
2013; Valis et al., 2019). Overall these data conclude that memantine is a weak 
low-affinity KATP channel antagonist, however, further work is required to decipher 
is mechanism of action, as well as its effect on gain-of-function mutant KATP 
channels for the treatment of NDM and DEND syndrome. 
6.4 The consequences of acute and long-term KATP channel inhibition 
Acute KATP channel inhibition is a characteristic feature of metabolic sensors and 
critical to the central control of glucose metabolism and energy regulation, as 
seen in pancreatic β-cells and hypothalamic GE neurons (A. Tarasov et al., 2004; 
Evans et al., 2004). Acute KATP channel inhibition, through pharmacological 
antagonism, can increase insulin release and glucose homeostasis. However, 
acute inhibition may have wider reaching impacts. Exposure of rat VMH to 
glibenclamide significantly blunts the CRR to hypoglycaemia and reduces 
pancreatic GSIS (Evans et al., 2004). Furthermore, the activation of KATP 
channels under periods of heightened metabolic stress, such as in 
cardiomyocytes and non-glucose sensing neuronal populations, play pivotal roles 
in ischemic preconditioning (Broadhead et al., 2004; Y. Wang et al., 2015) and 
the regulation of neuronal excitability (T. G. J. Allen & Brown, 2004; Tanner et al., 
2011; Lemak et al., 2014), respectively. Therefore, the acute inhibition of KATP 




cell types adequately respond to stress. Furthermore, acute administration of 
KATP channel antagonists has been previously demonstrated to cause alterations 
in glucose metabolism (Salani et al., 2017) and mitochondrial ATP production 
(Skalska et al., 2005; Sato et al., 2006), leading to a reduced energy availability 
and fuel sensing capability. 
Data shown here indicate that acute pharmacological KATP channel inhibition 
causes no significant effect on cellular metabolism (Chapter 4). However, these 
data do show that 48-hour treatment with glibenclamide, also shown to 
significantly reduce KATP channel mediated membrane conductance after 48 
hours (Chapter 3), instigates an increase in glycolytic rate and a reduction in 
mitochondrial ATP production in GT1-7 cells. This corroborates similar reports 
from loss-of-function KATP channel expressing β -cells that show alterations to 
genes associated with glucose metabolism and a reduction in mitochondrial mass 
(C. Li et al., 2017). However, whether this is due to increased cellular excitability 
(Shyr et al., 2019), raised calcium accumulation (Glass-Marmor et al., 1999b; 
Sato et al., 2006) or alterations to mKATP channel activity (Skalska et al., 2005)is 
unclear, but worth investigation. Similarly, chronic sulfonylurea exposure and 
KATP channel inhibition causes significant reductions in GSIS and blood glucose 
control, as seen in secondary treatment failure (A. Takahashi et al., 2007). 
Potentially due to defective, or reduced, glucose-stimulated ATP production or 
instead a direct effect of sulfonylureas on metabolic machinery (Salani et al., 
2017). Interestingly, these data also show that long-term KATP channel inhibition, 
using the sulfonylureas gliclazide and tolbutamide, significantly increased KATP-
channel mediated membrane conductance upon removal, indicating that direct 




converse of that observed with KCOs (Haythorne et al., 2016). However, further 
work is required to unpick this hypothesis.  
Finally, whilst systemic KATP channel inhibition may prove detrimental in most 
cases, in the case of individuals with DEND gain-of-function mutations this may 
prove beneficial. Reports have demonstrated that long-term KATP channel 
inhibition with sulfonylureas significantly improves individuals’ glycaemic control 
(Bowman et al., 2018), maintaining blood-glucose concentrations within a healthy 
range (3.8 – 5 mM). Secondly, while DEND individuals are reported to display 
with a variety of neurological syndromes (Gloyn et al., 2006), no similar reports 
exist in the literature from individuals living with loss-of-function KATP channel 
mutations, as well as no significant cardiac abnormalities (Clark et al., 2012). This 
observation is most probably due to KATP channels being predominantly closed 
at rest in non-glucose sensing cells, only being activated under periods of 
heightened metabolic stress (such as during hypoxia, ischemia or heightened 
neuronal action potential firing). Therefore, long-term inhibition of KATP channels 
in the CNS of DEND individuals may prove beneficial in establishing “healthy” 
neuronal function, in addition to glycaemic control (Bowman et al., 2019). Data 
presented here in aimed to assess memantine as a potential pharmacological 
agent (Chapter 5). However due to its high IC50 and various off target effects, 
the jury is still out. Further work is therefore required on mutant channels and in 
a more physiological setting before definitive conclusions are reached.  
6.5 Limitations of studies 
Daily changes in the peptide expression profile and secretory capacity of GT1-7 
cells has been observed (S. Zhao & Kriegsfeld, 2009). Whilst important to 




were conducted within the same 4-6 hour time window per day, as well as cell 
passaging and treatment performed within similar time windows to limit the impact 
of innate circadian rhythm on results. In addition, when pharmacological agents 
were applied, studies were adequately controlled.  
Undoubtedly, concerns also exist with the use of immortalised cell lines in the 
study of cellular metabolism. Examination on the effects of passage number on 
enzymatic profile have shown that expression of key enzymes can decline 
significantly as passage number increases (Castell et al., 2006), with cells used 
in these studies being at passage number at circa 45-60. However, in the 
absence of primary neuronal/ pancreatic β-cells in vitro culture or a viable in vivo 
model, and with these limitations in mind, experiments proceeded. Regardless of 
potential pitfalls, the use of immortalised cells lines enabled relatively guaranteed 
KATP channel currents in every cell, easy cell culture, facilitated research and 
reduced our animal use. However, careful consideration must be taken when 
extrapolating results from cell lines to potential in vivo effects. 
In addition, mild fluctuations in starting ECAR and OCR values were recorded 
across the culture microplate during seahorse metabolism assays, an effect 
highlighted in chapter 4. Qualitative analysis implied differences between the 
centre and the edges of the plate, which may impact results due to the localisation 
of wells injected with particular treatment. However, further detailed analysis of 
pH and oxygen saturation concentrations prior to drug injection using a multi 
effects model are required to observe if these differences are significantly 
different, or if they impact cellular responses to identical stimuli.   
Furthermore, whilst stated in the methodology, both sodium pyruvate and L-




of pharmacological KATP channel modulation on both mitochondrial activity and 
glycolytic flux. However, when assessing mitochondrial function using O2 
consumption as a proxy measure it is wise to maximise flux through oxidative 
phosphorylation, using this methodology may have silenced a potential minor 
effect of both sulfonylureas and KATP channel openers on mitochondrial function. 
Both pyruvate and L-Glutamine are both mitochondrial substrates and so their 
addition, even under hypo-glycaemic conditions used to increase KATP channel 
activation, may have skewed the results of these studies by providing a viable 
ATP source. Further work must aim to remove all potential substrate sources prior 
to metabolic analysis or, at least, factor them in in further analysis.  
Furthermore, the statistical power of conducted studies must be considered, 
requiring further experiments to further validate some results presented in this 
work due to its inherent variability.  
6.6 Further Work 
Firstly, whilst data shows that gliclazide and tolbutamide increased membrane 
conductance after 48 hours in GT1-7 cells the mechanism behind this result is 
unclear. Further investigation onto the impact of treatment on single-channel 
gating kinetics and ATP-inhibition relationship, using single channel recordings, 
will be vital in understanding if chronic sulfonylurea act to increase channel open 
proability through a conformational change to the channel structure. An 
assessment of Kir6.2 and SUR1 protein expression, as well as the proportion 
displaying surface/ membrane expression using western blotting and surface 
biotinylation will be important in understanding if the observed increase in 
conductance is due to an increase in channel surface expression. Furthermore, 




pancreatic β-cells, cultured neurons and hypothalamic brain slices to determine 
whether the same effect is observed.  
Secondly, our data show that memantine is a low-affinity KATP channel antagonist. 
However, future work should focus on understanding the mechanism of blockade 
utilising an in depth analysis of channel open probability in the presence of 
memantine and intracellular nucleotides. It would be interesting to observe the 
impact of memantine using perforated patch clamp electrophysiology to observe 
the impact of memantine treatment on intact cells due to the effects of whole-cell 
patch clamp.   
Thirdly, Neonatal Diabetes Mellitus (NDM) is a rare genetic condition (Slingerland 
et al., 2009). Activating mutations in the pore-forming Kir6.2 (KCNJ11) subunit of 
the KATP channel have been identified as main contributors to the development of 
NDM (Gloyn et al., 2004). In such mutations, ATP is less efficacious at closing 
the channel resulting in a greater level of ongoing activity. A range of disease 
phenotypes arise from such activating mutations with the observed 
pathophysiological outcomes dependent on the extent of reduction in ATP 
sensitivity. Mutations that cause small reductions in ATP sensitivity (e.g. R201H) 
produce PNDM, reducing glucose control. Whilst, mutations that render the 
channel highly insensitive to ATP, and greatly perturb channel gating, can cause 
DEND syndrome. These neurological symptoms include, delayed motor and 
mental development, hyperactivity, aggression, intellectual disability and seizures 
(Beltrand et al., 2015), however, the full pathways  behind the development of 
these CNS symptoms is largely unknown. Previous work has shown that the long 
term treatment of neonatal diabetes patients with sulfonylureas, a common T2D 
therapy targeting KATP channels, improves glycaemic control. However, such 




the CNS outcomes are not simply a manifestation of poor glycaemic control. Why 
CNS symptomatology is drug resistant is not understood, it may be due to inability 
of the sulfonylureas to target neuronal KATP channels or due to the treatment 
being delivered too late to reverse developmental issues. As such, it is important 
to understand the effect of KCNJ11 activating mutations on neuronal maturation, 
development and neurophysiological activity, to better understand how KATP 
channels, and mutations thereof effect neuronal behaviour. In addition, it is 
important to examine the potential for a novel therapeutic agent, such as 
memantine, to adequately treat neurological symptoms of DEND.  
6.7 Concluding Remarks  
Overall, I feel that this this work contributes significantly to our understanding of 
both pharmacological impacts to KATP channel activity, as well as the role of 
membrane excitability and KATP channel activation on cellular metabolism. In 
addition, this work furthers our understanding of the effects of memantine on KATP 
mediated membrane conductance and its effectiveness, or lack thereof, as a 
novel treatment for NDM.  
Results presented herein shed a new light onto KATP channel function, identifying 
new and exciting areas for exploration, including: the role of KATP channels in 
neurodevelopment and neuronal function, the impact of mutations on network 
development and the search for CNS-permeant KATP channel antagonists for use 
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